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CHEMICAL MODIFICATION AND IMMUNOLOGICAL STUDIES ON 
RECOMBINANT FACTOR VHI
Fiona Manning B.Sc. (NUI)
Factor VIII (FVIII) is a high molecular weight glycoprotein which is deficient or 
functionally defective in Haemophilia A. It circulates in normal plasma as part of a 
complex with von Willebrand factor (vWF). In the absence of vWF, FVIII is highly
unstable.
The effects of chemical modifiers on recombinant FVIII (rFVIII) were investigated. A 
variety of homobifunctional and heterobifunctional chemical cross-linkers and protein- 
modifying agents with different side chain specifities was employed. The amino-specific 
reagents, with the exception of 2-Iminothiolane, caused significant loss of FVIII activity. 
However, reaction with thiol-specific compounds did not lead to any loss of FVIII 
activity. It would appear therefore, that amino groups are involved in FVIII activity.
Monoclonal and polyclonal antibodies were produced to rFVIII. The effect of binding 
of these antibodies on FVIII procoagulant activity was investigated. It was found that 
the binding of the monoclonal antibodies caused loss of activity, whereas, binding of the 
polyclonal antibodies did not neutralise procoagulant activity.
The antibodies were used in the development of enzyme-linked immunosorbent assays 
(ELISAs) for the detection and quantitation of rFVIII and anti-rFVIII antibodies using 
a number of different formats.
The antibodies were also utilised in the development of a biosensor. Using this device, 
FVin in normal human plasma and calibration plasma, as well as anti-rFVIII antibodies 
could be detected. The biosensor also provides a novel method to monitor antibody- 
antigen interactions. rFVIII was immobilised onto an electrode surface and incubated in 
a horseradish peroxidase-labelled anti-rFVIII antibody solution. The electrochemical 
response was based on the enzymic reduction of H20 2 in the presence of an electron 
mediator (hydroquinone). The oxidised quinone produced was reduced at the electrode 
surface and current measured.
CHAPTER 1 
INTRODUCTION
1
1.1 Introduction
The coagulation mechanism of vertebrate blood was first proposed to be composed of a 
series of reactions which function as a biological amplifier by Macfarlane in 1964. This 
basic hypothesis has not been altered, although knowledge of the basic components and 
reactions, as well as the involvment of other mechanisms besides the coagulation factors 
(platelet) has greatly increased.
Factor VIII (FVIII) is an essential component of the blood coagulation cascade. A 
deficiency or abnormality in this protein results in the bleeding disorder known as classic 
haemophilia.
The low concentration of FVIII in normal plasma (approximately 5-10 pg/ml), in addition 
to its extreme sensitivity to proteolysis, hampered early attempts to isolate the protein. 
Isolation and purification were eventually achieved and led to the determination of the 
complete amino acid sequence (Toole et al., 1984; Vehar et al., 1984).
In early attempts to study Factor VIII a much larger protein was always co-isolated. This 
protein, von Willebrand factor (vWF), is very closely associated with FVIII. The two 
proteins circulate in normal plasma as a non-covalently linked complex. vWF comprises the 
majority of the protein mass of the FVIII/vWF complex (approx. 95%-99%) and, hence, 
these early studies on "FVIII" actually described properties of vWF, which were generally 
unaffected by the presence or absence of FVIII, the procoagulant activity of the complex. 
Thus, to avoid confusion, the International Committee on Thrombosis and Haematosis 
proposed a nomenclature to describe the properties of the FVIII/vWF complex (Table 1.1). 
von Willebrand protein functions in the cellular aspects of coagulation. It facilitates platelet- 
vessel wall interactions (Roth, 1992). FVIII functions as a cofactor in the intrinsic phase of 
the blood coagulation cascade (Hoyer, 1981). It forms a complex, the "tenase complex", 
in combination with calcium ions, phospholipids and activated Factor IX (IXa), which 
activates Factor X. (Figure 1.1).
The two proteins FVIII and vWF are under the control of different genes. FVIII is a product 
of the X chromosome, and, thus, classic haemophilia is inherited as a recessive, sex-linked 
disorder. The vWF gene is located on the short arm of chromosome 12 (Ginsberg et al.,
1985). von Willebrand disease, a condition resulting from a deficiency or abnormality in 
vWF, is inherited as an autosomal disorder.
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Abbreviation Corresponding property of the 
FVIII/vWF complex
FVUI/vWF The FVm/vWF complex
FVIII:C The procoagulant activity of FVI1I, 
measured by clotting assay.
FVniC:Ag The antigenic determinants of FVIII:C, 
measured by immunological methods.
FVIII:R FVin-related protein, von Willebrand factor.
FVIII:RAg Antigenic determinants on FVIILR, determined by 
immunological techniques employing heterologous 
antisera against the FVin/vW f complex.
FVIIIR:R Ristocetin cofactor activity, the property of vWF which
supports ristocetin-induced agglutination of normal 
platelets.
Table 1.1 Nomenclature of the FVIII/vWF complex.
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FVIII is inherently unstable in the absence of vWF. Its optimal pH lies between 6.9 and 
7.2, with marked decrease in stability below pH 6 and above pH 8 (Wolf, 1959). Calcium 
ions (Ca2+) are also necessary for FVIII stability, but other divalent cations have a 
comparable effect (Mikaelsson, 1983). The optimal calcium concentration lies between 0.3 
and 1.0 mM. The presence of protease inhibitors (DFP or heparin) increases the stability 
(Rock et al., 1983). Removal of Ca2+ reduces initial activity and leads to increased 
instability (Rock et al., 1983). Activity and stability can be recovered upon recalcification 
(Ganz et al., 1987). Sakuragawa et al. (1988) modified FVIII using polyethylene glycol and 
found that the modified protein was stable against inactivation by activated Protein C and 
plasmin, but not against thrombin.
1.2 Purification
Structural and other studies on factor VIII require the isolation of the pure protein. Despite 
FVIII’s low concentration in normal plasma and its susceptibility to proteolytic attack, 
bovine, porcine and human FVIII have now been successfully isolated.
Vehar and Davie (1980) isolated bovine FVIII and estimated its molecular weight (Mr) to 
be in the region of 300 kiloDaltons (kDa). After reducing the protein and subjecting it to 
sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE), they observed 
three bands corresponding to Mr of 85, 88 and 90 kDa. Knutson (1982) and Fass (1982) 
both isolated porcine FVIII which showed similar properties to the bovine FVIII reported 
by Vehar and Davie, but their protein gave a different series of bands when run on SDS- 
PAGE. Bands were observed at Mr 166, 130 and 76, kDa. The 130 kDa band was found 
to be derived from the 166 kDa peptide but the Mr 76 kDa was a distinct protein bound by 
calcium ions to the other chain.
Human FVIII was much more difficult to isolate. Both bovine and porcine FVIII had been 
isolated from large volumes of fresh plasma. Use of the same volume of human plasma 
was not feasible, so alternative methods for the isolation had to be used. Fulcher and 
Zimmerman (1982) employed a heterologous antibody to isolate the protein. When this 
FVIII was run on SDS-PAGE, two main bands at Mr 70 kDa and 80 kDa were evident, 
with others up to Mr 188 kDa. Weinstein et al. (1983) confirmed Fulcher and 
Zimmerman’s earlier results that all these bands were derived from the FVIII protein.
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These findings suggest that some degree of proteolysis must have occurred during 
purification. Rotblat (1985) purified FVIII from human plasma to which protease inhibitors 
had been added. A band was identified which corresponded to a molecular weight (Mr) of 
365 kDa which was proposed to be the molecular weight of native FVIII. Minor bands of 
lower Mr were said to result from limited proteolysis.
1.3 The Structure of the FVIII molecule
The purification of bovine, porcine and human FVIII, free of von Willebrand’s factor, the 
cloning of the factor VIII gene and the isolation of complementary cDNA encoding Factor 
VIII represents the major steps in the understanding of Factor VIII. The molecular cloning 
and characterization of the FVIII coding region (Gitschier et al., 1984; Wood et al., 1984) 
allowed the nucleotide sequence to be determined and from this the 2351 amino acid 
sequence of the FVIII molecule was deduced. The first 19 amino acid residues constitute 
a signal sequence similar to the leader sequence for most secretory proteins and are lost 
during post-translational modifications. Thus, the mature FVIII polypeptide consists of 
2332 amino acids with a calculated Mr of 264,763 Da. Glycosylation, mainly in the central 
B domain, accounts for the anomaly between the calculated Mr and that observed following 
purification (Mr 360 kDa).
Analysis of the sequences revealed that the protein is made up of three distinct structural 
domains (Figure 1.3). The triplicated A domains each contain approximately 330 amino 
acids and are found at positions 1-329, 380-711 and 1649-2019 of the mature polypeptide. 
A unique B domain containing approximately 980 amino acids, is located between the 
second and third A domains. The duplicated C domains, each containing about 150 amino 
acids, are located at the COOH-terminal of the molecule. The central B domain contains 
19 of the 25 potential asparagine-linked glycosylation sites. The majority of the cysteine 
residues, meanwhile, are situated in the A and C domains, suggesting internal disulphide 
bond formation.
6
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Figure 1.3 The domain structure of FVIII. The 2332 amino acid sequence of the FVIII 
molecule is made up of repeated domains. Two regions of a triplicated A 
domain are separated from the third region by a unique B domain containing 
approximately 980 amino acid residues. The duplicated C domains are located 
beside the third A domain at the carboxyl terminal end of the molecule. After 
thrombin activation of FVIII, the central B domain is excised, leaving the A 
and C domains to form the functional molecule.
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Although FVIII is synthesised as a single polypeptide chain (Toole et al., 1984; Wood et 
al., 1984), it is isolated from plasma as a series of heterodimers, ranging in size from 
approximately 80 to 210 kDa, linked by divalent ions (Fass et al., 1982). These are formed 
as a result of proteolysis between the B-A3 domains, and within the B domain (Vehar et 
al., 1984). The A l and A2 domains represent the majority of the FVIII heavy chain, but 
some or all of the B domain may also be present. The heavy chain thus exhibits a large 
degree of size heterogeneity. The light chain is composed of the A3-C1-C2 domains with 
an invariant size of 684 residues of Mr 80 kDa. (Figure 1.3). The binding sites for von 
Willebrand factor (Foster et ah, 1988) and phospholipids (Bloom et al., 1987) have been 
localised in the light chain.
The A domains show considerable internal homology (about 30%) and share approximately 
30% homology with ceruloplasmin, the copper-binding protein present in human plasma 
(Vehar et al., 1984). This suggests some metal binding capabilities for FVIII. The C 
domains exhibit internal homology (approximately 40%) and show about 20% homology 
with discoidin I, a phospholipid-binding lectin from the slime-mold Dictyostelium 
discoidium (Kane and Davie, 1988). They also show homology to a mammary epithelial cell 
surface protein (Stubbs et al., 1990).
1.4 Homology between FVIII and Factor V
The similarities between FVIII, Factor V (FV) and ceruloplasmin were noted by Fass et al., 
(1983). Factors V and VIII both function as cofactors in the blood coagulation cascade. 
FVIII is involved in the activation of factor IX in the intrinsic phase, and FV in the 
activation of factor X during the common phase of the coagulation cascade (Figure 1.1). 
Both cofactors are also activated by thrombin.
Analysis of their amino acid sequences revealed a homology of approximately 40%, with 
the greatest similarities occurring at the amino- and carboxyl-terminals (Kane and Davie,
1988). These regions represent the active form of the protein after thrombin activation. 
Both proteins are composed of repeated domains - a triplicated A domain, a duplicated C 
domain and a unique B domain situated between the second and third A domains (Vehar 
et al., 1984; Toole et al., 1984).
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The amino-terminal A domains show similarities with the copper-binding plasma protein, 
ceruloplasmin, suggesting that these three proteins constitute a family of structurally related 
proteins (Church et al., 1984). The central B domains which are released during thrombin 
activation of both FVIII and FV, contain the majority of possible glycosylation sites, but 
apart from this similarity, they share only about 14% homology.
1.5 Activation and inactivation cleavages of FVIII by thrombin
FVIII has no detectable activity prior to proteolytic activation. Thrombin and FV are the 
only enzymes capable of activating FVIH. The activation of FVIII is initiated by cleavage 
between Arg 740-Ser 741 in the heavy chain, producing a uniform 90 kDa fragment. This 
is followed by further cleavages at Arg 372, between the A l and A2 domains of the heavy 
chain, and Arg 1689 in the light chain (Figure 1.5.1). The 50 and 43 kDa heavy chain- 
derived peptides, and the 73 kDa light chain, are thought to constitute the active form of 
FVIII.
The structure of activated FVIII (FVIIIa) has been difficult to discern due to its lability. 
Lollar et al. (1989) isolated thrombin-activated porcine FVIII, consisting of a heterotrimer 
of the A l, A2 and A3-C1-C2 peptides. They proposed that loss of procoagulant activity was 
due to dissociation of the A2 subunit (Lollar et al., 1991). Fay et al. (1991b) suggested that 
human FVIIIa was also a heterotrimer. Dissociation of the A2 subunit resulted in loss of 
procoagulant activity, but this could be restored by reconstitution of the inactive A1/A2-C1- 
C2 dimer and the A2 subunit. An acidic region at the COOH terminus of the A l subunit 
is thought to be involved in the association of the A2 subunit with the A1/A3-C1-C2 dimer 
(Fay et al., 1993). Addition of the A2 subunit to the A1/A3-C1-C2 dimer of recombinant 
human FVIII increased the procoagulant activity by 22 fold (Pittman et al., 1992). 
Lamphear et al. (1992), showed that both the A l and A1/A3-C1-C2 subunits were required 
for association with FIXa, suggesting that assembly of the "tenase complex" stabilises 
FVIIIa by preventing subunit dissociation.
Using site-directed mutagenesis, Pittman et al. (1988) selectively mutated the arginine 
residues at 740, 372 and 1689 to isoleucine and studied the effect of these mutations on 
FVIII activity.
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Figure 1.5.1 Thrombin activation of FVIII. The initial cleavage by thrombin occurs after 
residue 740. Further cleavages at 372 and 1689 release peptides of molecular 
weight 50, 40 and 73 kDa, respectively, which are thought to constitute the 
active form of FVIII. The peptides are thought to be linked by calcium 
bridges. Cleavage at residue 336 (by thrombin, activated Protein C and factor 
Xa) inactivates the protein.
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Mutation at 740 inhibited thrombin cleavage, but had minimum effect on FVIII 
procoagulant activity. In contrast, while both Arg 372 —>Ile and Arg 1689 —» lie mutants 
exhibited low levels of intrinsic procoagulant activity, they were both resistant to thrombin
cleavage and thrombin activation.
Resistance to thrombin cleavage at one site did not affect susceptibility at the other site. 
These results seem to suggest that while cleavage at 740 is not essential for thrombin 
activation, cleavage at the remaining sites (372 and 1689) is, but the order in which they 
occur is irrelevant.
The importance of the 372 and 1689 cleavage sites has been highlighted by Gitschier et al. 
(1988). They identified haemophilia A patients with missense mutations at residues 372 and 
1689, resulting in normal levels of circulating FVIII:Ag, but no detectable FVIII coagulant 
activity.
Longer exposure to thrombin causes inactivation. Further cleavage of the heavy chain 
occurs at residue 336, resulting in the formation of a 45 kDa fragment. Activated Protein 
C and Factor Xa also cleave at this position, inactivating FVIII (Fulcher et a l,  1984; Eaton 
et al., 1986: Eaton et al., 1987). The presence of protease inhibitors does not prevent 
inactivation (Rick and Hoyer, 1977; Hultin and Jesty, 1981) so other inactivation processes 
must be involved. The dissociation of subunits has been implicated as a possibility, as 
chelation of metal ions causes loss of activity (Eaton et al., 1987). Fay et al. (1987) cross- 
linked the heavy and light chains, stabilising FVIIIa and preventing dissociation.
In plasma FVIII circulates as part of a complex with von Willebrand factor. In order to 
participate in coagulation, the FVIII must be released from this complex (Figure 1.5.2). 
Cleavage after residue 1689 serves to release the 70 kDa light chain fragment from vWF 
(Hamer et al., 1987b; Lollar et al., 1988). FXa is also capable of activating FVIII, with 
cleavage also occurring at residue 1689 (Eaton et al., 1986).
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Figure 1.5.2 The activation of FVIII in vivo. FVIII circulates in normal plasma complexed 
with von Willebrand factor (vWF). Thrombin cleaves the light chain, releasing active FVIII. 
Inactivation occurs as a result of further proteolytic processing by thrombin, activated 
Protein C and factor X, or by dissociation of the subunits. The light chain is composed of 
the A3-C1-C2 domains, while the A1-A2 domains make up the heavy chain.
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1.6 Inactivation of FVin by activated Protein C
Protein C, a potent circulating anti-coagulant, is a zymogen of a vitamin K-dependent serine 
protease (Valcarce et al., 1993). Activation of protein C occurs on the surface of the 
endothelium and is catalysed by a complex of thrombin bound reversibly to a cell surface 
receptor, thrombomodulin (Esmon, 1989). Complex formation accelerates the activation of 
protein C, while inhibiting the ability of thrombin to promote clotting (Esmon et al., 1993). 
Thrombin cleaves an internal peptide bond (Arg-Ile) in the heavy chain of protein C, in the 
presence of Ca2+ and phospholipids. Activated Protein C (aPC) then inactivates FVIII by 
cleavage of the light chain. Walker et al. (1990) located regions of the light chain A 
domain (the A3 domain) that served as a binding site for aPC (residues 2009-2019). 
Koedam et al. (1988) and Rick et al. (1990) reported that association of FVIII with von 
Willebrand factor protects the cofactor from aPC. Fay et al. (1991a) suggested that the 
protection conferred on FVIII by vWF results from a reduced affinity of the complex for 
the phospholipid membrane. aPC is inactivated by an unknown inhibitor present in normal 
plasma (Marlar et al., 1982).
1.7 The FVIII/von Willebrand factor complex
FV in circulates in normal plasma as part of a complex, in which it is non-covalently bound 
to von Willebrand factor (vWF). The larger vWF constitutes approximately 95%-99% of 
the protein mass. The two proteins differ functionally, immunologically and are under 
different genetic control. FVIII functions as a cofactor in the blood coagulation cascade and 
possesses distinct antigenic determinants (FVIILAg). It is deficient or abnormal in classic 
haemophilia.
vWF plays a role in platelet-blood vessel wall interactions, and has its own distinct 
antigenic determinants (vWFAg or VIIIR:Ag). Abnormality or deficiency in vWF results 
in the bleeding disorder called von Willebrand disease.
Evidence that FVIII and vWF exist in normal plasma as a complex can be gained from 
studies in which FVIII and vWF were both isolated together. Using gel filtration and 
sucrose-density gradient ultracentrifugation, under conditions of high ionic strength 
(1M NaCl or 0.24M CaCl2), several groups found that the two proteins could be separated
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(Owen et al., 1972; Rick and Hoyer, 1973; Weiss et al., 1973). vWF behaved as a high 
molecular weight protein, eluting in the void volume. FVIII, being the smaller of the two 
components, remained in the column and was released on addition of 0.24M CaCl2. The 
dissociation is not irreversible, the two proteins reassociate when the ionic strength is 
returned to physiologic levels (Cooper et al., 1973; Zucker et al., 1983).
Immunological evidence also suggested that the complex was composed of two distinct 
molecules. Antibodies raised against vWF, which were cross-linked to agarose beads, 
isolated both vWF and FVIII but the FVIII could be released upon equilibration with 0.24M 
CaCl2 (Tuddenham et al., 1979; Fulcher et al., 1982). Fulcher et al. (1982) produced 
antibodies against human FVIIIrC which precipitated FVIII:C in normal plasma but were 
unreactive against haemophilic plasma, containing functional vWF. The association between 
FVIII and vWF can be disrupted by exposure to thrombin (Davies et al., 1981).
The role of calcium in the FVIII/vWF complex was investigated by Mikaelsson et al.
(1983). They proposed that in normal plasma, FVIII circulates as a calcium-linked complex 
(with vWF). Upon exposure to EDTA (a chelating agent), the calcium is removed, the 
complex dissociates and coagulant activity is lost. It would, therefore, appear that Ca2+ ions 
are essential for FVIII coagulant function. They may also act as a stabiliser in the 
quaternary structure of the complex. The two proteins may also be linked by Ca2+ bridges. 
Using monoclonal antibodies, Foster et al. (1987) located a major binding site for FVIII in 
the first 272 residues of the amino terminal of each vWF subunit. Each monomer is capable 
of binding one FVIII molecule, but in vivo not all binding sites are occupied. Lollar et al. 
(1987) calculated a stoichiometry of 1.2 vWF monomers per FVIII molecule for porcine 
FVIII. Hamer et al. (1987a) found that one FVIII molecule was bound per four vWF, using 
a human in vitro system under saturating conditions with excess FVIII. Zucker et al. (1983), 
meanwhile, reported a ratio of one FVIII to eight vWF monomers.
The binding site for vWF has been localised in the light chain of FVIII between Val 1670- 
Glu 1684, using antibodies which inhibit the binding of FVIII to vWF (Foster et al., 1988). 
Thrombin cleavage at position 1689 in the light chain releases a 41-residue amino-terminal 
peptide, abolishing binding to vWF (Lollar et al., 1988). Thus, the binding site must be 
contained within this fragment, preceeding residue 1689.
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This region, containing a high proportion of acidic residues, also contains a sulphated 
tyrosine residue at position 1680. Mutation of this tyrosine to phenylalanine, with 
subsequent inhibition of sulphonation, reduces the affinity for vWF (Pittman et al., 1987). 
It can be concluded, therefore, that sulphonation of this Tyr residue is critical for a 
successful interaction between FVIII and vWF.
The reason for the complexation of FVIII to vWF in normal plasma seems to be the 
stabilisation of the coagulant protein (Weiss, 1977). The life-time of FVIII in the 
circulation is increased by binding to vWF (Tuddenham et al., 1982). The FVIIIrC is highly 
unstable in the absence of vWF, and is prone to proteolytic attack. Weiss (1977) suggested 
that the vWF protects the FVIII:C from proteolysis. vWF also functions as a carrier protein 
for FVIII. It localises FVIIIrC at the site of vascular damage, by binding to the sub- 
endothelial cells (Sakariassen et al., 1979) and to the thrombin-stimulated platelets.
1.8 The functions of FVIII and vWF
FVIII and vWF are both involved in haemostasis. FVIII is a component of the blood 
coagulation cascade and vWF is involved in platelet-sub-endothelial cell interactions. The 
importance of each of these proteins is evident from the bleeding disorders which result 
from deficiency or abnormality in either of them (classic haemophilia in the case of FVIII 
and von Willebrand disease in the case of vWF).
The function of FVIII is to act as a cofactor in the activation of Factor X (FX) during the 
intrinsic pathway of the blood coagulation cascade. It forms a complex along with Ca2+, 
phospholipids and activated Factor IX (FIXa) to achieve this activation. 1987). McGee et 
al. (1991) showed that blood monocytes can promote fast activation of FX by FIXa/FVIII. 
FVIII does not possess any intrinsic ability to activate FX, rather it is the enzymatic activity 
of FIXa which is responsible for the activation of FX. FIXa can slowly activate FX in the 
presence of Ca2+ and phospholipids without FVIII but the rate of activation is greatly 
increased (by as much as 104 fold) in the presence of FVIII (van Dieijen et al., 1981).
FX exists in normal plasma as a zymogen consisting of two polypeptide chains held 
together by one or more disulphide bridges.
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The heavy chain contains the active site, while the light chain contains the characteristic y- 
carboxyglutamic acid residues of the vitamin K-dependent clotting factors (Factors II, X and 
VII). These residues are responsible for the Ca2+-mediated binding of FX to phospholipids. 
Activation of FX involves cleavage of a specific peptide bond in the heavy chain, causing 
a peptide to be released from the amino terminal.
FVIII must also be activated from its precursor form. The single chain polypeptide is 
activated by proteolytic cleavage at specific sites. This modification can be achieved by 
thrombin and by activated factor X (FXa) (Vehar and Davie, 1980). FIXa has also been 
shown to activate FVIII (Rick, 1982). Although this activation is not as effective as that 
achieved by thrombin or FXa, it is important in producing initial levels of FVIIIa. 
Phospholipids play an important role in the FX activating complex. Both FX and FIXa bind 
to the phospholipid surface of the platelet by means of calcium bridges. It is thought that 
FVIII aligns FX and FIXa in such a way as to provide optimal conditions for the two to 
interact. The interaction of FVIII with phospholipid appears to cause the FVIII to become 
dissociated from vWF. Griffin et al. (1982) showed that thrombin-activated FVIII was 
unstable, but its stability was increased when bound to phospholipid. 
vWF fulfils dual roles in haemostasis. It forms a non-covalently linked complex with FVIII, 
stabilising and protecting the cofactor. It also plays a role in platelet plug formation. Here 
it acts as a ligand between the sub-endothelium at the site of vascular damage, and platelets 
in the arterial circulatory system (Roth, 1992). This function is dependent on the high shear 
rates characteristic of this system (Weiss et al. 1991). Under these conditions, vWF binds 
to a receptor on the platelet surface, GP-Ib (Roth, 1990) and to components of the sub­
endothelium, possibly type VI collagen (Rand et al., 1991). vWF thus acts as a linker 
between the platelet and the damaged arterial wall. In venous circulation the plasma 
coagulation system is predominant as the high shear forces necessary for the interaction 
between vWF and GP-Ib are not present.
vWF contains a number of binding sites associated with its functions in normal haemostasis. 
The FVIII binding site has been localised (Foster et al., 1987), as have those for GP-Ib 
(Mohri et al., 1989) and collagen (Pareti et al., 1987).
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1.9.1 The Deficiency disease of FVIII
Classic haemophilia is a hereditary disorder of blood coagulation caused by deficient or 
abnormal FVIII:C. It is inherited as a recessive sex-linked disorder and occurs in 
approximately 1 in 10,000 males.
Haemophilia B (also known as Christmas Disease, after the first patient diagnosed with the 
condition) is caused by a deficiency in FIXa. It is also a sex-linked disorder, unlike 
deficiency disorders of the other vitamin K-dependent factors (FII, FX and FVII) which are 
inherited as autosomal traits. The incidence of haemophilia B is about 1 in 40,000 males. 
Classic haemophilia (sometimes known as haemophilia A) and haemophilia B are clinically 
indistinguishable. The clinical features of classic haemophilia include abnormally prolonged 
or excessive bleeding, producing characteristic haematomas, extensive bruising, bleeding 
into joints and other forms of deep tissue bleeding. Patients with the disorder are prone to 
intra- and/or post-operative bleeding.
The severity of the disease (classic haemophilia) is dependent on the degree of deficiency 
of FVIII:C, the defect being constant throughout the life of the patient. Severe 
haemophiliacs are classed as having less than 5% of the normal level of FVIIIrC. Moderate 
cases have between 5% and 10% of the normal level and mild sufferers have between 10% 
and 15% of the normal FVIIIrC concentration.
Using human anti-FVIIIrC antibodies, FVIIIrCAg has been detected in approximately 10% 
of patients with severe haemophilia. This FVIIIrC was non-functional but was antigenically 
cross-reactive. These plasmas were designated cross reacting material positive (CRM+) and 
were later found to have normal antigen levels, while the coagulant activity was very low
(2%-10% of normal) (Lazarchick et al., 1978).
Studies using heterologous antisera, showed that all haemophiliac plasma contained normal 
levels of vWFAg. Thus, in haemophiliac patients, only the FVIIIrC activity is impaired, 
while the vWF function remains intact.
Lazarchick et al. (1978), using anti-human FVIIIrC antibodies, found a number of different 
patterns involving FVIIIrC and FVIIIrCAg. In severe haemophilia, there is no detectable 
FVIII coagulant activity but there are variable levels of FVIIIrCAg. Most sufferers have no 
FVIIIrCAg but in approximately one-quarter of severe haemophiliacs there are low levels 
of the antigen (1%-10% of normal).
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Almost all patients with mild or moderate haemophilia have detectable levels of FVHI:CAg, 
most having more FVILCAg than FVIILC. Some patients even have normal levels of 
FVIILCAg while the coagulant activity (FVIILC) is low. These are patients with CRM+ 
haemophilia. An X chromosome mutation which modifies the FVIILC structure, rendering
it inactive, is responsible for this condition.
Patients can now be screened by recombinant DNA analysis to find the genetic defects that 
cause haemophilia. Point mutations, deletions and insertions have all been identified 
(Tuddenham, 1989). Point mutations involving single nucleotides can cause premature 
termination of FVIII translation, resulting in a shorter, non-functional FVIIL Deletions in 
the FVIII gene result in severe haemophilia.
Female carriers of haemophilia have normal FVIILCAg levels but FVIILC is reduced (only 
half of the X chromosome directs synthesis). Even though the levels of FVIILC and 
FVIILCAg can change (e.g. during pregnancy), the ratio between the two remains constant 
(Hoyer et al., 1982).
With the advent of reliable methods of estimating FVIILCAg (Peake et al., 1978; 
Lazarchick et al., 1978), the prenatal diagnosis of haemophilia has become possible. Foetal 
blood samples obtained by foetoscopy can be assayed for FVIILC or FVIILCAg (Firshein 
et al., 1979).
1.9.2 Treatment of Classic Haemophilia
Factor VIII concentrates derived from pooled plasma were originally used in the treatment 
of haemophilia. Certain complications arose over the use of such products as the risks of 
blood-borne diseases, hepatitis and AIDS (from HIV) became apparent. Screening of donors 
and heat-inactivation of blood products reduced, but did not remove, the risks posed by 
these viruses. Peertinck and Vermylen (1993) reported cases of hepatitis A infection in 
haemophilic patients treated with a solvent/detergent-treated FVIII concentrate. The use of 
recombinant FVIII (rFVIII) in the treatment of previously treated haemophilic patients was 
reported by White et al. (1989). They found that the recombinant protein was effective in 
the control of haemostasis and had several practical advantages over plasma-derived FVIII.
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Schwartz et al. (1990) also used rFVIII and found that the low frequency of inhibitors was 
consistent with studies using plasma-derived FVIII concentrates. Lusher et al. (1993) 
administered rFVIII to previously untreated patients and found that it was well tolerated and 
that patients responded well to treatment. There was, however, a relatively high incidence 
of low titre inhibitor antibodies. Despite this, the authors concluded that the benefits of a 
recombinant FVIII outweighed the risks.
Cases have been reported where patients have developed inhibitors to monoclonal antibody- 
purified FVIII (Bell et al. 1990; Kessler et al., 1990; Montoro et al., 1991). These cases 
were unusual in that the inhibitors developed under conditions not normally associated with 
inhibitor production. These may be related to the use of highly purified FVIII, where new 
immunogenic regions have been recognised.
The presence of inhibitors creates problems in the treatment of haemophilia. To overcome 
such problems, patients were treated with activated prothrombin complex concentrate 
(aPCC), containing porcine FVIII or activated factor IX. Hedner et al. (1988) showed that 
activated factor VII (FVIIa) was capable of inducing haemostasis in haemophilia, and he 
successfully used recombinant FVIIa (rFVIIa) during synovectomy on a haemophilic patient. 
Ingerslav et al. (1991) also reported the successful use of rFVIIa during oral surgery.
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1.9.3 Inhibitors to FVIII
Inhibitors to FVIII are pathologic circulating IgG antibodies which specifically neutralise 
the procoagulant activity of FVIII (Kessler et al., 1990). They develop in 5-15% of patients 
who receive factor VIII replacement therapy (Shapiro, 1984), with two-thirds of these cases 
developing inhibitors in the first 20 years of life (McMillan et al., 1988). Algiman et al. 
(1992) found, however, that 17% of normal sera taken from healthy blood donors contained 
FVIII-neutralising IgG antibodies.
The risk of severe haemophiliacs, i.e., those with FVIII activity less than 5% of normal, 
developing inhibitors in the first 25 years of life is 2% (Schwarzinger et al., 1987). 
Children under five are four times more likely to develop inhibitors than adults, as are 
patients with FVIII:C levels less than 0.03 U/ml (McMillan et al., 1988; Ehrenforth et al.,
1992). McMillan et al. (1988) also found that high titre inhibitors appeared less than 75 
days after exposure to FVIII, with all inhibitors appearing within 250 days.
Ewing et al. (1988) induced immune tolerance to FVIII in haemophiliacs with inhibitors, 
using 50 U/kg body weight of FVIII. The treatment was particularly effective for patients 
with low levels of inhibitors. They proposed that the treatment was suitable for patients with 
low levels of inhibitors who had not been exposed to high levels of FVIII since developing 
the antibodies. The procedure was, however, expensive.
1.10 vWF Disease
von Willebrand disease is the condition which results from deficiency or abnormality in 
vWF. It is an autosomal disorder which can appear in a severe, mild or moderate form. 
Type I von Willebrand disease is probably the most common form of the disorder. Levels 
of both FVIII and vWF are decreased, and bleeding time is prolonged. The multimeric 
composition of the complex is normal and vWF can be detected in endothelial cells.
Type II von Willebrand disease is characterised by the lack of the large vWF multimers in 
plasma. In Types HA and IIB, ristocetin cofactor activity is affected. FVIII:C is normal or 
reduced in both cases. In Type IIC, the repeating triplet in normal vWF is replaced by a 
repeating doublet.
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Type III von Willebrand disease is the most severe form and is relatively uncommon. 
There is no ristocetin cofactor activity, no detectable vWFAg, and no vWF can be detected 
in endothelial cells.
1.11.1 Biosynthesis of FVIII
The exact cellular site of synthesis of FVIII is unclear, but the liver has been proposed as 
the primary site of synthesis. Transplantation studies in haemophilic dogs (Marchioro et al., 
1969; Webster et al., 1971) and in patients (Lewis et al., 1985; Bontempo et al., 1987;) 
have shown that replacement of normal livers increases FVIII coagulant levels. FVIII 
mRNA has been detected in many tissues, including liver, kidney, spleen and lymph nodes 
(Wion et a l, 1985). FVIII antigen has also been detected immunochemically in hepatocytes 
using both light (Kelly et al., 1984) and electron microscopy (Zelechowska et al., 1985). 
No known naturally derived cell lines express FVIII. With the discovery of the FVIII gene, 
mammalian cells can now be transfected with copies of this gene allowing expression of 
the protein in culture. Kaufman et al. (1988) successfully transfected Chinese hamster ovary 
(CHO) cells and were able to study the probable biosynthetic pathway of FVIII.
The protein is synthesised as a 2351 amino acid chain, the first 19 of which are lost during 
translocation into the lumen of the endoplasmic reticulum (e.r.). In the e.r. a considerable 
proportion of the FVIII binds to a resident protein GRP78 (also known as BiP, 
immunoglobulin binding protein) (Domer et al., 1987). It is not known whether this FVIII 
is subsequently secreted or degraded. High-mannose oligosaccharides are added to 
asparagine residues in the "free", i.e., unbound FVIII. The protein is released from the e.r. 
and enters the Golgi apparatus. Here, the majority of the FVIII is cleaved, generating the 
heterologus heavy chain amino-terminal-derived fragments, and the COOH-terminal-derived 
light chain. Modifications are also carried out. Carbohydrates are added to serine and 
threonine residues. The asparagine-linked high mannose oligosaccharides are modified to 
complex types, and specific tyrosine residues in both the heavy and light chains are 
sulphonated.
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In the presence of vWF in the medium, the heavy and light chains associate upon secretion, 
forming a stable complex with vWF. In the absence of vWF, the chains do not associate 
and are degraded. When vWF is co-expressed by the cells, synthesis and secretion of FVIII 
remains unaffected, but recovery of the protein in the medium is higher (Kaufman et a l,
1989).
1.11.2 Biosynthesis of vWF
von Willebrand factor (vWF) circulates as a large glycoprotein consisting of a series of 
multimers ranging in size from 500 to 2000 kDa. (Chopek et a l, 1986). It is synthesised 
in endothelial cells (Jaffe et al., 1973) and megakaryocytes (Nachman et al., 1977), as a 
2813 residue polypeptide of approximately 360 kDa (pro-vWF), including a 741-residue, 
95 kDa propeptide. This propeptide functions in the multimerisation process and is cleaved 
during post-translational processing in the Golgi apparatus (Wagner et al. 1990).
The pro-vWF subunits dimerise, through the formation of disulphide bridges at the carboxyl 
terminal, to form the protomer of the multimeric series (Sadler, 1991). These protomers 
undergo a certain amount of processing including cleavage of the pro-peptide (Wagner et 
al., 1990), glycosylation, sulphonation (Browning et al., 1983) and further disulphide 
formation. These bonds, involving cysteine residues at the amino-terminals, link the 
protomers to form the biologically functional multimers.
The multimerisation process is believed to take place in the Golgi apparatus (Wagner et a l, 
1986) and is dependent on the presence of the pro-peptide, an acidic pH - less than 6.2 with 
an optimum of 5.8 - and the presence of free sulphydryl groups on the vWF protomer 
(Mayadas et al., 1989). These multimers are then either secreted constitutively (Spom et al.,
1986) or stored in specialised storage organelles called Wiebel-Palade (W-P) bodies 
(Wagner et a l, 1982). The two pools of vWF (i.e., those secreted and those stored in the 
W-P bodies) are structurally different. The secreted vWF is largely dimeric, with pro-vWF 
and mature subunits also present (Spom et a l, 1986). In constrast, the stored vWF in the 
W-P bodies consist only of large multimers (the biologically active form of vWF). Free 
propeptide is also present in a stoichiometry of 1:1 with the multimers.
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vWF multimers also occur in the a-granules of platelets (Cramer et al., 1985).
The release of stored vWF can be triggered by a-thrombin (Spom et al., 1986), plasmin, 
adrenalin, bradykinin and interleukin-1 (Booth et al., 1987).
1.12 Analysis of FVIII
The diagnosis of bleeding disorders, including haemophilia A, depends on the ability to 
analyse the blood coagulation system in conjunction with the patient’s bleeding history. It 
has proved extremely difficult to reproduce the entire coagulation cascade in vitro because 
of the complexity of the coagulation process. Therefore, only partial components of the 
process can be analysed at one time. An example of one such assay is the Activated Partial 
Thromboplastin Time (APTT). This test is used to screen components of the intrinsic phase 
of blood coagulation (Figure 1.1). APTT reagent contains phospholipids and a contact phase 
activator (a negatively charged compound). Patient plasma is incubated with the APTT 
reagent and CaCl2 is then added. The time taken for the formation of a clot (the Activated 
Partial Thromboplastin Time) is measured in seconds. Normal clotting times are between 
20 and 30 seconds, with an increase of 10 seconds or more in this time indicating a defect 
in the clotting system. Prolonged APTT may be due to a deficiency or abnormality in one 
or several of the factors in the intrinsic phase of the coagulation process, the presence of 
coagulant inhibitors or heparin. APTT reagents may differ in their contact activator (the 
most common being allagic acid, glass, charcoal, celite or kaolin) and the origin of the 
phospholipids (brain extracts, placenta and plant phospholipids being the most widely used).
The need to quantitate levels of anti-haemophilic factor (FVIII) in the diagnosis of 
haemophilia led to the development of biological assays for the measurement of FVIII 
coagulant activity in the 1950’s. The one-stage assay developed by Langdell et al. (1953) 
was the first of these. Biggs et al. (1955) developed an assay based on the thrombin 
generation test, called the two-stage assay. This assay formed the basis of most of the 
assays carried out today, although some modifications have been made. Denson (1976) 
simplified the method, allowing for the possibility of automation, and Rosen et al. (1984) 
used a chromogenic substrate for the detection of FXa.
23
Lazarchick et al. (1978) and Peake and Bloom (1978) developed immunoradiometric assays 
for the detection of FVIII:CAg, using inhibitor antibodies from haemophilic patients. This 
opened a whole new field in the detection of FVIII - the use of immunological techniques. 
Dinesen (1983) developed the first ELISA using peroxidase-labelled inhibitor antibodies. 
Recent modifications to this method include the use of F(ab’)2 fragments and microtitre 
plates (Nordfang et al., 1983) and the use of monoclonal antibodies (Jourquera, 1989). The 
avidin-biotin complex has also been used to increase the sensitivity of the assay (Tackaberry 
et al., 1987). Recent advances in biosensor technology have led to an increasing number of 
novel techniques. Included in these are sensors which can monitor the coagulation process 
and detect factor VIII (Muramatsu et al., 1991).
1.12.1 Estimation of FVIII:C
The one-stage clotting assay: This assay, developed by Langdell et al. (1953), is based on 
the ability of FVIII to correct the prolonged clotting time of FVIII-deficient plasma to a 
degree determined by the amount of FVIII present. Phospholipids are added to the plasma 
(as a substitute for platelets) along with an activator (e.g., kaolin) to provide a negatively 
charged surface to initiate the cascade. Ca2+ ions are also added to start the FVIII-dependent 
part of the coagulant cascade.
The assay may be influenced by contamination with coagulation factors that act 
subsequently, particularly when the samples being measured are blood-derived. Clotting 
times are also shortened by traces of thrombin and tissue factor. Thus, the assay suffers 
from a lack of specificity. However, the assay does have the advantage of being rapid and 
simple.
The two stage assay: This was developed by Biggs et al. (1955) and is based on the 
formation of activating complexes (Figure 1.12). In the first stage, FVIII is added to a 
source of FIXa, Ca2+ and phospholipids (PL). These form a complex which activates FX 
(FXa). FXa in turn forms prothrombinase along with FV, Ca2+ and PL. In the second stage, 
prothrombin and fibrinogen are added, resulting in the formation of a clot.
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This assay provides a more direct measurement of FVIII and is less susceptible to the 
influence of other factors. However, it can give artificially high levels of FVIII in FVIII 
concentrates (Kirkwood, 1978) but it detects relatively more activity in the more highly 
purified preparations than does the one-stage assay (Kirkwood, 1977).
Chromogenic Assay: Seghatchian et ah (1978) modified the two-stage assay by using a 
highly selective FXa substrate, S-2222, which released p-nitroaniline, (pNA), when 
hydrolysed by FXa. The free pNA could be measured by a spectrophotometer at 405nm. 
The assay was somewhat insensitive for detecting low levels of FVIII, and so Rosen et al.
(1984) developed a chromogenic assay, using bovine coagulation factors, which proved to 
be highly sensitive, accurate and had a high degree of precision. A thrombin inhibitor, I- 
2581, was included to prevent hydrolysis of the substrate by thrombin, van Dieijen et al. 
(1987) developed a similar assay for the detection of human FVIII in plasma and 
Wagenvoord et al. (1989) modified this assay for clinical use, using lyophilised reagents 
and minimising the number of pipetting steps. The assay was highly sensitive, detecting less 
than 1% FVIII:C. In addition, the lyophilised reagents could be stored for several months. 
Mazurier et ah (1990) compared the different FVIII coagulant assays, and the effect of pre­
diluent, using high purity FVIII concentrates. They found that shorter clotting times were 
always obtained when using the one-stage assay, when the concentrate was diluted in FVIII- 
deficient plasma. However, the prediluent had less influence on the chromogenic assay than 
on the one-stage assay. Therefore, they concluded that the use of the chromogenic assay, 
with FVIII-deficient plasma as a diluent, provided the best results.
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STAGE 1
(a) Formation of Complex 1
FVin + FIXa, Ca2+, phospholipids ----------------------- » Complex 1
(b) Activation of FX and the formation of Complex 2
Complex 1 + FX ------------------------ » FXa
+
Ca2+, phospholipids, FV .......  > Complex 2
STAGE 2
Complex 2 
Prothrombin------------------------
Fibrinogen------------------------------ > Fibrin
Clot
Figure 1.12.1 The two-stage clotting assay. FVHI forms a complex with activated factor 
IX (FIXa), Ca2+ and phospholipids which activates factor X (FX). This in 
turn forms a complex with factor V (FV), Ca2+ and phospholipids which, 
in the second stage of the assay, leads to the formation of an insoluble clot.
-» Thrombin
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1.12.2 Estimation of FVIIICAg
The immunological properties of FVIILC have been studied, using antibodies from multi­
transfused haemophilic patients who have developed inhibitors, or from patients with 
autoantibodies. Quantitative immunoradiometric assays for the determination of FVIII:CAg, 
utilising radiolabelled human antibodies, were developed. These assays, consisting of either 
a two-site solid phase immunoradiometric assays (Lazarchick and Hoyer, 1978; Peake and 
Bloom, 1978) or a one-site fluid phase immunoradiometric assays (Rotblat and Tuddenham, 
1981) showed a good correlation between FVIII:C and FVIILCAg in normal plasma. 
These assays made use of polyclonal antibodies which differed in their specificities and 
affinities. With the advent of monoclonal antibody technology, anti-FVIII:C antibodies with 
defined specificities and affinities were produced. Muller et al. (1981) described a 
monoclonal antibody against FVIILC which neutralised FVIII:C. They used this antibody 
in an immunoradiometric assay (IRMA) for FVIILCAg. Similarly, Brown et al. (1983) 
described a one-step two site IRMA for FVIILCAg in which I125-labelled monoclonal IgG 
was used to detect FVIII:CAg.
One of the first enzyme-linked immunosorbent assays (ELISA) for estimation of FVHLAg 
was developed by Dinesen et al. (1983). They used protein A-purified IgG from 
haemophilic patients with inhibitors. The ELISA was carried out using polystyrene cuvettes 
as the solid phase. The inhibitor antibody was bound to this, test samples were added, and 
bound antigen was detected using horseradish peroxidase (HRP)-labelled inhibitor IgG. 
Nordfang et al. (1985) and Ingerslev et al. (1986) both describe a micro ELISA using 
inhibitor antibodies from haemophilic patients. Polystyrene microtitre plates were used as 
the solid phase and bound FVIILC was detected using HRP-labelled F(ab/) fragments of 
the inhibitor antibody. Use of these fragments resulted in decreased non-specific binding 
(caused by the Fc portion of the antibody molecule).
Jorquera et al. (1989) developed an ELISA in which the test antigen was sandwiched 
between a polyclonal human anti-FVIII antibody bound to the solid phase and a commercial 
anti-FVIII monoclonal antibody. Any bound monoclonal antibody was detected using a 
polyclonal goat anti-mouse IgG labelled with HRP.
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Hawes et al. (1982) developed a procedure for the assay of antibodies in sera based on the 
application of the antigen as a spot on nitrocellulose paper. This system requires only 
microgram quantities of antigen, but it is prone to a greater degree of non-specific binding. 
Tackaberry et al. (1987) used the avidin-biotin amplification system to detect picogram 
quantities of FVIILCAg. The sensitivity of the assay can be attributed to the capacity of 
nitrocellulose paper to bind proteins, the high titre of monoclonal antibodies for FVIII, and 
the amplification of the second antibody signal by the avidin-biotin complex.
Muramatsu et al (1991) have developed a biosensor which they used to detect factors VIII 
and IX. They employed a quartz crystal viscosity sensor with a monitoring system made 
up of 16 oscillating circuits, a channel selector, a frequency counter, a temperature 
controller and a microcomputer. The resonant frequency of quartz crystal is known to vary 
with changes in the viscosity of a liquid and, thus, can be used as a viscosity monitoring 
sensor. The authors used this device to monitor the coagulation procedure. The FVIII (or 
FIXa) was incubated along with an activated partial thromboplastin time reagent with pre­
incubated FVIII- (or FIXa-) deficient plasma. CaCl2 was also added. The mixture was 
poured over the quartz crystal sensor and the resonance frequency monitored.
The use of factor VIII in replacement therapy in the future will very much depend on the 
availability of essentially pure contaminant-free supplies of the protein. The availability of 
pure, contaminant free FVIII has meant that giant steps forward have been possible in the 
understanding of FVIII and its role in haemostasis (Kaufman, 1991). This in turn could 
lead to novel techniques for the treatment of, and perhaps ultimately a cure for, 
haemophilia.
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1.13 Monoclonal Antibody Production
1.13.1 Introduction
By definition, all of the antibody produced by a single clone, will have the same 
specifity and affinity for the target antigen. It is not possible to isolate individual B- 
lymphocytes and grow them in culture, as they have a finite life-span. Kohler and 
Milstein (1975) described the technique of cell hybridization, fusing an immunized 
splenocyte with a myeloma cell (Figure 1.13.1). Tumor cells have an infinite life-span, 
and, thus, the hybrid cells inherit the ability to survive in culture from the myeloma, and 
the ability to secrete antibody from the lymphocyte. The importance of monoclonal 
antibodies has increased enormously in recent years. Today, the applications of 
monoclonal antibodies (MAbs) are wide-spread, from clinical use in the diagnosis and 
treatment of disease, to preparative uses as well as uses in basic research (Campbell, 
1984; Peters and Baron, 1993). New technologies including human MAbs, bispecific, 
catalytic and recombinant antibodies (Peters, 1993b) are constantly being developed.
1.13.2 Antigen
The production of monoclonal antibodies is dependent on a number of factors. The 
antigen should be capable of eliciting a good immune response. Proteins and large 
molecules are good immunogens, eliciting a good immune response. Some antigens, i.e., 
those with low molecular weights, are too small to be immunogenic and must be 
conjugated to a protein carrier such as bovine serum albumin (BSA), ovalbumin, 
thyroglobulin or keyhole limpet haemocyanin (KLH). Immunisation with these 
conjugates, however, results in the production of antisera against determinants on the 
carrier protein as well as against the antigen (Tijssen, 1985).
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Myeloma cell Spleen Cell 
(immunised with 
specific antigen)
FUSE
FREEZE AND STORE 
IN LIQUID NITROGEN
HYBRIDOMA
SCREEN
V
HYBRIDOMA SECRETING 
SPECIFIC ANTIBODY
MONOCLONAL ANTIBODY SOLUTION
Purification
Antibody 
PURE SPECIFIC ANTIBODY
Figure 1.13.1 The Production of Monoclonal Antibodies.
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1.13.3 Adjuvant
Adjuvants are used to enhance the immune response. They stimulate non-specific 
production of antibody and cause a polyclonal activation of the immune system. 
(Baumgarten, 1993). The most commonly used adjuvants are Freund’s complete (CFA) 
and incomplete (IFA) adjuvant, but aluminum hydroxide can also be used. Freund’s 
adjuvant consists of water-in-oil emulsions, with heat-inactivated Mycobacterium 
tuberculosis also present in CFA. The antigen is injected emulsified in CFA or IFA and 
is slowly released from the emulsion, prolonging exposure to the immune system. CFA 
is used only for the first immunisation, with boosting being given with IFA. 
Aluminum hydroxide can also be used as an adjuvant, and is commercially available in 
ready-to-use forms (Tijssen, 1985). It is also possible to immunise with antigens bound 
to a solid matrix such as Sepharose, nitrocellulose paper or acrylamide gel, even after 
staining with Coomassie Blue. The incorporation of antigen into polymers which then 
release them slowly, without causing damage to the animal, has also been described 
(Schroder and Stahl, 1984; Gurvick and Korukova, 1986; Kohn et al., 1986). Antigens 
can also be incorporated into liposomes. These consist of phospholipid double layered 
membranes, separated by an aqueous phase and can be prepared from nonimmunogenic, 
biologically degradable materials (Baumgarten, 1993). No adjuvant is required when 
cells are used as immunogens.
1.13.4 Immunisation Protocol
Rats and mice are generally used for the generation of MAbs. Larger animals, such as 
rabbits, sheep, goats and donkeys are used for the production of polyclonal antibodies. 
The site of immunisation can influence the immune response (Baumgarten and Schulze,
1993). Antigens can be injected at a number of different sites: intradermally, 
intraperitoneally, intravenously, intraorally, intrasplenically, intramusculary and 
subcutaneously. The difference in injection sites affects the speed with which the antigen 
is presented to the immune system. Injections may be given at single or at multiple-sites. 
The amount of antigen required to elicit an immune response is small. An animal is 
typically immunised with between O.lmg/ml and lmg/ml of a soluble antigen (e.g., a 
protein) in adjuvant and between 106 and 107 cells without adjuvant (Campbell, 1984).
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Injections can be given at 2-4 week intervals. Animals are bled after 2 weeks and the 
antibody levels measured.
Immunisation can also be carried out in vitro. This is particularly relevant to the 
production of human MAbs as in vivo immunisation is not feasible. There are a number 
of advantages over the in vivo system: the concentration of antigen required is smaller 
(pg rather than mg quantities), the system is less complex and allows responses against 
self-antigens, it is a simple and rapid method, with immunisations complete in 3 to 5 
days as opposed to several weeks. There are also disadvantages to the system. The 
responses are mainly primary producing predominantly IgM antibodies. However, a 
secondary response may be obtained if the animal used as a source of lymphocytes is 
given an in vivo immunisation 28 days or more prior to in vitro immunisation (De Boer 
et a l, 1988).
A rich source of B-lymphocytes as well as a source of T-cell derived growth factors 
(supplied by T-cell conditioned medium) are essential for this system.
1.13.5 Feeder Cells and Conditioned Medium
Feeder cells or conditioned medium are used during the production of MAbs and are 
essential during the cloning of hybridomas. Newly formed hybridomas do not grow well 
at low densities. They require the presence of a monolayer of non-growing cells. Feeder 
cells should have a limited lifetime and should be able to provide metabolites which 
nourish the hybridomas during initial stages of growth (Peters, 1993a). Macrophages are 
commonly used as feeder cells. They are actively phagocytic and provide an excellent 
post-fusion clean-up mechanism, removing dead myeloma and parent lymphocytes 
(Campbell, 1984).
Alternatively, conditioned media provide a convenient source of soluble growth factors 
to cells without the problems of feeder cells. Growth factors like interleukin-6 (IL-6) are 
used to promote hybridoma growth and have proved to be highly successful (Debus et 
al., 1993). Problems can arise with the use of such additives, including variation 
between batches, increase in protein concentration and an increase in undefined 
substances (Debus et al., 1993). Some of these problems can be overcome with the use 
of a defined substance like a recombinant protein, e.g. recombinant IL-6.
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1.13.6 Myeloma Cell Lines
In order to perform a successful fusion, the myeloma cell line must satisfy a number of 
criteria. It must not secrete antibody itself, it must have an enzymatic defect which 
allows for the selection of hybridomas, and it must show good fusion properties. The 
cells should originate from the same system as the immunised splenocytes (the murine 
system is generally used). Balb/c mice are the usual strain of mouse chosen for 
immunisation as they are compatible with all murine myeloma cell lines. Hybridomas 
can subsequently be grown as an ascitic tumor in Balb/c mice. In the human system, no 
cell lines exist so far with anything like the favourable properties of the mouse myeloma 
cell lines. As a result, human myeloma cells, lymphoblastoid cell lines or 
heteromyelomas are used (Baron, 1993a). Epstein-Barr Virus (EBV) is used in the 
transformation of human B-lymphocytes, producing immortalised B-cells which are still 
capable of synthesising specific antibody. This enables the generation of monoclonal 
antibodies without involving cell fusion (Baron, 1993a).
1.13.7 Fusion Procedures
Early fusions used inactivated viruses, such as Sendai virus to fuse cells but chemical 
fusogens have replaced these. Polyethylene glycol (PEG) is the major chemical used. 
The exact mechanism by which it acts has not been elucidated, although it is known to 
be a complex one, involving cell agglutination, membrane fusion and cell swelling 
(Campbell, 1984). The molecular weight of PEG is variable, molecular weights between 
1000 and 6000 have been successfully used (Fazekas de St. Groth et al., 1980).
The temperature at which the fusion takes place is critical. PEG is held at 37°C until it 
is added to the fusion mixture. Too low a temperature hinders the production of clones 
after a fusion step (Campbell, 1984).
Other methods for fusion are also available. The use of viruses was the original method 
used by Kohler and Milstein in 1975. Herpes-, myxo- and paramyxoviruses contain 
proteins which are capable of mediating fusion. The frequency of hybridization is lower 
however, than that achieved by PEG (Baron, 1993b).
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Cells can also be fused by electrofusion. Using this method, the frequency of 
hybridisation can be increased 500-fold as compared with chemically mediated fusion. 
(Baron, 1993b). The process consists of two stages:
(i) Dielectrophoresis - leading to cell-cell contact. Here, an AC current is applied and 
the cells migrate to form a chain between the electrodes. This is called pearl chain
formation.
(ii) Pulsing. A high voltage is applied which induces pore formation, allowing mixing 
of adjacent cell contents. The membrane reforms around the two adjacent cells forming 
a hybrid cell.
1.13.8 S election of Hybridomas
The fusion procedures do not have a hybridisation frequency of 100%. Therefore, after 
the fusion, there will be unfused cells present, as well as the fused hybridomas. 
Lymphocytes will die off naturally with time, while macrophages or other cells used as 
feeder cells will grow slowly, or not at all. The myeloma cells are capable of survival 
in culture, and within a short period of time, will outgrow the hybridomas. A selection 
method must, therefore, be used which allows for growth of the hybridomas but not of 
the myeloma cells. The myeloma cell line should contain a selective drug marker, which 
allows for post-fusion selection of the hybridomas.
Nucleic acids can be synthesised by two pathways - the de novo main metabolic 
pathway and the salvage pathway (Figure 1.13.8). If there is a defect in the main 
pathways, the cell is still capable of survival, provided there are exogenous supplies of 
nucleosides.
Aminopterin blocks the main metabolic pathway for the synthesis of purines and 
pyrimidines, by inhibition of the enzyme dihydrofolate reductase. The cell can switch 
to the salvage pathways provided exogenous nucleosides are provided. Hypoxanthine is 
utilized in the synthesis of purines, by the enzyme hypoxanthine guanine phosphoribosyl 
transferase (HGPRT). Thymidine is utilized in the synthesis of pyrimidines, by the 
enzyme thymidine kinase (TK). Myeloma cell lines may be deficient in one of the 
enzymes (HGPRT or TK) and so, if the main nucleic acid metabolic pathway is blocked, 
the cells are unable to synthesise either pyrimidines or purines and, thus, are unable to 
survive.
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Figure 1.13.8 The synthesis of DNA precursors. There are two pathways leading to the 
production of DNA, the de novo pathway and the salvage pathway. Cells 
normally utilise the de novo pathway, but in the presence of aminopterin, 
this route is blocked. The cell can switch to the salvage pathway 
provided exogenous nucleosides (hypoxanthine and thymidine) are 
supplied. Myeloma cells contain a genetic defect in that they do not have 
the enzymes (thymidine kinase (TK), or hypoxanthine guanine 
phosphoribosyl transferase (HGPRT)) to utilise these nucleosides and 
they subsequently die. Hybridoma cells survive because of their ability 
to utilise the salvage pathway inherited from the lymphocyte.
Cells can be made deficient in one of these enzymes by growing them in 
bromodeoxyuridine (which selects for TK-negative cells) or 8-azaguanine or 6- 
thioguanine (which selects for HGPRT-negative cells).
The immunised B-lymphocytes used in the fusion contain no enzymic defect. The 
hybridomas formed after fusion will not have the genetic defect either, because of 
genetic complementation, i.e., the B-lymphocyte will compensate for the defect in the 
myeloma. The hybridoma will therefore be insensitive to the aminopterin, as it can use 
hypoxanthine and thymidine. The myeloma cells cannot and they die.
1.13.9 Large Scale Production of Antibodies
Large amounts of MAbs can be produced in vivo or in vitro. The method chosen is 
dependent on the amount of antibody required and also in the facilities available. 
Antibodies can be produced in vivo as ascitic fluid (Baumgarten and Peters, 1993). This 
is grown in the peritoneal cavity of a primed mouse. Priming can be carried out with 
pristane (2,6,10,14-tetramethylpentadecane) or IFA (Baumgarten and Peters, 1993). 
Ascitic fluid contains about l-10mg/ml of antibody and each mouse can yield up to 
10ml of fluid (Campbell, 1984). The ascites is, however, contaminated with mouse 
immunoglobulins.
Production in vitro involves the growth of hybridomas in large culture vessels 
(bioreactors). The concentration of antibody in these systems is less than that of ascites 
(about lOOpg/ml) (Campbell, 1984) but the end product has a higher degree of purity. 
The supernatants may contain contaminating foetal calf serum (FCS) which is used in 
the growth medium. To remove this, cells can be grown in serum-free medium prior to 
harvesting. A wide range of methods are available for the production of MAbs in vitro: 
from culture flasks, spinner flasks and roller bottles for laboratory use, to large scale 
fermenters and hollow-fibre systems for industrial production (Franze and Baumgarten, 
1993).
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1.14 Protein Stabilisation
1.14.1 Introduction
The generation of stable or stabilised proteins is one of the main priorities of modem 
biotechnology. The requirement for protein use in biotechnological industries such as 
therapeutics, diagnostics, bioreactors, fine chemicals and biosensors requires molecules 
be highly stable, have a long shelf-life and be able to withstand the harsh conditions 
experienced in these applications.
There are many ways of analysing protein stability. In studying thermodynamic stability, 
a number of physical parameters are monitored, to detect changes in the protein structure 
caused by the unfolding and dénaturation of the native structure. The reversible change 
in the proportions of these states make it possible to calculate the thermodynamic 
parameters of dénaturation - AGD, the free energy value of dénaturation, AHD, the 
enthalpy of dénaturation, ASD, the change in entropy, which is characteristic of the 
degree of protein unfolding, and Acp, the change in heat capacity on dénaturation 
(Mozhaev, 1993).
Long-term stability is the ability of a protein to withstand irreversible changes of 
structure under denaturing conditions. To measure this, protein is heated to a high 
temperature, samples removed at intervals and assayed for activity. The rate of 
disappearance of the native form of the protein (Vin), is considered a quantitative 
measure of long-term stability.
Using these parameters, it is possible to study and compare the loss of activity of a 
native protein and mutant or modified protein.
1.14.2 Protein Dénaturation
It is important to distinguish between the terms "dénaturation" and "inactivation" . 
Dénaturation refers to the conformational changes (usually unfolding) that result in the 
loss of molecular function; these changes may or may not be reversible. Inactivation, on 
the other hand, is caused by changes in the degree of association or aggregation of the 
molecule, along with possible primary structural changes, such as peptide bond 
hydrolysis or destruction of amino acid side chains (Ô Fâgâin and O ’Kennedy, 1991). 
Such changes are irreversible.
Inactivation is considered to be a two-step process:
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K k
N < » U -— > I
while dénaturation is an "all-or-nothing" transition between the two states:
K
N < > U
where N is the native form, U is the reversibly unfolded form and I is the irreversibly 
inactivated form of the protein. K is the equilibrium constant for the transition from the 
native state (N) to the unfolded state (U) and k is the rate constant for the transition 
from the reversibly denatured state (U) to the irreversibly inactivated state (I). 
Inactivation mechanisms involve specific changes in protein structure. The relative 
importance of a particular mechanism is dependent on the experimental conditions. 
Ahem and Klibanov (1985) showed that at 90°C, the primary cause of inactivation of 
ribonuclease A at pH 4 was hydrolysis of peptide bonds while, at pH 8, reactions 
involving disulphide bonds were the major inactivation mechanism.
The inactivation rate depends on both K and k. Therefore, strategies to increase protein 
stability will alter these rates by preventing unfolding (decreasing K) or decelerating the 
inactivation process (k).
1.14.3 Stabilisation of proteins
There are a number of approaches to the stabilisation of proteins. The most commonly 
used ones are as follows:
(i) Use of additives
(ii) Suspension of proteins in organic solvents
(iii) Immobilisation
( iv ) Protein engineering
(V) Chemical modification
(Vi) Screening for stable proteins
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1.14.3.1 Use of Additives
A variety of compounds can be used to increase the stability of proteins in solution or 
when undergoing processes like freeze-drying. These include sugars (sucrose), salts 
(ammonium sulphate), polyols (glycerol), and other proteins (O Fagain and O’Kennedy, 
1991).
1.14.3.1.1 Osmolvtic stabilisers
Osmolytic stabilisers are compounds which are not strongly charged and have little 
effect on the protein activity up to concentrations of at least 1M (Yancey, 1973). Their 
major effects are on the viscosity and surface tension of water and hence on solvent 
ordering. Osmolytes can be polyols, sugars, polysaccharides, neutral polymers, amino 
acids and their derivatives, and large dipolar molecules like trimethylamine N-oxide 
(TMAO) (Schein, 1990). Glycerol is the most commonly used osmolyte. Its stabilisation 
effect on proteins seems to be due to its ability to enter into and strengthen the lattice 
structure of water (Schein, 1990). Xylitol is a good alternative to glycerol (which is an 
excellent substrate for bacteria).
1.14.3.1.2 Ionic stabilisers
Ionic compounds and salts can stabilise protein structure by shielding surface charges. 
A particular salt is stabilising or destabilising depending on its position in the
Hofmeister lyotropic series:
(CH3)4N+ > NH4+ > K+, Na+ > Mg"+ > Ca2+ > Ba2+
S 042+ > Cl' > Br > NO; > C104 > SCN
Both cations and anions are ranked in order of their stabilising effects. Therefore, 
(NH4)2S 04 should be a strong stabiliser whereas NaSCN should destabilise proteins. The
stabilising ions "salt out" hydrophobic residues in the protein causing the adoption of
a more compact structure.
39
1.14.3.1.3 Dénaturants, chaotrophs, cryoprotectants and other additives 
It is possible to solubilise almost any protein (usually at the expense of its activity) by 
chemical dénaturation with perturbing ions. Urea stabilises the unfolded states of 
proteins because essentially all protein parts are more soluble in 6M urea than water 
(Schein, 1990).
Another class of dénaturants, "chaotrophs" like guanidinium, disrupt hydrogen bond 
formation and disturb the hydration shell around proteins (Gekko and Timmasheff,
1981). Organic solvents are another class of dénaturants. The denaturing activity of 
hydrophobic solvents is due to a limited detergent effect and the provision of a 
competing interaction for the intramolecular hydrophobic interactions responsible for a 
stable tertiary structure.
Some organic solvents such as dimethylsulphoxide (DMSO) and ethylene glycol, are 
used as cryoprotectants. They maintain the native protein conformation at temperatures 
below the freezing point of water.
1.14.3.2 Proteins in organic solvents
Enzyme catalysis in organic solvents is being increasingly used for a variety of 
applications. It is possible to catalyse unusual reactions with enzymes in bi-phasic 
aqueous-organic systems. However, certain rules govern the activity of enzymes in such
systems:
(i) the solvent must be hydrophobic and show little affinity for water. In bi-phasic 
systems, the enzyme molecule remains in an aqueous milieu (Klibanov, 1989). Sufficient 
water remains to hydrate the enzyme molecule and maintain its correct, functional 
conformation. Hydrophilic solvents tend to strip away the aqueous monolayer 
surrounding the protein molecules.
(ii) enzymes should be lyophilised from solutions with pH values corresponding to the 
enzyme’s optimum. Enzymes retain the ionic state they possessed in the previous 
aqueous system throughout lyophilisation and redispersal in organic phase (Kilbanov, 
1989). The enzyme will, therefore, function best if it retains its pH optimum.
(iii) the enzyme should be agitated vigorously or sonicated to ensure homogeneous 
dispersion in the organic solvent. Enzymes are suspended and not truly dissolved in an 
organic solvent. Heterogeneous dispersions are therefore, plagued by problems of
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diffusional limitation. These can be prevented by the formation of a homogeneous 
solution.
1.14.3.3 Protein Engineering
The stability of a protein may be altered by changing amino acids which affect either 
stabilising or destabilising interactions in the folded or unfolded form of the protein. 
Protein engineering refers to the use of genetic manipulation to alter proteins in specific 
ways. It is one of the most powerful and useful techniques recently developed. There 
are a number of key techniques:
(i) Site-directed mutagenesis is probably the most widespread technique used. Synthetic 
oligonucleotides are used to direct the required mutations (O Fagain and O’Kennedy,
1991). It is highly specific, allowing for individual bases within a codon to be altered. 
The synthetic oligonucleotide containing the desired mutation is annealed to a single­
stranded gene copy. Extension of the oligonucleotide occurs from the 3’ end.
(ii) Cassette mutagenesis involves the insertion of a double-stranded segment of DNA 
into a suitable DNA vector between two non-identical restriction sites. The resulting 
recombinant DNA contains no mismatches and results in highly efficient mutagenesis 
since DNA repair does not occur (O Fagain and O’Kennedy, 1991).
Known sequences from mesophilic and thermophilic organisms should be used to work 
out the necessary mutations required for increased thermostability, and highly conserved 
residues within proteins should not be altered (Imanaka et al., 1986).
1.14.3.4 Immobilisation
Proteins can be immobilised in a variety of ways, onto a variety of matrices. 
Immobilisation can influence the stability of proteins by steric hindrance, partitioning 
or diffusion restrictions (Volkin and Klibanov, 1989). A wide range of supports have 
been used, including porous glass and ceramics, charcoal, sand, stainless steel, synthetic 
polymers and cellulose (Axen et al., 1970). Immobilisation is usually via an amine or 
carboxyl group on the protein, and involves two stages: activation of the solid support, 
and attachment of the protein.
41
Proteins can be entrapped in polymeric gels (O Fagain and O’Kennedy, 1991). The 
protein is added to a solution of monomers and gel formation initiated, by a change in 
temperature or adding a gel-inducing chemical. The gels may be covalent (e.g., 
polyacrylamide cross-linked with N,N’-methylenebisacrylamide) or non-covalent (e.g., 
calcium alginate).
The encapsulation of proteins involves the envelopment of the protein in a membrane 
that is permeable only to low molecular weight substrates and products (e.g., liposomes).
1.14.3.5 Chemical Modification of Proteins
Soluble proteins can be chemically modified in a variety of ways, altering properties 
which can lead to increase in catalytic activity and stability. A wide range of reagents 
are available with selectivity for specific groups on amino acids (Table 1.14). 
Bifunctional compounds are widely used.
The mechanisms of chemical stabilisation are categorised into four areas:
(i) Cross-linking by bifunctional reagents
(ii) Strengthening of hydrophobic interactions by non-polar reagents
(iii) Introduction of new polar or charged groups leading to additional ionic or 
hydrogen bonds.
(iv) Hydrophilisation of the protein structure to reduce unfavourable surface 
hydrophobic contacts with water.
(i) Bifunctional cross-linking reagents, including homobifunctional and 
heterobifunctional reagents, have been successfully used to stabilise a wide range of 
proteins (Wold, 1972). They are also used to conjugate enzymes to antibodies for use 
in immunological techniques (Tijssen, 1985). They act by forming a "bridge" of variable 
length either inter- and intra-molecularly. Particular amino acids containing specific 
functional groups can be targeted using certain bifunctional reagents.
(ii) Chemical modification of proteins by non-polar reagents strengthens hydrophobic 
interactions. The most efficient mechanism for hydrophobic stabilisation should be the 
introduction of non-polar molecules inside the hydrophobic nucleus of the protein
(Mozhaev and Martinek, 1984).
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Residue for 
Modification
Reagent Reaction
Amine
(Lys) O-Methylisourea Guanidination
Acid Anhydrides Acylation
Imidates Amidation
Iodoacetic Acid Alkylation
Borohydrides and Reductive
Carbonyl compounds Alkylation
Carboxyl
(Asp, Glu) Carbodiimides Amidation
Guanidino
(Arg) Dicarbonyls Not fully known
Imidazole
(His) Diethylpyrocarbonate Addition
Indole
(Tip) N-bromosuccinimide Oxidation
Thiol
(Cys) Maleimido compounds Addition
Iodoacetic Acid Reduction and
N-ethylmaleimide
S-caiboxymethylation
Alkylation
Table 1.14 Side-chain modification reagents used in protein stabilisation.
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The protein is unfolded, and changes introduced by
(a) refolding under "non-native" conditions, e.g., in the presence of organic solvents or 
at elevated temperatures.
(b) refolding in the presence of substances which interact non-covalently with the protein 
in a multipoint fashion. For example, non-polar compounds can be incorporated into 
the protein in such a way as to leave the polar or charged fragments of the protein 
exposed to the solvent (Mozhaev and Martinek, 1984).
(c) chemical modification, followed by refolding.
(iii) Introduction of new polar or charged groups
New polar or charged functional groups can be introduced into the protein molecule by 
chemical modification, leading to formation of additional salt or hydrogen bonds.
(iv) Hydrophilisation of the protein surface reduced the surface area responsible for 
thermodynamically unfavourable hydrophobic interactions (Mozhaev and Martinek,
1984). Amine groups on the protein surface, can be substituted by more hydrophilic 
groups, such as -HCH,COO' groups, by chemical modification (Melik-Nubarov et al., 
1987; Mozhaev et a l, 1988).
1.14.3.6 Screening for stable proteins
There is a wide variety of microorganisms that are capable of survival at elevated 
temperatures (Ô Fâgâin and O’Kennedy, 1991). Proteins derived from such thermophilic 
organisms have been extensively studied and compared with their mesophilic 
counterparts in an effort to elucidate the molecular basis of their thermostability. While 
this approach cannot be considered strictly as a method of stabilisation, it has, however, 
provided an insight into the mechanisms of stabilisation.
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1.15 Biosensors
1.15.1 Introduction
A biosensor can be defined as a probe that encorporates a biological sensing component 
with a physiochemical transducer. The field of biosensor development is one of the most 
rapidly expanding areas of both analytical chemistry and biochemistry. Since Clark and 
Lyons developed the first real biosensor in 1962, the field has expanded to incorporate 
a wide range of disciplines, ranging from micro-electronics to immunology.
The "model" biosensor should exhibit a number of characteristics. It should be relatively 
small in size, have a fast response time, be highly selective and show targeted specificity 
and the electronic processing should allow for easy manipulation of data and integration 
with other devices (Griffiths and Hall, 1993).
A biosensor is composed of two components: a means of recognition and a method of 
transduction. The means of recognition is provided by a biological element and a 
transducer converts the biochemical signal into a electronic signal which can be further 
processed or outputted as data (Coulet, 1991). The biological component can be either 
catalytic e.g., enzymes, or based on affinity, e.g., antibodies (Vadgama and Crump,
1992). The biomolecule determines the selectivity of the sensor. This is based on the 
interaction of molecules with complementary structures, binding to each other (enzyme 
to substrate; or antibody to antigen). The development of monoclonal antibody 
technology has been a major step in the field of bioaffinity biosensors.
There are a wide range of transduction techniques currently in use. These include 
electrochemical, optical, calorimetric, acoustic and piezoelectric crystal transducers. The 
nature of the interaction of the biological component with the analyte has a major 
influence on the choice of transducer. Other considerations include the intended use of 
the biosensor and the cost (Griffiths and Hall, 1993).
Biosensors offer a number of advantages over conventional analytical techniques. They 
can provide "real time" analysis, are generally highly sensitive and selective, and are 
simple to use (Taylor et al., 1991). At the current stage of development however, there 
are a number of problems associated with their development. The biological component 
often has a relatively short operating life-span and needs frequent calibration. 
Problems also arise when the analyte is present in a complex matrix, for example blood, 
where some degree of sample "clean-up" is necessary.
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Despite these problems, biosensors have the potential to revolutionise the fields of 
analytical chemistry and biology. Some of the main types of of biosensor technologies 
and configurations are summarised below.
1.15.2 Voltammetry
Electrochemical techniques are the biosensor-transduction method most widely used. The 
most commom of these, amperometry and potentiometry, involve electrical changes (in 
current or potential) which can be detected by the transducer and reported. Voltammetry 
is the study of current-potential relations in an electrolysis cell where the current is 
determined solely by the rate of diffusion of an electrochemical species. The current is 
defined as the rate at which charge passes through the electrode-solution interface.
The potential is the driving force of the reaction, causing the electrochemical species to 
be oxidised or reduced at the surface of the working electrode. The applied potential 
determines the strength of the oxidation/reduction reaction. At negative potentials, the 
current is cathodic (positive) causing reduction, while at positive potentials, the current 
is anodic (negative) causing oxidation.
In thermodynamic systems, the standard potential E°, is dependent on the concentration 
of the electrochemical species. The Nemst equation describes this dependence:
Ox + ne' **■ Red
E = E° - 2.3026RT log fRedl 
nF [Ox]
where
Ox = Oxidised state of a species
Red = Reduced state of a species
E = reduction potential at specific concentration.
n = number of electrons transferred in the reaction.
R = gas constant (8.3143 V coul deg'1 mol'1).
T = absolute temperature.
F = Faraday constant (96,487 coul e q 1).
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Therefore, at 25°C,
E = E° - 0.059 log fRedl 
n [Ox]
The faradaic current is the current resulting from a change in the oxidation state of the 
electroactive species. It is a direct measure of the rate of the redox reaction taking place 
at the surface of the working electrode. It is dependant on the rate at which a species 
moves from the bulk solution to the electrode surface, and the rate of electron transfer 
between the electrode and the species in solution.
1.15.3 Electrochemical Transduction
There are two methods used in electrochemical transducers
(i) Amperometry
(ii) Potentiometry
Amperometry involves the application of a constant potential with respect to a reference 
electrode, while the current between the working and the counter electrodes is measured. 
The current is generated by the oxidation or reduction of an electrochemical species at 
the working electrode, and is proportional to the concentration of the analyte (Czaban,
1985).
Potentiometric transducers measure the difference in potential between the working 
electrode and a second reference electrode, while the current remains constant. Under 
these conditions, there is no consumption of the analyte. They are based on the Nemst 
equation, resulting in a logarithmic relationship between the potential and the activity 
of the ion in solution. Examples of potentiometric devices include ion-selective 
electrodes and gas-sensing electrodes (Vadgama and Crump, 1992).
1.15.4 The Electrochemical Cell
Electrochemical reactions take place in an electrochemical cell. The cell contains three 
electrodes, the working, reference and the counter electrodes, immersed in the sample 
solution (Figure 1.15.4).
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Nitrogen inlet Reference
Electrode
Working 
Electrode
Counter
Electrode
«& ////////% &
Stirring bar
Figure 1.15.4 The electrochemical cell. The reaction takes place at the working
electrode as a result of the potential applied. Current flows between the 
working electrode and the counter electrode and is measured by a 
potentiostat. A stirring bar provides convective transport if required. 
Dissolved oxygen is purged from the electrolyte solution using nitrogen 
gas.
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Convective transport is provided (if required) by a magnetic stirring bar. The relative 
placement of the three electrodes is important. They should be arranged in a way that 
provides a symmetrical electric field and uniform current distribution across the working 
electrode surface (Smyth and Vos, 1992).
The redox reaction takes place at the surface of the working electrode. It is vital that the 
electrode itself does not interfere with either the redox reaction or with the electron 
transfer process. They are usually made from inert metals (e.g., platinum) or carbon 
(glassy carbon has excellent electrochemical properties).
The reference electrode monitors the potential of the working electrode. The potential 
of the reference electrode must be known and remain constant. There are two main 
reference electrodes: the saturated calomel electrode (SCE) and the silver/silver chloride 
electrode.
The counter or auxiliary electrode completes the electrical circuit and allows current to 
flow between it and the working electrode. They are usually made from platinum or 
carbon and are in the form of a gauze or foil. This gives them a relatively large surface 
area compared with the working electrodes.
The removal of oxygen from the solution is essential. Oxygen is reduced at a potential 
of -0.01. Attempts to reduce species at potentials more negative than this will also result 
in the reduction of oxygen, giving large background currents. A further problem arises 
from the products of oxygen reduction. These may react with the analyte (e.g., formation 
of hydroxides in the determination of heavy metals). To alleviate these problems, the 
solution is purged with an inert gas (such as nitrogen) for 20-30 minutes prior to the 
electrochemical reaction.
1.15.5 Immobilisation of Biological Components onto the Electrode Surface 
Modification of an electrode is achieved by immobilising a biological molecule onto the 
surface. A number of factors are important in the immobilisation of a biomolecule. A 
high level of activity must be retained so the immobilisation technique used, the 
thickness of the immobilised layer and the loading onto the surface are important 
(Bardeletti et al., 1991).
49
Immobilisation can be carried out in a number of different ways:
(i) Covalent attachment
(ii) Adsorption
(iii) Polymeric coating
(i) Covalent attachment can be achieved by silanisation or direct binding. Silanisation 
involves the formation of surface hydroxy or oxide groups which are reacted with 
trialkoxy or trichloro silanes to form one to three bonds to the underlying electrode 
material (Srinivasan et al., 1977; Moses et al., 1978; Diaz et al., 1977). These 
modifications generally give rise to monolayers, although the formation of multilayers 
is possible (Lenhard and Murray, 1978). Bifunctional reagents (e.g., glutaraldehyde) can 
also be used to form inter-molecular cross-links, binding a protein to the solid support. 
The reaction can however be difficult to control and a large amount of the biological 
component is sometimes required (Bardeletti et al., 1991). Direct binding can be 
achieved to the platinum or carbon of the electrode by a variety of methods such as 
mechanical abrasion and vacuum pyrolysis (Smyth and Vos, 1990).
(ii) A variety of substances adsorb enzymes and other proteins onto their surface. This 
provides an excellent method for immobilisation, as no reagents are required and the 
process is less disruptive to the protein than chemical methods of attachment. The 
adsorption involves forces such as hydrogen bonding and Van der Waal’s forces. The 
disadvantage of this method is that these forces are weaker than chemical linkages and 
are more susceptible to changes in pH temperature and ionic strength (Bardeletti et al., 
1991).
(iii) The entrapment of biomolecules behind or within a polymer film has a number of 
advantages -it provides a stable environment and it is porous, allowing for the movement 
of both substrate and electrolyte. Physical entrapment in a gel matrix (e.g., gelatin) 
which is then cast over the electrode surface and held in place by a dialysis membrane, 
use of membranes (cellulose acetate, polyvinylalcohol and polyurethane) and entrapment 
within polymer matrices (polyacrylamide and agarose) have all been reported (Gorton 
et al., 1990).
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1.15.6 Applications of Biosensors
Biosensors are set to make a significant impact in the future. They offer the prospect of 
measuring biomolecules important in medicine, biotechnology and other fields, in a 
convenient, rapid and relatively inexpensive way. A wide range of substances can 
currently be measured using biosensors, from enzymes in clinical chemistry and the food 
and cosmetic industries, to environmental monitoring.
(i) Medical applications
Clinical diagnostics have been the focus of biosensor application over the last number 
of years, approximately 20 self-contained analysers based on enzyme electrodes for the 
determination of a range of analytes are currently available (Bardeletti et al., 1991). In 
vitro diagnostic biosensors have a worldwide market worth an estimated US$9 billion 
per annum (Griffiths and Hall, 1993). Biosensors can be used in a number of situations 
from in-hospital use, to use by the general public. A wide range of analytes can be 
determined using enzyme-based sensors. The Exac Tech™ glucose monitors 
manufactured by Medi-Sense (Abington, UK) is a pen-size sensor for the determination 
of glucose levels in blood, and is the world’s smallest blood glucose monitor (Bardeletti 
et a l,  1991). Glucose and lactate levels in blood, as well as uric acid, can be 
successfully monitored using a number of commercially available biosensor devices 
(Bardeletti et al., 1991). Biosensors are also available for other clinically important 
analytes, including cholesterol (Bertrand et al., 1979; Wollenberger et al., 1983), 
acetylcholine (Mascini et a l, 1986) and bilirubin (Renneberg et a l, 1982). Blood- 
glucose monitoring kits and pregnancy tests are the most common consumer biosensors 
(Griffiths and Hall, 1993).
The development of miniaturised voltammetric probes aimed at in vivo monitoring is an 
area of intense research activity (Vadgama and Desai, 1991). Research into brain 
neurotransmitters is an area of particular interest, and recent developments, including the 
use of ion-selective membranes, have lead to great advances in this area (Wightman et 
al., 1988). The problems associated with in vivo monitoring are numerous. 
Biocompatibility and allergenicity together with technical and ethical problems are major 
difficulties. However, future work will most likely focus on the development of selective 
probes for organic drugs and analytes of clinical importance, the coupling of enzymic 
and immunochemical reactions with in vivo electrodes, the design of new non-invasive
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and multispecies probes, and the search for means of protecting in vivo electrodes 
against biological matrix effects (Vadgama and Desai, 1991).
(ii) Food Industry
Biosensors are used in the monitoring of food samples during the manufacturing and 
processing stages. Mannino and Wang (1992) recently reviewed the status of 
electroanalysis in the food industry. Specific enzyme-based sensors have been developed 
for sugars (Schubert et al., 1986), as well as other important analytes such as ethanol 
(Kitagawa et al., 1989) and ascorbate (Matsumoto et al., 1981). The determination of 
L-glutamate is important in fermentation control as many food stuffs contain L- 
glutamate as a flavouring agent (Palleschi et al 1992).
(iii) Environmental monitoring
Biosensors are widely used in the monitoring of pollution. Kolvoda (1990) recently 
reviewed current technologies used in environmental monitoring. Monitoring of 
pesticides and herbicides can be carried out using biosensors. The development of 
reliable, robust, multifunctional and self-contained biosensors capable of working in the 
gaseous or organic phases will allow for future developments in the areas of monitoring 
of ozone, acid rain and industrial atmospheric pollutants, as well as air, soil and water 
analysis.
(iv) Industrial applications
The pharmaceutical industry provides an ideal environment for the use of biosensors. 
Use in process control is viable as well as in purity and potency testing of its products. 
Other areas of interest include product testing and monitoring raw materials or product 
intermediates. Opportunities in other industrial areas are limited at the present time. 
Technological limits do not allow for the use of biosensors under the harsh conditions 
required for many industrial processes. This is one area for possible future development.
In conclusion, the potential for biosensor application is enormous. Improvements in 
existing transduction techniques, as well as the development of novel methods of 
measurment, will allow for the wide-spread use of biosensors in the future.
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1.15.7 Electrochemical Immunoassays
Immunosensors utilise the characteristic selectivity of antibodies for their antigens and 
combine them with a suitable transducer, to form highly selective and sensitive 
biosensor. There has been extensive development in this area over the last decade, 
mainly because of advances in immunotechnology. With current improvements in 
biosensor-related technologies such as micro- and opto-electronics, the potential for 
further development is vast. There are two main types of immunosensors - labelled and 
non-labelled. Labelled immunosensors are similar to ELISAs in that a signal, produced 
by a labelled antibody or antigen, is measured. In contrast, the antigen-antibody complex 
is determined directly in non-labelled sensors (Aizawa, 1991).A variety of substances 
can be used as labels, including enzymes and redox substances. Enzymes can increase 
the sensitivity of a sensor by amplification of the signal. Enzyme product can be 
detected with a variety of electronic or optoelectronic devices. Peroxidase, for example, 
catalyses the luminescent reaction of luminol, producing photons which can be measured 
in an optical enzyme immunosensor. In homogeneous immunoassays, where there is no 
separation of the immune-complex from free antibody and antigen, fluorescent and 
chemiluminescent labels have been described (Aizawa, 1991). Non-labelled 
immunosensors measure some physical change brought about by the antibody-antigen 
complex. Antibody (or antigen) is bound to a surface capable of detecting complex 
formation (eg, piezoelectric crystals). Antigen (or antibody) in solution binds to the 
surface causing a change in surface characteristics, and generating a signal.
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1.16 Immunoassay
An immunoassay is a technique for measuring the presence of a substance using an 
immunological reaction, generally an antibody-antigen reaction. There are a variety of 
different immunoassays from simple precipitation to radioimmunoassay (RIA) and 
enzyme-immunoassay (EIA) (Kemeny, 1991). The choice of assay is dependent on a 
number of factors - sample concentration, precision, ease of use and facilities available. 
EIA are based on two events: the antibody-antigen reaction and the detection of this 
reaction using enzymes as indicators (Campbell, 1984). There are several formats for 
EIA. The immunological reaction can be heterogeneous, where there is a separation of 
the immune complex from the immunoreactants, or homogeneous, where no separation 
takes place (Tijssen, 1985). In heterogeneous immunoassays, either the antibody or 
antigen can be immobilised onto the solid phase. The sample is added and test substance 
bound. This is then reacted with a labelled immunoreactant, substrate added, and enzyme 
product measured. The concentration of the immunoreactant in the test can then be 
determined. In homogeneous assays there is no requirement for a separation step because 
the immune reaction influences the enzyme reaction. Both heterogeneous and 
homogeneous assays can be further categorised into competitive or non-competitive 
systems (Tijssen, 1985). Competitive assays are usually used for the quantitation of an 
immunoreactant. The assay is based on the competition between an enzyme-labelled 
immunoreactant and free immunoreactant in solution or bound to the solid phase. The 
signal is inversely proportional to the concentration of free immunoreactant in solution 
(Tijssen, 1985). In non-competitive systems, there is no competition for binding. 
Enzyme-linked immunosorbent assay (ELISA) is perhaps the most widely used EIA. 
They provide an quick, easy to use, sensitive and reliable method for the detection and 
determination of antibodies and/or antigens.
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1.17 Conclusions
FVIII is notoriously unstable. Stability studies can help to understand how and why it 
denatures and will help in the design of an altered molecule (by genetic or other means) 
for use in therapeutic or as an in vitro test standard. For this reason, analysis of FVIII’s 
stability was undertaken together with a programme of chemical modification in an 
attempt to increase FVIIIs in vitro thermal stability. Current methods for the analysis of 
FVIII are based on its procoagulant activity. These techniques rely on the ability of 
FVIII to correct the prolonged clotting time of FVIII deficient plasma. They are not, 
therefore, specific for the cofactor itself, as the process of blood coagulation is a 
complex one involving over 13 different reactions, any of which could be involved. 
There is much scope for improvements and further developments of the techniques. 
There are substantial risks from infectious agents, associated with the handling of human 
blood. Any novel techniques which reduce the possibility of infection from contaminated 
samples would be a major improvement. Monoclonal antibodies could provide an ideal 
way of isolating particular constituents of blood because of the high specificity they 
exhibit for their particular antigen. The possibility of viral or bacterial contamination 
would subsequently be dramatically reduced. ELISAs have been developed for the 
detection of FVIII but these generally utilise inhibitor or autoantibodies from 
haemophiliac patients. The incorporation of monoclonal or polyclonal antibodies into an 
ELISA system for the detection of FVIII would provide a safer alternative to these 
human-derived antibodies.
Biosensor technology offers the prospect of easy to use, sensitive and rapid techniques 
for the detection and quantitation of analytes. The prospect of a system for the detection 
of FVni in whole blood could revolutionise the diagnosis and treatment of haemophilia. 
Home testing kits could be developed which would allow doctors or even the patients 
themselves, to monitor the disease without the need for time-consuming and expensive 
in-hospital patient care.
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AIMS OF THIS PROJECT
General Aims
The general aims of this project were to investigate the effects of chemical modification 
on recombinant factor VIE (rFVIII) procoagulant activity, to develop novel antibodies 
and analytical systems to detect and quantitate recombinant factor VIII and anti-rFVIII 
antibodies.
Specific Aims
1. To investigate the effects of chemical cross-linkers and protein modifying reagents 
on rFVIII procoagulant activity, and determine whether any modifications caused by 
these reagents resulted in an increase in the thermostability of rFVIII.
2. To develop monoclonal and polyclonal antibodies against rFVIII, and to investigate 
the effects of the binding of these antibodies on rFVIII procoagulant activity.
3. To develop assay systems using the above antibodies, for the detection of rFVIII and 
anti-rFVIII antibodies.
(i) An ELISA consisting of a number of different formats
(ii) A biosensor, incorporating antibody recognition with an electrochemical
transduction system.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 MATERIALS
Recombinant Factor VIII (rFVIII) was a gift from Baxter Biotech., Hyland Division, 
Glendale, California, U.S.A. The following lot numbers were used:
9A03L007,
9A03L023,
9A03L026,
C010Q1803,
C011Q1803,
C006Q1803,
Factor VIII Chromogenic Assay kit (cat. no. 281068), Coag Cal N calibration plasma 
(cat. no. 291040) and Factor VUI-deficient plasma (cat. no. 281042) were gifts from 
Baxter Diagnostics AG, Diidingen, Switzerland.
All tissue culture products including media, foetal calf serum and L-glutamine were 
supplied by Flow Laboratories Ltd, Richmondsworth, Herts. WD3 1PQ, UK.
Cell culture vessels were obtained from Flow, Costar, Cambridge, MA 02140, U.S.A. 
and Nunc, Denmark.
T24 cells from human bladder were supplied by Dr. J. Tager, University of Amsterdam, 
1105 AZ, Amsterdam, Netherlands.
NSO murine plasmacytoma were supplied by EC ACC, PHLS, Porton Down, Salisbury, 
Wiltshire SP4 0JG, UK. (catalogue number 84112004).
NRK cells were obtained from ATCC, 12301 Park Lawn Drive, Rockville, Maryland 
20861, U.S.A.
All chemicals were of analytical grade and were obtained from Sigma Chemical Co., 
Poole, Dorset, UK, BDH Chemicals Ltd., Poole, Dorset, UK, or Riedel de Haen AG, 
Seelze, Hannover, Germany. Exceptions were activated Sepharose and Sephadex 
purchased from Pharmacia, Uppsala, Sweden. Bis-(maleimido-methyl) ether was 
supplied by Boehringer Mannheim, Hannover, Germany. Sheep anti-Factor VIII 
polyclonal antibody was from Serotec, 22 Bankside, Kidlington, Oxford OX5 1JE UK.
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Hoechst 33258 fluorescent stain was purchased from Calbiochem, Behring Diagnostics, 
La Jolla, CA 92037, U.S.A. Nafion and Hydroquinone was supplied by Aldrich 
Chemical Company, Gillingham, Dorset SP8 4JL, UK. Nitrocellulose paper (0.45pm) 
was from Schleicher and Schuell, Postfach 4, D-3354, Dassel, Germany. 
Microconcentrators were supplied by Amicon Inc, Beverly, MA 01915, U.S.A. Liquid 
nitrogen was from Coopers Cryoservice Ltd, Dublin, Ireland. C 02 and N2 was supplied 
by Irish Industrial Gasses, Dublin, Ireland.
2.2 Equipment
A Morgan Grundy (Crowley, Middlesex, UK) waterbath with a Techne Tempette Junior 
TE-8J heating unit were used in denaturation experiments.
A Titretek Twinreader type 381 (Flow Laboratories Ltd., Scotland) was used to read 
absorbances on microtitre plates.
Holten LaminAir HB 2448K laminar flow cabinet was used for all tissue culture work. 
Cells were incubated at 37°C in a 5% C 02 environment in a Jouan EG 115 1R water- 
cooled incubator.
Heraeus Christ Labofuge 6000 centrifuge was used to centrifuge universal tubes (1 - 
20mls) and a Heraeus Biofuge A was used for smaller volumns (0.5 - 1.5mls).
A Beckmann J2-21 Centrifuge was used in conjunction with the Amicon micro­
concentrators to concentrate samples of antibody.
Union Carbide freezing trays and liquid nitrogen containers were used to freeze and 
store cells in liquid nitrogen.
Atto Model AE-6450 electrophoresis equipment was used for gel electrophoresis.
LKB 2050 Midget Electrophoresis Unit and a Bio-rad semi-dry transfer system were 
used for Western blotting.
A Beckmann System Gold HPLC system with programmable solvent module 126, 
detection module 166 at absorbance units full scale (AUFS) 0.05, with detection at 
280nm was used.
An EG&G PAR (Princeton Applied Research, Princeton, NJ, U.S.A.) Model 264A 
polargraphic analyser was used with a WPA (Linton, Cambridge, UK) model CQ95 
recorder in voltammetric studies.
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Name Source Address
Dade Factor VIII 
Chromogenic Assay Kit
Baxter Diagnostics AG. Diidingen,
Switzerland
Bicinchoninic Acid 
(BCA Protein Assay Kit)
Pierce Chemical Co. Rockford, Illinois, 
61105, U.S.A.
Murine Monoclonal 
Antibody Isotyping Kit
Sigma Chemical Co. Poole, Dorset, UK.
Antibody Isotyping Kit Serotec 22 Bankside, Oxford 
0X 5 1JE, UK.
Table 2.1.1 Analytical diagnostic kits used
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2.3 FVIII Chromogenic Assay
Factor VIII activity was measured using the Factor VIII Chromogenic Assay kit from 
Baxter Diagnostics AG. Reagents were reconstituted according to the manufacturer’s 
instructions. The assay was miniaturised so that it could be performed on a 96-well 
microtitre plate. 25pl of sample was pipetted into duplicate wells of a microtitre plate 
held at 30°C. 25pl of each of factor X and factor IXa reagents (prewarmed to 30°C) were 
added, mixed and incubated for 90 seconds. 125pl of substrate/stopping buffer (also 
prewarmed to 30°C) was added, mixed, and absorbance at 405nm read every 15 seconds 
for 2 minutes on a Titertek Twinreader Plus automatic plate reader.
Coag Cal N calibration plasma and Factor VUI-deficient plasma diluted in 0.9% (w/v) 
NaCl, served as controls and were included in every assay.
2.4 Buffers
The buffers used for modification experiments were lOmM Tris buffer pH 7.5, 
containing 0.9% (w/v) NaCl, 5mM CaCl2, and 0.05% (w/v) azide and lOmM barbital 
buffer, pH 7.5 also containing 0.9% (w/v) NaCl, 5mM CaCl2 and 0.05% (w/v) azide. 
Samples were diluted in 0.9% (w/v) NaCl before being assayed.
2.5 Dénaturation of rFVIII
Dénaturation studies were carried out as follows: solutions of native and modified rFVIII 
were incubated in a 55°C waterbath. Samples were withdrawn at regular intervals (0, 2, 
5, 10, 20, 40 and 60 minutes), stored on ice and then assayed in 0.9% (w/v) NaCl. 
Coag Cal N (positive) and FVIII-deficient plasma (negative) controls, along with a 
control containing rFVIII and the diluent in which the cross-linker or the modifying 
reagent was dissolved, were included in each experiment.
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2.6 Transfer of rFVIII into Barbital buffer
For amino-specific reagents, the rFVIII was transferred to barbital buffer. This does not 
contain free amino groups which could interfere with the cross-linking reaction. 
Sephadex G-25 was swollen with barbital buffer and packed into a Pasteur pipette, to 
form a chromatography column. rFVIII was applied in small aliquots (lOOpls), to the 
column at 4°C. The protein was subsequently eluted using barbital buffer. The protein 
concentration of each fraction was estimated using the BCA assay (Section 2.7)
2.7 Determination of Protein Concentration
Protein concentration was determined using the bicinchoninic acid (BCA) method of 
Smith et al. (1985). In this method, protein reacts with Cu2+ in an alkaline environment 
producing Cu1+. BCA is a sensitive, stable and highly specific reagent for Cu1+, forming 
a water soluble product which exhibits strong absorbance at 562nm. The BCA Assay, 
supplied in kit form by Pierce Chemical Company, contains two reagents:
Reagent A: an alkaline buffer containing sodium carbonate, sodium bicarbonate, 
sodium tartrate and BCA reagent.
Reagent B: 4% (w/v) copper sulphate solution 
The working solution was prepared by mixing 50 parts of Reagent A with 1 part of 
Reagent B. A range of protein standards was prepared from a 2mg/ml solution of BSA 
using PBS as diluent. lOpl of each standard or unknown protein sample was pipetted 
into duplicate wells of a 96-well microtitre plate. Controls consisting of lOpl of diluent 
were also included. 200pl of working reagent was added and the solutions mixed. The 
plate was covered and incubated at 37°C for 30 minutes. Absorbance at 560nm was read 
on a Titertek Twinreader Plus.
2.8 Accelerated Storage Studies
Accelerated storage studies were performed as described by Kirkwood (1984). 
Accelerated storage studies were performed on rFVIII diluted in lOmM Tris-HCl buffer 
with 0.9% (w/v) NaCl, pH 7.5, containing either different concentrations (5mM, lOmM 
or 20mM) of CaCl2, or different concentrations of BSA (2mg/ml, 5mg/ml or 20mg/ml). 
Solutions were filter sterilised, aliquotted into sterile microtubes and incubated at 
particular temperatures.
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Temperatures used were 15°C, 27°C, 37°C and 45°C with reference temperatures of 4°C 
and -20°C.
After certain times, samples were withdrawn and a series of dilutions on 0.9% (w/v) 
NaCl made. Each of these was assayed in duplicate for FV in activity.
2.9 CHEMICAL MODIFICATION OF rFVHI
2.9.1 Amino-specific Reagents
2.9.1.1 Modification of rFVIII using Bis-imidates
rFVIII was transferred to lOmM barbital buffer containing 0.9% (w/v) NaCl, pH 7.5, for 
modification with the bis-imidates. Dilutions of the protein were reacted on ice with 
final concentrations ranging from 0 to 40mM of the particular bis-imidate in dimethyl 
formamide (DMF). The reaction was allowed to proceed for thirty minutes before being 
stopped by the addition of 1/10 volume of ice cold lOmM Tris-HCl buffer, pH 7.5. FVin 
activity was then measured in a 1:31 dilution in 0.9% (w/v) NaCl.
2.9.1.2 Modification of rFVIII using Glutaraldehyde
From a stock solution of lOOmM glutaraldehyde in water, the following final 
concentrations were prepared and reacted with rFVIII in barbital buffer: 0, ImM, 2mM, 
3mM. The reaction took place on ice for 1 hour before being terminated on addition of 
l/io volume ice cold lOmM Tris-HCl buffer, pH 7.5, and FVIII activity was measured.
2.9.2 Thiol-specific Reagents
2.9.2.1 Modification of rFVIII using Bis-maleimides
rFVIII, in lOmM Tris-HCl buffer containing 0.9% (w/v) NaCl, pH 7.5, was reacted with 
a range of concentrations (0 to lOOpM) of two members of the bis-maleimide group of 
cross-linkers. The cross-linkers were dissolved in either acetone (Bis-(maleimido-methyl) 
ether (BMME), or dimethyl formamide (N-N-bis (3-maleimidopropionyl)-2-hydroxy 1,3- 
propanediamine (BMPPD)). The reaction took place at room temperature, for ten and 
sixty minutes. Addition of 5jil of a lOOmM solution of 2-mercaptoethanol terminated the 
reaction and FVin activity was measured.
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2.9.3 Modification of rFVIII using heterobifunctional reagents 
A stock solution of the heterobifunctional, N-(y-maleimidobutyryloxy) succinimide 
(GMBS), (2.5mM) in DMF was prepared, and from this, final concentrations of IOOjjM 
and 250pM were reacted with rFVIII in lOmM barbital buffer containing 0.9% (w/v) 
NaCl, pH 7.5, at either 4°C for ten minutes, or room temperature for thirty minutes. The 
reaction was terminated upon addition of l/io volume of ice cold lOmM Tris-HCl buffer, 
pH 7.5. This was then incubated for a further five minutes at 4°C. The solutions were 
then assayed for FVIII activity.
rFVIII, in lOmM barbital buffer containing 0.9% (w/v) NaCl, pH 7.5, was reacted with 
a 100-fold molar excess solution of the heterobifunctional succinimidyl 4-(N- 
maleimidomethyl) cyclohexane carboxylate, (SMCC) in DMF, for one hour at room 
temperature (with and without stirring). 1/10 volume of ice-cold lOmM Tris-HCl buffer, 
pH 7.5, was added and incubated for an additional thirty minutes with stirring, to 
terminate the amino-specific reaction. FVIII procoagulant activities were then measured.
2.10 Protein Modifying Reagents
2.10.1 Reaction of rFVIII with Polyethylene glycol
rFVIII in lOmM barbital buffer containing 0.9% (w/v) NaCl, pH 7.5, was reacted with 
cyanuric chloride-activated Polyethylene glycol (PEG) to final molar concentrations of 
0.5X and 5X with regard to rFVIII lysines (approx 40). The reaction took place at room 
temperature for 1 hour, before being terminated by addition of 10% volume of ice-cold 
Tris-HCl buffer, pH 7.5. This was further incubated for fifteen minutes before being 
assayed for FVIII activity.
2.10.2 Reaction of rFVIII with Copper/phenanthroline chelate
ImM stock solutions of CuS04 and o-phenanthroline (o-Ph) in lOmM Tris-HCl 
containing 0.9% (w/v) NaCl, pH 7.5 were prepared. From these, various combinations 
of each (lOpM, 20pM and 50pM CuS04 and 25)aM, 50pM and 100pM o-Ph) were 
reacted with rFVIII on ice for twenty minutes. FVIII activity was then assayed and 
denaturation studies carried out.
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2.10.3 Reaction of rFVin with Hydrogen Peroxide
Final concentrations, ranging from 0 to 1M H jOj were reacted with rFVin on ice for 
15 minutes, 1 hour and 2 hours. The reaction was terminated by addition of 2% (w/v) 
of a 1 mg/ml solution of catalase enzyme. This was further incubated for 15 minutes on 
ice and FVin activity measured.
2.10.4 Reaction of rFVin with 2-Iminothiolane
rFVIII in lOmM barbital buffer containing 0.9% (w/v) NaCl, pH 7.5, was initially 
reacted with final concentrations of 0, 0.25mM, ImM, and 6mM 2-Iminothiolane (2- 
IT),in water. The reaction took place on ice over a two hour period. 10% volume of ice 
cold Tris-HCl buffer, pH 7.5, was added to terminate the reaction. FVIII activity was 
then measured, and dénaturation studies carried out. In the second stage of the 
experiment, the modified rFV in was reacted with either hydrogen peroxide (40mM 
solution) or with o-phenanthroline (lOOpM solution with 50pM CuS04). These two 
reactions were carried out in an attempt to promote disulphide bond formation between 
thiol groups introduced via 2-IT, and free thiol groups on rFVIII. FVin activity was 
measured and dénaturation studies performed.
2.10.5 Addition of Xylitol
rFVIII in lOmM Tris-HCl buffer containing 0.9% (w/v) NaCl, pH 7.5, was reacted with 
final concentrations of lOmM, 50mM and lOOmM Xylitol. The reaction took place on 
ice for 30 minutes and FVIII activity was then measured. A control consisting of rFVIII 
and buffer was also included.
2.11 TISSUE CULTURE TECHNIQUES
2.11.1 Media
The following media were used:
DMEMSq consisted of Dulbecco’s modified Eagles Medium (DMEM) containing 2% 
(w/v) pyruvate, 1.5% (w/v) NaHC03 and 10% (w/v) HEPES, pH 7.4.
DMEMS10 consisted of DMEMS0 supplemented with 10% (v/v) foetal calf serum (FCS), 
and 1% (w/v) 200mM L-glutamine.
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DMEMSio/T24 consisted of DMEMS10 supplemented with 5% (v/v) T24 conditioned- 
medium.
2.11.2 Preparation of T24-Condidioned Medium
T24 cells were grown in 75cm2 culture flasks at 37°C in 5% C 02. After passaging twice, 
the supernatant was removed, centrifuged at 2000 rpm for 10 minutes and filter 
sterilised. It was then used to supplement DMEMS10 at a concentration! of 5% (v/v) 
(DMEMS10/T24), or stored in small aliquots at -20°C.
2.11.3 Storage and Recovery of Cells
Long term storage of cells was carried out in liquid nitrogen. Cells were centrifuged at 
1500 rpm for 10 minutes, the supernatant decanted and the cells resuspended in ice-cold 
FCS supplemented with 5% (v/v) DMSO to a final concentration of 1 x 107 cells/ml. 
lml aliquots were pipetted into cryotubes and placed in a freezing tray which was 
gradually lowered into the gaseous phase of liquid nitrogen. When frozen, the cells were 
placed into canes and stored immersed in the liquid nitrogen.
Cells were recovered from liquid nitrogen by thawing rapidly at 37°C. When only a 
small piece of ice remained, the cells were transferred to a sterile universal containing 
10ml of DMEMS0. The cells were washed and centrifuged at 2000 rpm for 10 minutes. 
The pellet was resuspended in fresh DMEMS10 medium and transferred to a 24-well 
plate.
2.11.4 Maintenance of Cell Lines
(i) Non-adherent cell lines
The NS0 non-adherent cell line was maintained in 25cm2 tissue culture flasks in 
DMEMS10. Cultures were plated out at a density of 1 x 10s cells/ml and were maintained 
at 37°C in a humidified incubator containing 5% C 02. Cells were harvested by flushing 
them from the bottom of the flask with media using a sterile pasteur pipette and 
centrifuging at 1200 rpm for 10 minutes. The supernatant was decanted and the pellet 
resuspended in fresh DMEMSt0 and transferred to fresh culture flasks.
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(ii) Adherent cell lines
The T24 adherent cell line was maintained in similar conditions to those above. 
However, because they adhere to the surface of the flask, mild trypsinization was 
necessary to remove them. This was achieved by decanting the culture medium and 
adding 1ml trypsin/EDTA solution (0.25% (w/v) trypsin and 0.02% (w/v) EDTA in 
PBS) to the flask. The flask was rotated gently and the trypsin discarded. A further 2ml 
of trypsin was added and the flask incubated at 37°C for 10 minutes until the cells 
became detached. 5ml of DMEMS10 was added aseptically and the cells centrifuged at 
1200 rpm for 10 minutes in a universal. The supernatant was discarded and the pellet 
resuspended in DMEMS10 and passaged.
2.11.5 Cell Viability Testing
Cell viability was determined using the trypan blue dye exclusion method. A cell 
suspension was prepared and 50pl removed. An equal volume of trypan blue was added 
and this was left for 1 minute. A small amount of this suspension was transferred, using 
a micropipette, to a Neubauer haemocytometer covered with a coverslip. The number 
of viable cells (not stained) in 5 squares was counted and the total number of cells 
calculated using the following equation:
Total number of cells =
N (viable cells) x 5 (no. of squares counted) x 2 (dilution factor) x 104
2.11.6 Mycoplasma Testing
Cells were routinely tested for the presence of mycoplasma using the fluorescent 
Hoechst 33258 stain. Sterile coverslips were placed in sterile petri dishes and 1ml of a 
5 x 103 solution of normal rat kidney (NRK) cells added. These were incubated 
overnight at 37°C in a humidified incubator containing 5% C 02. On day 2, 1ml of test 
sample or control (cell free supernatant) was added to the petri dishes and these were 
incubated for a further 3 days.
The supernatants were removed and the coverslips washed 3 times in PBS. The cells 
were fixed for 6 minutes in a 1:1 mixture of methanol:acetone. The coverslips were then 
transferred to PBS and rinsed twice.
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The cells were stained for 10 minutes in Hoechst 33258 stain (0.05 pg/ml in PBS), 
washed in PBS 3 times, air dried and mounted on slides. Mycoplasma, if present, could 
then be observed under the 40X magnification of a Leitz Labrolux microscope as 
defined spots of fluorescence in the cell cytoplasm.
2.12 Production of anti-rFVIII nolvclonal antibodies
A New Zealand White male rabbit was immunised intradermally (i.d.) at several sites 
with 0.3 mg/ml rFVIII emulsified in complete Freund’s Adjuvant using a Kikawerk 
Ultra-Turrax homogeniser. Booster injections of rFVIII in Incomplete Freund’s Adjuvant 
were given at fortnightly intervals until the titre was sufficiently high (1:100 000). 
Further injections were given two weeks prior to bleeding. 20 ml of blood was taken 
from the marginal ear vein and anti-rFVIII antibody was purified from this.
2.13 MONOCLONAL ANTIBODY PRODUCTION
2.13.1 Immunisation Protocol
A 0.1 mg/ml solution of rFVIII was emulsified in complete Freund’s adjuvant as 
described in Section 2.12. 500pl of this was injected intraperiteally (i.p.) into 8 week old 
Balb/C mice. Further immunisations were given at fortnightly intervals until a high 
antibody titre was obtained (i.e., 1:5,000). The final immunisation was given 3-4 days 
prior to cell fusion.
2.13.2 Testing myeloma cells for HAT-sensitivitv
NS0 myeloma cells were cultured in DMEMS10 containing O.lmM 8-azaguanidine for 
three days. HAT-sensitive cells can grow in this medium whereas HAT-resistant cells 
die. HAT-sensitive cells are subsequently grown in 8-azaguanidine-free medium for 1 
week prior to cell fusion.
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2.13.3 Isolation of Immune splenocytes
An immunised mouse was sacrificed by cervical dislocation and placed in 70% alcohol. 
Under sterile conditions, the spleen was removed and placed in a petri dish with lOmls 
of DMEMS10. Using the plunger of a sterile 20ml syringe, the spleen was pressed 
through the screen of a sterile dissociation sieve (Sigma, UK) to get a cell suspension. 
This was transferred to a 50ml centrifugation tube and centrifuged at 200Qrpm for 15 
minutes. The supernatant was decanted, and the pellet resuspended in lOmls of Gey’s 
haemolysis solution (Mishell and Shiigi, 1981). After 5 minutes the cells were 
recentrifuged (10 minutes at 1500rpm) and the supernatant discarded.
The cells were washed twice in DMEMS0 and a cell viability count carried out as 
described in Section 2.11.5.
2.13.4 Preparation of myeloma cells for cell fusion
A 75cm2 flask containing HAT-sensitive, mycoplasma-free myeloma cells in the mid-log 
phase of growth was harvested and centrifuged at 150Qrpm for 15 minutes. The cells 
were washed twice in serum-free medium and a cell viability count carried out as in 
Section 2.11.5.
2.13.5 Cell Fusion
Immunised splenocytes and myeloma cells were mixed in a ratio of 2:1 in a 50ml 
centrifuge tube and centrifuged at 1500rpm for 5 minutes. The resulting pellet was 
washed twice in DMEMS0 to ensure all traces of serum had been removed and was then 
recentrifuged at 2000rpm for 15 minutes. The supernatant was discarded and the pellet 
warmed to 37°C for 3 minutes in a waterbath. The cells were transferred back to the 
laminar flow cabinet and the pellet tapped gently to loosen it from the bottom of the 
tube. 1ml of a solution of 50% (w/v) PEG1500 pre-warmed to 37°C, was added to the cells 
slowly over 1 minute with continuous gentle stirring. The solution was gently mixed for 
a further 1 minute. 3mls of DMEMS0 (pre-warmed to 37°C) was added over 3 minutes 
and the solution mixed. A further 7ml of DMEMS0 was added over the next 5 minutes 
and the solution left at 37°C for 20 minutes. The pellet was centrifuged (lOOOrpm, 5 
minutes) and the supernatant removed.
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The cells were resuspended in DMEMSio/T24 conditioned medium to a concentration 
of 1 x 106 cells per well. lOOpl of this was dispensed into each well of a 96-well 
microtitre plate and incubated at 37°C in 5% C 02.
On Day 2, lOOpl of DMEMS10 supplemented with 2X HAT selection medium was added 
to each well and the plates reincubated. Thereafter, the cells were fed at 5 day intervals. 
lOOpl of medium was carefully removed and replaced by lOOpl of fresh DMEMS10 
containing 2X HAT.
After 2 weeks, the unfused myeloma cells should all have died in the presence of 
aminopterin, and the unfused splenocytes will die off naturally, leaving only the 
hybridomas. These are weaned off aminopterin by feeding them with medium containing 
HT for a further two weeks. Thereafter, the cells were fed on DMEMS10/T24.
2.13.6 Cloning by Limiting Dilution
To ensure antibodies are monoclonal, the cells must be derived from a homogeneous 
population. Thus, it is necessary to clone the hybridomas to isolate stable colonies of 
specific antibody-producing cells.
Cell viability counts (Section 2.11.5) were carried out on each of the wells to be cloned. 
A solution containing 1 X 106 cells/ ml was prepared from each well. From this, a 
1:1000 dilution was made by initially making a 1:100 dilution in DMEMS0 and then a 
1:10 dilution of this, also in DMEMS0. This yields a solution of 1 cell/1 pi. lOOpl of this 
was made up to 20mls of DMEMS10/T24 and 200pl aliquoted into each well of a 96-well 
microtitre plate. These were incubated at 37°C in a 5% C 02 environment.
2.14 Screening for Antibody Production
2.14.1 Dot Blot
Dot Blotting was carried out according to the method of Hawes (1982). lpl of a 
0.1 mg/ml solution of rFVin was blotted onto nitrocellulose paper (0.45pm pore size, 
Schleicher and Schuell) which had previously been wetted with PBS (0.15M, pH 7.2). 
The dots were air dried and free binding sites were blocked for 1 hour at room 
temperature using a 1% (w/v) solution of bovine serum albumin (BSA) in PBS. The 
blocking buffer was decanted and the blots were washed 4 times in PBS and 4 times in
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PBS containing 0.5% (v/v) Tween 20 (PBS-Tween). Test solution (cell culture 
supernatants, or purified antibody diluted in blocking buffer) was added and this was 
incubated at room temperature for 1 hour on a shaker. The blots were washed as before, 
and anti-mouse (or anti-rabbit) antibody conjugated to alkaline phosphatase, diluted 
1:1000 in blocking buffer, was added. These were incubated for 1 hour at room 
temperature. Unbound secondary antibody was decanted, the blots washed and bound 
antibody detected using a solution of 0.5M Tris-HCl, pH 8.9 containing 0.46mM 5- 
Bromo-4-chloro-3-indolyl phosphate, 0.12mM nitroblue tétrazolium, 4mM MgCl2 and 
4% (v/v) N,N-dimethyl-formamide. Substrate was incubated for 2-5 minutes, or until the 
appearance of purple dots. Prolonged incubation periods (i.e., longer than 15 minutes) 
resulted in false positives. The reaction was terminated by flushing the blots with 
distilled water.
2.15 Antibody Production
2.15.1 Expansion of Hybridomas in vitro
Hybridomas which were actively growing were transferred from 96-well plates to 24- 
well plates. These were further expanded into 25cm2 flasks and 75cm2 flasks. 
Supernatant was harvested, any cells which may have been present were removed by 
centrifugation and the remaining supernatant stored at -20°C.
2.15.2 Production of Antibody Rich Ascitic Fluid
Balb/c mice were primed by injection of 0.5ml of incomplete Freud’s Adjuvant
intraperitonially (i.p.). 24 hours later, hybridoma cells from growing homogenous
cultures were harvested, centrifuged (200Qrpm, 10 minutes) and the supernatant 
removed. The pellet was resuspended in DMEMS0 to give a final cell concentration of 
1 x 106 /ml. 0.5ml of this was injected into each of the primed mice. Ascitic fluid in the 
form of abdominal swelling became apparent after 10 to 20 days. The mice were 
sacrificed and fluid drained. Cells were removed by centrifugation and the supernatant 
was further purified or stored at -20°C.
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2.16 Antibody Purification
2.16.1 Saturated Ammonium Sulphate
Antibody was purified according to the method of Hudson and Hay (1980). Ascitic fluid 
or rabbit serum was purified initially by ammonium sulphate precipitation. The pH of 
the serum was adjusted to 7.2 and an equal volume of cold 100% saturated ammonium 
sulphate (SAS) was added dropwise while stirring. The solution was then stirred for 1 
hour in an ice bath. The precipitated immunoglobulin was collected by centrifugation 
(4°C, 5000rpm for 20 minutes). The pellet was resuspended in 50% SAS and 
recentrifuged. This step was repeated. The pellet was then resuspended in a minimum 
volume of PBS and exhaustively dialyzed against PBS at 4°C.
2.16.2 Affinity chromatagraphv
0.4g of activated Sepharose (Pharmacia) was suspended in 3ml of ImM HC1 and 
transferred to a sintered glass funnel. It was washed over 15 minutes, with a further 
80ml of ImM HC1 , followed by 2ml of coupling buffer (0.1M NaHC03 with 0.5M 
NaCl, pH 8.3). rFVIII (0.8mg/ml), was diluted in coupling buffer to a total volume of 
2.8ml and added to the washed gel. This gave a buffengel ratio of 2:1. The gel and 
ligand were then mixed in a shaking waterbath at room temperature for 2 hours. The 
mixture was returned to the sintered glass funnel and washed with 5ml of coupling 
buffer. It was then transferred to a conical flask containing 3 ml of blocking buffer 
(0.2M glycine in coupling buffer, pH 8.3) and left for 1 hour at room temperature. To 
remove any non-covalently bound protein, the gel was washed with 3 cycles of 
alternating pH buffers (0.1M sodium acetate with 0.5M NaCl, pH 4.5 and 0.1M Tris- 
HC1 with 0.5M NaCl, pH 8.0). The gel was then suspended in PBS (0.15M, pH 7.2) and 
used to pour a column in a 1ml syringe barrel with a small piece of cotton wool as a 
plug. PBS was added to prevent the gel drying out.
The column was washed with PBS to remove any protein that may have leached off. 
Fractions were monitored for protein content using the BCA protein assay as described 
in Section 2.7. Antibody sample was slowly added to the column, followed by washing 
with PBS. 1ml fractions were collected and protein concentration monitored using the 
BCA protein assay.
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Dissociation buffer (0.1M glycine-HCl, pH 2.5) was added and the column clamped and 
left for 15 minutes. 1ml fractions were collected and monitored for protein as before. 
The pH of antibody-containing fractions was returned to physiological levels by addition 
of lOOpl of 1M Tris-HCl, pH 10.5.
The column was regenerated by washing with 5ml of each of 0.1M Tris-HCl with 0.5M 
NaCl, pH 8.5, 0.1M sodium acetate, pH 4.5 and 0.15M PBS, pH 7.2. The column was
stored at 4°C in PBS containing 0.02% (w/v) sodium azide.
2.16.3 Protein A Affinity Chromatography
Antibodies were also purified by affinity chromatography on immobilized Protein A. 
The pre-poured column was equilibrated with lOmM Tris, pH 7.5 (binding buffer). The 
serum was diluted with binding buffer to within the binding range of the gel and 2ml 
of this was applied to the column. The column was washed with binding buffer to 
remove unbound protein. 1ml fractions were collected and the protein concentration 
monitored using the BCA protein assay (Section 2.7). Bound IgG was eluted with 0.1M 
glycine buffer, pH 2.5. The pH of the IgG fractions was returned to physiological levels 
by addition of lOOpl of 1M Tris, pH 7.5. Pooled fractions containing eluted 
immunoglobulins were desalted on a 10ml Sephadex G-25 column.
2.16.4 Gel Filtration
Monoclonal antibodies were also purified by gel filtration through Sepharose 6B 
(Pharmacia). A 0.9cm x 24cm column with a bed height of 18cm was used, with a flow 
rate of approximately 0.4ml/minute. 1ml of antibody solution was applied to the column 
which had been equilibrated with 0.15M PBS, pH 7.2. 1ml fractions were collected and 
protein content monitored using the BCA protein assay (Section 2.3.5). The 
immunoreactivity of each fraction was assessed by Dot Blot (Section 2.9.1).
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2.17 Isotvping Analysis
(i) Enzyme-linked Immunosorbent Assay (ELISA)
An isotyping kit (Sigma, UK) was used. 2 formats were used: indirect and capture 
ELISAs. In the indirect system, test antibody was diluted in PBS (0.15M, pH 7.2) to a 
concentration of 1 pg/ml, lOOpl applied to wells of a microtitre plate and the plate 
incubated at 37°C for 1 hour. The wells were washed in PBS containing 0.05% (v/v) 
Tween 20 and the goat anti-mouse isotype-specific antibodies (diluted in PBS) were 
added (lOOpl). Plates were further incubated at room temperature for 30 minutes before 
being washed as before, and lOOpl of horseradish peroxidase-labelled rabbit anti-goat 
IgG applied for 30 minutes at room temperature. Following washing, lOOpl of substrate 
[lOmg o-phenylenediamine and 5pl H20 2 in 25ml citrate buffer (0.5M Na2HP04 with 
0.1M citric acid, pH 4.5) was added and incubated for 30 minutes at room temperature. 
Colour was allowed to develop at 37°C for 20 minutes.
In the capture ELISA, the isotype-specific antibodies were coated onto the plate 
(10pg/ml, lOOpl). This was then incubated at 37°C for 1 hour, washed as above, and test 
antibody added (lOOpl). The plates were further incubated, (1 hour at room temperature) 
washed and lOOpl of alkaline-phosphatase-labelled goat anti-mouse IgG added.
This was then incubated at room temperature for 30 minutes, washed and substrate 
added (lmg/ml BCIP in AMP buffer). Colour developed over 20 minutes at 37°C.
(ii) Agglutination
A Serotec antibody isotyping kit was used. The kit is based on the principle of cell 
agglutination. A highly specific antibody is coupled to sheep red blood cells. This 
recognises and binds to the particular isotype to which it is directed. This "binding" 
forms a lattice on the bottom of the microtitre plate well and is termed agglutination. 
30pl of diluted antibody (in 0.15M PBS, pH 7.2) was pipetted into each of 8 wells of 
a 96-well "U" bottomed microtitre plate. 30pl of each specific isotyping reagent was 
added and the solutions mixed. The plate was covered and incubated on a flat surface 
for 1 hour at room temperature. A part or full carpet of agglutination indicated a positive 
reaction. A small red circle or "button" was indicative of a negative reaction. Here, no 
agglutination occured, so the reagents fall to the bottom of the well forming the red 
circle.
75
2.18 Electrophoresis
Polyacrylamide gel electrophoresis (PAGE) was carried out according to the method 
of Laemmli (1970) using a Tris-Glycine buffer system in the presence of sodium 
dodecyl sulphate (SDS). Stock solutions of 1.5M Tris-HCl, pH 8.8, 0.5M Tris-HCl, pH 
6.8, 30% (w/v) acrylamide containing 0.8% bisacrylamide, 10% (w/v) SDS, 1% (w/v) 
ammonium persulphate (APS) freshly prepared, were used to prepare both resolving 
(10% (w/v) and 7.5% (w/v) acrylamide) and stacking gels (5% (w/v) acrylamide) 
according to Table 2.18.1.
Samples for electrophoresis were dissolved in sample buffer consisting of 0.08M Tris- 
HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol and 0.2% (w/v) bromophenol blue (2- 
mercaptoethanol (0.5% (v/v)) was included when reducing conditions were required), 
and boiled at 100°C for 3 minutes. 20ul was applied to each well on the gel and 
electrophoresis carried out in electrode buffer (0.192M glycine, 25mM Tris-HCl, 0.1% 
(w/v) SDS, pH 8.3) at a constant current of 20mA/gel until the dye front approached the 
bottom of the gel.
Gels were stained for 45 minutes in 0.5% (w/v) Coomassie Brilliant Blue in a 5:1:4 
solution of water:acetic acid:methanol. Destaining was earned out overnight in a 5:1:4 
solution of water:acetic acid:methanol.
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Stock Solution Resolving gels 
7.5% 10%
Stacking gels 
5%
30% (w/v) Acrylamide 3.8ml 5.0ml 0.8ml
Distilled Water 8.0ml 6.8ml 3.6ml
1.5M Tris-HCl, pH 8.8 3.0ml 3.0ml —
0.5M Tris-HCL, pH 6.8 — — 0.5ml
SDS 150pl 150pl 50pl
TEMED 9pl 7.5pl 5pl
APS 60pl 50pl 17pl
Table 2.18.1 Resolving and stacking gels used in Electrophoresis and Western blotting.
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2.19 Western Blotting
The method was essentially that of Towbin et al. (1979). rFVIII (120pg/ml) was 
incubated with human thrombin (lU/ml) at 37°C for 5 minutes. It was then dissolved in 
sample buffer and SDS-PAGE, as described in Section 2.18, carried out on a 0.75mm 
thick, 7.5% resolving gel (Table 2.18.1) using a LKB Mini-gel system. The gel was 
washed in transfer buffer (25mM Tris-HCl, 192mM glycine, pH 8.3) and placed on a 
sheet of nitrocellulose (NC) paper (0.45pm pore size; Schleicher and Schuell) cut to the 
appropriate size and presoaked in transfer buffer. The NC-gel sandwich was then placed 
between sheets of filter paper (Whatman 3M) soaked in transfer buffer and placed into 
a blotting tank (Biorad) with the NC facing the anode. Electrophoretic transfer was 
carried out at 15V (with an upper limit set at 340mA) for 30 minutes.
Blots were removed, washed in TBS (lOmM Tris-HCl, 150mM NaCl, pH 7.5) and free 
binding sites on the NC blocked using 1% (w/v) BSA in TBS. After 2 hours incubation 
at room temperature with agitation, the blots were washed 3 times as before and 
monoclonal antibody, diluted in blocking buffer, added. The blots were incubated on a 
shaking waterbath for 2 hours at room temperature. The NC was washed 5 times in TBS 
to remove unbound antibody, and alkaline phosphatase-labelled anti-mouse IgG, (Sigma, 
UK), diluted in blocking buffer, was added. This was incubated, with shaking, for 2 
hours at room temperature. The blots were washed 5 times as before, with the final wash 
in alkaline phosphatase buffer (lOOmM Tris-HCl, with lOOmM NaCl and 5mM MgCl2, 
pH 9.5). Substrate solution, consisting of 66pl nitroblue tetrazolium (0.5g in 10ml 70% 
(v/v) dimethyl formamide (DMF)), and 33pl 5-bromo-4-chloro-3-indolyl phosphate 
(toluidine salt) (BCIP) (0.5g in 10ml 100% (v/v) DMF) in 10 ml alkaline phosphatase 
buffer. Colour development was allowed to proceed at room temperature for no more 
than 30 minutes. The reaction was stopped by addition of 0.15M PBS, pH 7.2 containing 
20mM EDTA.
2.20 HPLC Analysis of antibodies
lOpl of purified antibody diluted in PBS (0.15M, pH 7.2) was applied to a Waters 
Protein Pak 300SW 10pm column pre-equilibrated with mobile phase buffer (0.1M 
phosphate buffer pH 7.2) (filtered and degassed). A flow rate of 0.5ml/minute was used 
and the presence of protein was monitored by reading absorbance at 280nm.
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2.21 Conjugation of Horseradish peroxidase to anti-rFVIII IgG 
The method of Tijssen and Kurstak (1984) was followed. There are three steps involved 
in the procedure (i) activation of horseradish peroxidase (HRP) (ii) conjugation of 
activated HRP to the immunoglobulin (iii) purification of the conjugate.
(i) Activation of HRP: 2mg of HRP was dissolved in 5mls of freshly prepared lOOmM 
NaHCOa. 5mls of 8mM N aI03 was added to this, the tube sealed and stored in the dark 
at room temperature for 2 hours.
(ii) Conjugation: 1.5mls of a 5mg/ml solution of anti-rFVIII antibody was dialysed 
against 20mM Na^COs buffer, pH 9.5 overnight at 4°C. The solution was then added to 
lml of activated HRP. The mixture was transferred to a glass wool-plugged 1ml pasteur 
pipette with the tip sealed by a flame and dry Sephadex G-25 (5mg) added. The pipette 
was covered with foil and incubated at room temperature for 3 hours. The reaction 
mixture was eluted from the column and 1/20 volume (IOOjjI) of freshly prepared NaBH, 
(5mg/ml in O.lmM NaOH) added. This was incubated for 30 minutes at room 
temperature before a further 1/10 volume (200pl) of NaBH* (freshly prepared) was 
added. The mixture was incubated for 1 hour at 4°C.
(iii) Purification of the conjugate: free HRP is soluble in ammonium sulphate up to 70- 
80% (w/v) saturation. Therefore, an equal volume of SAS was added gradually with 
stirring and the mixture incubated for 1 hour. The precipitate was collected by 
centrifugation (5000rpm, 20 minutes), washed with 50% SAS and recentrifuged. The 
precipitate was suspended in a minimum volume of PBS and dialysed against PBS 
overnight at 4°C.
2.21.1 Measurement of the enzymic activity of the antibody/enzme conjugate 
The conjugate was diluted in PBS (1:1000), and 20pl of this was added to 3mls of 
freshly prepared substrate solution (lOmg of o-phenylenediamine in 25mls of 
citrate/phosphate buffer (0.1M sodium citrate, 0.1M disodium hydrogen phosphate, pH
4.5) with 5pl of H20 2). The mixture was covered in foil and incubated at room 
temperature. 200pl samples were withdrawn after intervals of 0, 2, 5, 10, 15, 20, 30 
minutes and transferred to duplicate wells of a microtitre plate. The reaction was stopped 
by addition of 25pl of 20% (v/v) H2S 0 4. The plate was stored in the dark between 
sample additions. Absorbance at 492nm was read on a Titertek Twinreader Plus.
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The conjugate was stored at -20°C in the presence of 50% (v/v) glycerol.
2.22 Binding of antibodies to rFVIII
The effect of antibody binding on the procoagulant activity of rFVIII was examined. 
rFVIII (0.66mg/ml) was incubated with equal volumes of a series of antibody 
concentrations at room temperature and 37°C for 2 hours. The activity of each sample 
was then assayed.
Samples were then subjected to dénaturation studies as described in Section 2.5.
2.23.1 Enzyme-linked Immunosorbent Assay
5jig/ml of rFVIII in carbonate/bicarbonate buffer (0.03M NaHC03, 0.01M NajCOj, pH
9.6) was coated onto the surface of duplicate wells of a microtitre plate (Nunc, 
Denmark) (1 hour incubation at 37°C). The plates were washed 3 times in PBS (0.15M, 
pH 7.2) and 3 times in PBS containing 0.05% (v/v) Tween-20 (PBS-Tween) with the 
final wash in PBS. Free binding sites were blocked with 200|il of a solutiom of 1% 
(w/v) BSA in PBS. After an hour at 37°C, the plate was washed as above, and lOOpl of 
primary antibody diluted in blocking buffer added. The plate was incubated at 37°C for 
1 hour. After washing, alkaline phosphatase-labelled anti-rabbit antibody, diluted 1 r4000 
in blocking buffer, was added (lOOpl) and incubated for 1 hour at 37°C. The plate was 
washed, and substrate added (1 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP) in 
2-amino-2-methy 1-1 -propanol (AMP) buffer, pH 9.5). After 30 minutes at 37°C, 
absorbance at 620nm was read on a Titertek Twinreader Plus.
2.23.2 IgG ELISA
10jig/ml of anti-rFVni antibody in carbonate/bicarbonate buffer (0.03M NaHC03, 0.01M 
NajCC^, pH 9.6) was coated onto the surface of duplicate wells of a microtitre plate 
(Nunc, Denmark) (1 hour incubation at 37°C). The plates were washed 3 times in PBS 
(0.15M, pH 7.2) and 3 times in PBS containing 0.05% (v/v) Tween-20 (PBS-Tween) 
with the final wash in PBS. Free binding sites were blocked with 200pl of a solution of 
1% (w/v) BSA in PBS. After an hour at 37°C, the plate was washed as above, and 100pl 
of alkaline phosphatase-labelled anti-rabbit antibody, diluted 1:4000 in blocking buffer, 
was added and incubated for 1 hour at 37°C. The plate was washed, and substrate added
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(lmg/ml 5~bromo-4-chloro-3-indolyl phosphate (BCIP) in 2-amino-2-methyl-l-propanol 
(AMP) buffer, pH 9.5).
After 30 minutes at 37°C, absorbance at 620nm was read on a Titertek Twinreader Plus.
2.24 Concentration of samples
Samples of rFVIII and anti-rFVIII antibodies were concentrated using 
microconcentrators (Amicon). 425jj1 of a 0.05mg/ml solution of rFVIII or 300jil of a 
0. lmg/ml solution of anti-rFVIII monoclonal antibody, was applied to a 
microconcentrator.
These were centrifuged in a fixed-angle centrifuge (Beckman J2-21) at 5000rpm for 30 
minutes. 60pl of rFVIII and 40pl of antibody were recovered. The protein concentration 
of the samples before and after concentration were assay using the BCA protein assay 
(Section 2.7).
2.25 Thrombin Activation of FVIII
lOOpl of Coag Cal N calibration plasma or normal human plasma in plastic test tubes 
was reacted with lOU/ml of thrombin (Sigma, UK) and incubated at 37°C for 90 
seconds. lOOpl of heparin was added to a final concentration of lOOU/ml to prevent the 
formation of a clot. This was then added to wells of a microtitre plate which had been 
coated with anti-rFVIII antibodies, and an ELISA carried out as described in Section 
2.23.1.
2.26 ELECTROCHEMICAL METHODS
2.26.1 Electrode Preparation
Before use, the bare glassy carbon electrode was polished with alumina slurry, after 
which it was sonicated in distilled water and allowed to dry in air. Modification of the 
electrode was achieved via drop coating of a 10|al aliquot of the appropriate 
concentration of rFVIII in Nafion onto the electrode surface. This was allowed to dry 
in air for 15 minutes and then further dried by gentle heating under an air gun.
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2.26.2 Amperometric Voltammetry
10mIs of 0.1M phosphate buffer (0.02M KH2P 0 4, 0.08M IQHPO^ pH 7.3) was placed 
in the reaction cell and purged with oxygen-free nitrogen for 20 minutes. The modified 
electrode was introduced into the cell and connected to the potentiostat. DC constant 
voltammetry was carried out at a potential of -0.03 vs saturated calomel electrode (SCE). 
The hydroquinone mediator (0.1M in phosphate buffer) was injected into the cell to a 
final concentration of 2mM immediatly prior to use. Hydrogen peroxide substrate was 
then added (to a final concentration of ImM) and the reduction current of the mediator 
measured.
2.21 Partial purification of FVIII samples and separation of the FVIIl/vWF complex 
This method was based on that described by Rick and Hoyer (1973). The FVin/vWF 
complex was separated in the presence of high ionic strength buffers by filtration 
through a Sepharose 6B gel filtration column. A 0.9cm x 24cm column with a bed 
height of 17cm was used, with a flow rate of approximately 0.4ml/minute. 0.5ml of 
Coag Cal N calibration plasma or normal human plasma was applied to the column 
which had been equilibrated with 0.1M imidazole buffer, pH 7.2 containing 0.24M CaCl2 
and 1ml fractions were collected. The presence of FVIII in each fraction was measured 
using the FVIII chromogenic assay (Section 2.3), along with the protein content 
(measured by the BCA protein assay (Section 2.7)).
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CHAPTER 3 
CHEMICAL MODIFICATION OF rFVIII
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3.1 Introduction
The use of chemical cross-linkers to modify protein structure is a widespread and 
powerful technique. The chemistry of such reactions is well understood allowing for 
specific side chains to be targeted. Such modifications can be used to enhance the 
stability of a protein by introducing inter- and intra-molecular cross-links. These 
"bridges" act by reinforcing the active conformation of the protein, decreasing the 
entropy and reducing the rate of denaturation (Wong and Wong, 1992).
Bifunctional cross-linking reagents are the most successfully used cross-linkers. They 
can be divided into three main subgroups (Ji, 1983):
(i) zero-length
(ii) homobifunctional
(iii) heterobifunctional
Zero-length cross-linkers induce direct conjugation between two chemical groups, 
without introducing extrinsic material. Examples include carbodiimides and 
carbonyldiimidazole, which induce condensation of a carboxyl and amine group forming 
an amide bond (Ji, 1983).
Homobifunctional cross-linkers contain two identical functional groups, separated by a 
spacer of varying length. The two functional groups react with similar amino acid side- 
chains, forming a link of defined length.
Heterobifunctional cross-linkers contain two different functional groups at either end of 
the molecule.
Acylating and alkylating agents are the most commonly used functional groups (Wong 
and Wong, 1992). The acylating agents are generally considered to be amino-specific 
while the alkylating agents are thiol-specific. Thus, homobifunctional reagents contain 
either acylating or alkylating agents, whereas heterobifunctionals contain a combination 
of both of these types. Examples of homobifunctional agents are the amino-specific bis- 
imidate series (Ji, 1983) and the thiol-specific bis-maleimides (Weston etal, 1980) while 
succinimidyl 4-(N-maleimidomethyl) cyclohexane carboxylate (SMCC) (Yoshitaki et al,
1982) is an example of a heterobifunctional cross-linker (Figure 3.1).
FVIII is stabilised in vivo by the large multimeric protein von Willebrand factor (vWF). 
In its absence FVIII becomes highly unstable. The effects of cross-linkers and other 
protein modifying reagents on rFVIII were investigated.
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Figure 3.1 Bifunctional cross-linking reagents
Bis-imidates and Bis-maleimides are examples of homobifimctional reagents
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3.2 Miniaturisation of FVIII chromogenic assay
The Baxter Factor VIII Chromogenic assay was used for the photometric determination 
of FVni activity. The assay is based on the detection of Factor X (FX). Thrombin 
activates FVIII in the sample and this in turn acts as a cofactor, along with Ca2+ and 
phospholipids, in the activation of FX by activated Factor IX (FIXa). Activated FX 
(FXa) then hydrolyses a p-nitroanilide substrate releasing a coloured product, p- 
nitroaniline, which can be detected photometrically at 405nm. The colour is directly 
proportional to FXa activity and, thus, to FVIII activity in the sample (Figure 3.2.1). 
The kit was capable of performing 40 macroassays and in order to maximise efficiency 
and save reagents, it was miniaturised. The volumes of each component were reduced 
by a factor of 4, to 25pl of sample, 25pl of FX and FIXa reagents and 125pl of 
substrate, and the assay carried out in a 96-well microtitre plate held at 30°C. The 
absorbances were read on a Titretek Twinreader Plus. Using this method, each kit was 
capable of performing approximately 160 assays.
Reagents were added to the plate by means of a multichannel pipette. An automatic 
dispenser was incorporated into the machine, but the time taken to dispense 
automatically into each well was longer than the time period of the assay.
The advantages of such a microassay include the capacity for a large number of 
samples, ease of performance of replicate assays, economy in its use of reagents, small 
sample volumes, a controlled temperature environment and automatic mixing.
Using the kinetic assay procedure with Coag Cal N calibration plasma and FVIII- 
deficient plasma as positive and negative controls respectively, FVIII activity was 
calculated as follows:
% FVIII activity of calibration plasma = 
AA/min calibration plasma =
AA/min zero standard =
AA/min sample =
Calibration factor =
C
B
S
F
A (= 107%)
A _ F
C - B
% FVIII activity in sample:
= (S - B) x F
8 6
(a) FVDI + thrombin — » FVIIIa
FVIIIa
(b) FX FXa
FIXa, Ca2+, phospholipids
(c) CHjOCO-D-CHG-Gly-Arg-pN A
I Fxa
CH3OCO-D-CHG-Gly-Arg-OH + pNA
Yellow
X*» 405nm
Figure 3.2.1 The chromogenic assay for the detection of FVIII activity.
FVIII was initially activated by proteolytic cleavage carried out by 
thrombin (a). Activated FVIII (FVIIIa) then acted as a cofactor in the 
enzymic activation of Factor X (FX) by activated Factor IX (FIXa) in 
the presence of Ca1* and phospholipids (PI) (b).
Substrate was added and hydrolysed by FXa (c), forming a coloured 
product which can be detected at 405nm.
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The rate of increase in absorbance for each dilution of Coag Cal was linear over 2 
minutes up to a dilution of 1:124 (equivalent to less than 1% FVIII activity) (Figure 
3.2.2). The change in absorbance for each dilution is shown in Figure 3.2.2.
3.3 Accelerated Storage studies
(i) The effects of Calcium on rFVIII activity.
The concentration of Ca2+ has an enormous effect of FVIII activity as shown in Figures
3.3.1 and 3.3.2. Any concentration greater than 5mM causes a marked decrease in FVIEI 
activity.
An immediate decrease in FVIII activity was noticable in the presence of lOmM Ca2+. 
At temperatures of 27°C and above, there was no activity recorded after Day 1, whereas 
at these temperatures the control exhibited activity up to Day 3. At 4°C no activity was 
recorded after Day 3, compared with the control (5mM Ca2+) which was active until Day
At -20°C and-70°C, activity was again decreased as compared with the control.
No activity was recorded in any of the samples incubated in 20mM Ca2+.
These results show that the concentration of Ca2+ in the buffer is critical for the 
expression of FVHI activity. Any concentration above 5mM caused a pronounced 
decrease and eventual loss of FVIII procoagulant activity.
(ii) The effects of albumin on rFVIII activity.
Results from this study indicate that in the presence of additional protein, FVIII activity 
is maintained over a number of temperatures for a longer period of time. At the higher 
temperatures (37°C and 45°C), activity persisted longer in the test samples as compared 
with the control (no excess protein).
The period over which activity remained in the test, but not in the control, depended on 
the amount of added protein i.e. the more protein present, the longer the activity 
persisted. (Figure 3.3.3)
The presence of protein in the buffer, therefore, appears to stabilise rFVIII.
This is the normal method of storage of FVIII for clinical applications in the treatment
of haemophilia A.
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Figure 3.2.2 Time course of the chromogenic assay for the detection of FVTII 
in a microtitre plate. A series of dilutions of Coag Cal N 
calibration plasma (i.e., normal human plasma) were prepared 
in 0.9% (w/v) NaCl ( O , 1:21 dilution; • ,  1:31 dilution; A, 1:62 
dilution; ▲, 1:124 dilution; ■ , FVIH-deficient plasma) and 
assayed. Absorbance was measured at 405nm at 15 second 
intervals over 2 minutes. Each point represents the mean of 
quadruple duplicates.
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Figure 3.3.1 Accelerated storage studies on rFVIII in the presence of 5mM 
Ca2+.
rFVIII was incubated in Tris-HCl buffer containing 5mM Ca2+ 
at the indicated temperatures. Samples were withdrawn at 
regular intervals and assayed for FVIII activity. The change in 
absorbance per minute (AA/min) was measured and used as an 
indicator of FVIII activity.
90
A
A
/m
in
 
at 
40
5n
m
TIME (days)
Figure 3.3.2 Accelerated storage studies on rFVin in the presence of lOmM
Ca2+.
rFV m  was incubated in Tris-HCl buffer containing lOmM Ca2+ 
at the indicated temperatures. Samples were withdrawn at 
regular intervals and assayed for FVIII activity. The change in 
absorbance per minute (AA/min) was measured and used as an 
indicator of FVIII activity.
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3,4 Diluent for FVIH assay
0.9% (w/v) NaCl and FVffl-deficient plasma were compared as diluents for the 
FVin assay. The results are shown in Table 3.4. When assayed in 0.9% (w/v) 
NaCl, the rate of increase in absorbance at 405nm for each dilution was higher 
than the corresponding dilution in FVIII-deficient plasma. For this reason and 
for economy and ease of handling, 0.9% (w/v) NaCl was chosen as diluent for 
all FV m  activity assays, with FVIII-deficient plasma being used as a negative 
control.
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Figure 3.3.3 Accelerated storage studies on rFVTII in the presence of 
additional protein.
rFVTII was incubated in Tris-HCl buffer containing 20mg/ml bovine 
serum albumin (BSA), at the indicated temperatures. Samples were 
withdrawn at regular intervals and assayed for FVIII activity. The 
change in absorbance per minute (AA/min) was measured and used as 
an indicator of FVIII activity.
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Dilution of Coag Cal N AA/min ± S.D. at 405nm 
in FVIII-deficient plasma
AA/min ± S.D. at 405nm 
in 0.9% (w/v) NaCl
1:21 .024 ± .002 .081 ± .006
1:31 .022 ± .003 .073 ± .005
1:62 .018 ± .001 .041 ± .002
1:124 .013 ± .001 .020 ± .001
Positive control .105 ± .011 .125 ± .020
Negative control .002 + .000 .005 ± .001
TABLE 3.4 Comparison between FVIII-deficient plasma and 0.9% (w/v) NaCl as 
diluent for FVIII chromogenic assay.
Dilutions of Coag Cal N were assayed in each diluent and the 
absorbance at 405nm was measured at 15 second intervals over 2 
minutes. The change in absorbance per minute (AA/min) was then 
calculated.
Coag Cal N calibration plasma (i.e. normal human plasma) and FVIII- 
deficient plasma were used as positive and negative FVIII controls, 
respectively.
S.D. is the standard deviation where n = 3.
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3.5 Stability of rFVIII in Tris-HCl and Barbital buffers
rFVm, in both Tris-HCl and Barbital buffers, was assayed to ensure that neither 
buffer interfered with the assay in any way. Dénaturation studies, as described in 
Section 2.5, were then carried out on rFVIII in each buffer. Chemical modification 
experiments (except those involving amino-specific reagents) were carried out with 
rFVIII in Tris-HCl buffer. An alternative buffer was used for amino-specific reagents, 
as the quarternary amino groups in Tris could interfere with the modification process. 
Barbital buffer was chosen as the alternative.
Figure 3.5 shows that while rFVIII was denatured at similar rates in both buffers, the 
residual FVIII activity appeared to be higher in Trsi-HCl buffer than in barbital 
buffer.
Therefore, it was concluded that these buffers were suitable for use in the 
modification experiments.
3.6 Chemical Cross-linking of rFVIII
A wide range of cross-linkers were used, including both homobifunctional and 
heterobifunctional reagents. The concentrations of the cross-linkers used were in 
relation to the moles of lysine (approximately 40) or cysteine (23) residues (Vehar 
et al., 1984) present in the recombinant FVIII molecule. Thus, the concentrations 
were in the mM to pM range.
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Figure 3.5 Comparison between the rate of denaturation of rFVIII in Tris- 
HC1 and barbital buffers.
rFVIII was diluted in each buffer and subjected to and incubated 
at 55°C for 1 hour. Samples were withdrawn at regular intervals 
and assayed for FVIH activity. The change in absorbance per 
minute (AA/min) was measured and used as an indicator of FVIII 
activity.
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3.6.1 Amino-specific reagents
3.6.1.1 Bis-imidates
Three of the bis-imidate series of cross-linkers, dimethyl adipimidate (DMA), 
dimethyl pimelimidate (DMP) and dimethyl suberimidate (DMS) (Ji, 1983), were 
reacted with rFVIII in barbital buffer. They contained 4, 5 and 6 methyl groups, 
respectively between the reactive ends of the molecule (Figure 3.1). The reaction 
resulted in an almost complete loss of FVin activity in the test samples, as compared 
with the control rFVIII (Table 3.6.1.1).
Denaturation studies were carried out on the control and test samples containing 
rFVIII and 40pM DMS and rFVIII with 40pM DMA, to determine whether there was 
any increase in thermostability (Figure 3.6.1.1). No increase was detected.
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Reactants AA/min ± S.D. at 405nm % Recovery
rFVIII control 0.172 ± .010 100
rFVIII + 40pm DMA 0.011 ± .001 6
rFVIII + 40pM DMP 0.010 ± .001 6
rFVIII + 40pM DMS 0.010 ± .001 6
Positive control 0.132 + .007
Negative control 0.004 ± .001
TABLE 3.6.1.1 Reaction of rFVIII with three of the amino-specific bis-imidate 
series of cross-linkers with rFVIII. rFVIII was reacted with the bis- 
imidates on ice for 30 minutes. The change in absorbance per 
minute (AA/min) was measured and used as an indicator of FVIH 
activity.
The addition of any of the cross-linkers caused almost complete 
loss of FVIII activity.
DMA: Dimethyl adipimidate 
DMP: Dimethyl pimelimidate 
DMS: Dimethyl suberimidate
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were used as positive and negative FVIII 
controls, respectively.
S.D. is the standard deviation where n = 3.
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Figure 3.6.1.1 Denaturation of native rFVIII, dimethyl suberimidate-(DMS) 
and dimethyl adipimidate-(DMA) modified rFVIII.
Samples of rFVIII and rFVIII modified with 40pM DMA and 
40jiM DMS were incubated at 55°C for 1 hour. Aliquots were 
withdrawn at regular intervals and assayed for FVIII activity. 
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at the particular time.
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3.6.1.2 Glutaraldehyde
The addition of glutaraldehyde (GA), a non-specific cross-linker (Steck, 1972), in 
concentrations greater than ImM resulted in loss of rFVIII activity (Table 3.6.1.2). 
Dénaturation studies were carried out on the control containing rFVIII only and 
rFVIII with ImM GA. The modified sample did not prove to be any more 
thermostable than the native protein (Figure 3.6.1.2). GA reacts with a number of 
different amino acid side chains, including those of lysine, cysteine, histidine and 
tyrosine. In dilute solution, GA exists in a number of different polymeric forms, and, 
therefore, the length of any cross-link formed cannot be estimated (Ji, 1983).
Reactants AA/min ± S.D. at 405nm % Recovery
rFVIII Control .308 ± .002 100
rFVIII + ImM GA .205 ± .002 66
rFV m  + 2mM GA .025 ± .001 8
rFVIII + 3mM GA .041 ± .002 13
Positive control .137 ± .010
Negative control .005 ± .000
TABLE 3.6.1.2. Reaction of rFVIII with glutaraldehyde (GA). rFVIII was reacted 
with increasing concentrations of GA on ice for 1 hour. The 
change in absorbance per minute (AA/min) was measured and used 
as an indicator of FVIII activity.
At concentrations greater than ImM FVIII activity is greatly 
reduced.
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma, were used as positive and negative FVIII 
controls, respectively.
S.D. is the standard deviation where n = 3.
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Figure 3.6.1.2 Dénaturation of native rFVIII and Glutaraldehyde (GA).
Samples of rFVIII and rFVIII with ImM G A were incubated 
at 55°C for 1 hour. Aliquots were withdrawn at regular intervals 
and assayed for FVIII activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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3.6.2 Thiol-specific reagents
3.6.2.1 Bis-maleimides
N-substituted bis-maleimide derivatives provide highly specific and mild bifunctional 
cross-linking reagents for sulphydryl groups (Ji, 1983). Two of this series of 
compounds were used in an attempt to form cross-links by an alkylation reaction. The 
first of these was bis-(maleimido)-methyl-ether (BMME) (Weston et al., 1980). 
Results showed that, unlike the amino-specific reagents, FVIII activity was not lost 
after addition of the cross-linker. For a range of BMME concentrations, O-IOOjjM, the 
FVIII activity was comparable with the control (Table 3.6.2.1). 
rFVm  and rFVIII which had been reacted with IOjiM and 40pM BMME, 
respectively, was subjected to denaturation (Figure 3.6.2.1.1).
No increase in thermostability was recorded.
A second bis-maleimide, N-N-bis (3-maleimidopropionyl)-2-hydroxy-l,3-propane- 
diamine (BMPPD), was used. Addition of the cross-linker proved to have no adverse 
effect on the activity of rFVIII (Table 3.6.2.1).
Denaturation studies, however, showed that bis-maleimide treated rFVIII was no more 
thermostable than the native rFVIII (Figure 3.6.2.2).
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Concentration of 
Bis-maleimide
AA/min ± S.D.
at 405nm
% Recovery
(i) BMME
0 (FVIII control) .315 ± .009 100
lOpM .271 ± .013 86
20pM .221 ± .015 63
40pM .295 ± .006 94
80pM .288 ± .012 91
lOOpM .234 ± .018 74
(ii) BMPPD
0 (FVIII control) .315 ± .009 100
lOpM .310 ± .008 98
20pM .312 ± .004 99
40pM .325 ± .010 103
80pM .244 ± .005 77
lOOpM .305 ± .004 97
Coag Cai N (positive FVIII control) .134 ± .008
FVIII-deficient plasma (negative control) .007 ± .001
TABLE 3.6.2.1 Reaction of rFVIII with two of the thiol-specific bis-maleimide 
series of cross-linkers. The reaction took place at room temperature 
for 10 minutes. The change in absorbance per minute (AA/min) was 
measured and used as an indicator of FVIII activity.
The presence of the cross-linker does not cause any significant loss 
of FVin procoagulant activity, even at the higher concentrations. 
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were included as positive and negative FVin 
controls, respectively.
S.D. is the standard deviation where n = 3.
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Figure 3.6.2.1.1 Dénaturation of native rFVTII and bis-(maleimido-methyl) 
ether (BMME)-modified rFVIII.
Samples of rFVIII and rFVIII modified with IOjjM and 
40pM BMME were incubated at 55°C for 1 hour. Aliquots 
were withdrawn at regular intervals and assayed for FVIII 
activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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Figure 3.6.2.1.2 Dénaturation of native rFVIII and N-N-bis (3-
maleimidopropionyl)-2-hydroxy 1,3-propanediamine 
(BMPPD)-modified rFVIII.
Samples of rFVIII and rFVIII modified with IOjjM and 
40pM BMPPD were incubated at 55°C for 1 hour. Aliquots 
were withdrawn at regular intervals and assayed for FVIII 
activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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3.6.3 Heterobifunctional cross-linkers
Two heterobifunctional cross-linkers, N-Cy-maleimidobutyryloxy) succinimide 
(GMBS) (Fujiwara et al., 1981), and succinimidyl 4-(N-maleimidomethyl) 
cyclohexane carboxylate (SMCC) (Yoshitaki etal., 1982), were used. Each contained 
an amino-specific succinimide moiety at one end of the molecule and a thiol-specific 
maleimide group at the other (Figure 3.1). Addition of GMBS caused a marked loss 
of FVIII activity when compared with the controls (Table 3.6.3). A control containing 
rFVTII and the diluent (dimethyl formamide, DMF) was included to ensure that any 
loss of activity was caused solely by the cross-linker. Addition of the other 
heterobifunctional reagent, SMCC, caused complete loss of activity (Table 3.6.3) 
similar to that observed with other amino-specific reagents.
Denaturation studies were carried out on rFVIII, rFVIII plus DMF and rFVIII with 
GMBS (Figure 3.6.3). No increase in thermostability was observed.
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Concentration of 
Heterobifunctional
AA/min ± S.D. 
at 405nm
% Recovery
(i) GMBS
0 (FVIII control) .284 ± .011 100
FVIII + DMF (diluent) .225 ± .012 80
0.05mM .091 ± .007 32
0.1 mM .051 ± .007 18
0.5mM .031 ± .002 5
(ii) SMCC
0 (FVIII control) .212 ± .005 100
FVIII + DMF (diluent) .123 ± .006 58
0.25mM .015 ± .002 7
0.5mM .008 ± .001 4
2.5mM .006 ± .001 3
Positive control .125 ± .010
Negative control .005 ± .001
TABLE 3.6.3 Reaction of rFVIII with two heterobifunctionals, N-(y-
maleimidobutyryloxy) succinimide (GMBS) and succinimidyl 4-(N- 
maleimidomethyl) cyclohexane carboxylate (SMCC). The reactions 
took place at room temperature for 30 minutes. The change in 
absorbance per minute (AA/min) was measured and used as an 
indicator of FVIII activity. Both cross-linkers were dissolved in 
dimethyl formamide (DMF) so a control containing rFVIII in DMF 
was included in each experiment.
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were used as positive and negative FVIII 
controls, respectively. S.D. is the standard deviation where n = 3.
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Figure 3.6.3 Dénaturation of native rFVIII and N-(Y-maleimidobutyryloxy) 
succinimide (GMBS)-modified rFVIII.
Samples of rFVIII, rFVIII in dimethyl formamide (DMF) and 
rFVIII modified with 0.05mM GMBS were incubated at 55°C for 
1 hour. Aliquots were withdrawn at regular intervals and assayed 
for FVffl activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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3.6.4 Protein Modifying Reagents
3.6.4.1 Oxidation using Hydrogen peroxide
The rFVIII molecule contains a number of inactivation sites, at least one of which 
is known to contain a methionine residue (Vehar et al., 1984; Toole et al., 1984). 
Oxidation of this residue to form the sulphoxide, with a view to altering the 
inactivation site, was attempted using hydrogen peroxide (H20 2) (Neuman, 1972). 
Concentrations of H2Oz above lOOmM caused loss of procoagulant activity, whereas 
at 50mM and lOOmM concentrations, around 55% of the control activity remained 
(Table 3.6.4.1).
Dénaturation studies were carried out using these two concentrations, along with a 
control (rFVIII alone). The modified samples showed no increase in thermostability 
(Figure 3.6.4.1).
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Reactants AA/min ± S.D. at 405nm % Recovery
rFVIII Control .266 ± .003 100
rFVIH + lOmM H20 2 .116 ± .004 44
rFVIII + 50mM H20 2 .145 ± .006 55
rFVIII + lOOmM H20 2 .143 + .001 54
rFVIII + 200mM H20 2 .012 ± .003 4
rFVIII + 500mM H20 2 .013 ± .002 5
rFVIII + lOOOmM H20 2 .015 ± .001 6
Positive control .145 ± .020
Negative control .004 ± .001
TABLE 3.6.4.1 Reaction of rFVIII with hydrogen peroxide. (H20 2). rFVIII was 
reacted with final concentrations of (H20 2) ranging from 0 to 1M, 
on ice for either 1 or 2 hours. The change in absorbance per minute 
(AA/min) was measured and used as an indicator of FVIII activity. 
Concentrations above lOOmM caused significant loss of 
procoagulant activity.
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were used as positive and negative FVIII 
controls, respectively.
S.D. is the standard deviation where n = 3.
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Figure 3.6.4.1 Dénaturation of native rFV in and hydrogen peroxide (H20 2)- 
modified rFVIII.
Samples of rFVIII and rFVIII modified with 50mM and 
lOOmM H20 2 were incubated at 55°C for 1 hour. Aliquots were 
withdrawn at regular intervals and assayed for FVIII activity. 
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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3.6.4.2 Copper/o-Phenanthroline
Copper/o-Phenanthroline chelate (Cu/o-ph) can be used to enhance the oxidation of 
sulphydryl groups to the disulphide form (Steck, 1972). The addition of each 
component of the mixture individually, and in the form of a chelate, did not cause 
any significant loss of FVHI procoagulant activity, even at higher concentrations 
(Table 3.6A2).
Dénaturation studies were carried out on each of the concentrations, along with 
controls. None of the modified samples exhibited any increase in thermostability as 
compared with the control (Figures 3.6.4.2.1 and 3.6.4.2.2).
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Reactants AA/min ± S.D. at 405nm % Recovery
rFVIII .339 ± .016 100
rFVIII + 50pM o-ph .267 ± .021 78
rFVIII + 50pM Cu2+ .315 ± .021 93
rFVIII + X .330 ± .030 97
rFVIII + Y .327 ± .014 96
rFVIII + Z .331 ± .022 97
Postive control .136 ± .013
Negative control .005 ± .001
TABLE 3.6.4.2 Reaction of rFVIII with varying concentrations of Cu/o-Ph. rFVin 
was reacted with each combination below (A, B and C), on ice for 
20 minutes.
X: lOpM CuS04 and 50pM o-Ph 
Y: 50pM CuS04 and 25pM o-Ph 
Z: 20pM CuS04 and lOOpM o-Ph 
The change in absorbance per minute (AA/min) was measured and 
used as an indicator of FVIII activity.
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were used as positive and negative FVIII 
controls, respectively. S.D. is the standard deviation where n = 3.
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Figure 3.6.4.2.1 Dénaturation of native rFVIII and rFVIII modified with the 
Copper/o-Phenanthroline chelate (Cu/o-ph).
Samples of rFVIII and rFVIII modified with lOpM Cu2+ + 
50pM o-ph (C), along with controls, were incubated at 55°C 
for 1 hour. The controls consisted of rFVIII in the presence 
of lOpM Cu2+ (A) and rFVIII with 50pM o-ph (B). Aliquots 
were withdrawn at regular intervals and assayed for FVIII 
activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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Figure 3.6.4.2.2 Dénaturation of native rFVIII and rFVIII modified with the 
Copper/o-Phenanthroline chelate (Cu/o-ph).
Samples of rFVIII and rFVIII modified with 20pM Cu2+ + 
lOOpM o-ph (F), along with controls, were incubated at 55°C 
for 1 hour. The controls consisted of rFVIII in the presence 
of 20pM Cu2+ (D) and rFVIII with lOOpM o-ph (E). Aliquots 
were withdrawn at regular intervals and assayed for FVIII 
activity.
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3.6.4.3 2-Iminothiolane
2-Iminothiolane (2-IT) reacts with the amino group of lysine residues to form amidine 
derivatives, introducing an additional thiol group (Kenny et al., 1979). Disulphide 
bonds may be formed when the derivative is subjected to oxidation if a second free 
thiol lies in close proximity. The addition of 2-IT to rFVIII does not cause any loss 
of activity over the given range of concentrations (0-6mM) (Table 3.6.4.3.1).
Reactants AA/min ± S.D. at 405nm % Recovery
rFVIII (Control) .268 ± .009 100
rFVIII + 0.25mM 2-IT .264 ± .012 98
rFVIII + l.OmM 2-IT .240 ± .020 90
rFVIII + 6.0mM 2-IT .123 ± .003 46
Positive control .128 ± .010
Negative control .004 ± .000
Table 3.6.4.3.1 Reaction of rFVIII with 2-Iminothiolane (2-IT). rFVIII was reacted 
with the above final concentrations of 2-IT on ice for 2 hours. The 
change in absorbance per minute (AA/min) was measured and used 
as an indicator of FVin activity.
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were used as positive and negative FVIII 
controls, respectively.
Dénaturation studies showed that the 2-IT modified rFVIII was no more stable than 
was the untreated rFVIII (Figure 3.6.4.3.1).
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Figure 3.6.4.3.1 Dénaturation of native rFVIII and rFVIII modified with 2- 
Iminothiolane (2-IT).
Samples of rFVIII and rFVIII modified with ImM 2-IT were 
incubated at 55°C for 1 hour. Aliquots were withdrawn at 
regular intervals and assayed for FVIII activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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The second stage of the experiment involved the oxidation of the thiolated amidine 
derivative in an attempt to form additional disulphide bridges. Two reagents were 
employed, hydrogen peroxide (H20 2) and the copper/o-phenanthroline chelate (Cu/o- 
ph). The addition of H20 2 destroyed rFVIII activity (Table 3.6.4.3.2). Approximately 
55% FVIII activity was retained, however, after the addition of Cu/o-ph. (Table
3.6.4.3.3). Figure 3.6.4.3.2 shows the results of the denaturation studies on the native 
and modified rFV in (rFVm + 2-IT + Cu/o-ph). While neither of the modification 
steps caused any major loss of activity, neither did they alter the stability of rFVIII.
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Reactants AA/min ± S.D. at 405nm % Recovery
0 (control) .247 ± .015 100
FVIII + 40mM H20 2 .014 ± .001 6
FVIII + 0.25mM 2-IT 
+ 40mM H20 2
.012 ± .002 5
FVIII + ImM 2-IT 
+ 40mM H20 2
.012 ± .001 5
FVin + 6mM 2-IT 
+ 40mM H20 2
.011 ± .001 5
Positive control .133 ± .012
Negative control .006 ± .000
TABLE 3.6A3.2 Reaction of rFVIII with 2-Iminothiolane (2-IT), followed by 
oxidation using 40mM H20 2.
rFVIII was initially reacted with varying concentrations of 2-IT 
on ice for 2 hours. These were then reacted with 40mM H20 2 on 
ice for 15 minutes. The change in absorbance per minute 
(AA/min) was measured and used as an indicator of FVIII 
activity. Addition of H20 2 causes substantial loss of FVIII 
procoagulant activity.
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were used as positive and negative FVIII 
controls, respectively.
S.D. is the standard deviation where n = 3.
119
Reactants AA/min ± S.D. at 405nm % Recovery
0 (rFVIII control) .334 ± .026 100
rFVIII + ImM 2-It .233 ± .020 70
rFVIII + ImM 2-It 
+ 10pM Cu2+
.166 ± .010 50
rFVIII + ImM 2-It 
+ 50pM o-ph
.172 ± .015 52
rFVIII + ImM 2-It 
+ Cu/o-ph
.192 ± .020 58
Positive control .125 ± .007
Negative control .005 + .000
TABLE 3.6.4.3.3 Reaction of rFVIII with 2-Iminothiolane (2-It) followed by 
oxidation with copper/o-phenanthroline chelate (Cu/o-ph)
[lOpM CuSo4 and 50pM o-Ph].
rFVIII was initially reacted with ImM 2-IT on ice for 2 hours. 
It was then reacted with Cu/o-ph on ice for 20 minutes. The 
change in absorbance per minute was measured and used as an 
indicator of FVIII activity.
Controls consisting of rFVIII with each component of the chelate, 
as well as Coag Cal calibration plasma (i.e. normal human 
plasma) and FVID-deficient plasma (positive and negative FVIII 
controls, respectively) were included.
S.D. is the standard deviation where n = 3.
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Figure 3.6.4.3.2 Dénaturation of native rFVIII and rFVIII modified initially 
with 2-Iminothiolane (2-IT), and then with Copper/o- 
phenanthroline (Cu/o-ph).
Samples of rFVIII and rFVIII modified with ImM 2-IT and 
followed by lOpM Cu2+ + 50pM o-ph (A), were incubated 
at 55°C for 1 hour. Aliquots were withdrawn at regular 
intervals and assayed for FVHI activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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3.6.4.4 Polvethelene Glycol
Proteins to which polyethelene glycol (PEG) has been attached have been shown to 
be stable and active in organic solvents, and to be less antigenic and allergenic 
(Imoto and Yamada, 189). PEG can be attached to a protein amino group (usually 
lysine) using cyanuric chloride-activated PEG (a conjugate of cyanuric chloride and 
PEG) (Jackson et al., 1987).
Approximately 80% of the control value remained after the addition of PEG to rFVIII 
(Table 3.6.4.4). Dénaturation studies again showed that no increase in thermostability 
was obtained (Figure 3.6.4.4).
Reactants AA/min ± S.D. at 405nm % Recovery
rFVIII (Control) .109 ± .001 100
rFVIII + 0.5X PEG .089 ± .001 81
rFVIII + 5X PEG .088 ± .001 80
Positive control .132 ± .010
Negative control .005 ± .001
Table 3.6.4.4 Reaction of rFVIII with polyethylene glycol (PEG).
rFVIII was reacted with final molar concentrations of 0.5X and 5X 
PEG with regard to lysines (approx. 40), at room temperature for 1 
hour. The change in absorbance per minute (AA/min) was measured, 
and used as an indicator of activity.
The modification with PEG did not cause substantial loss of FVIII 
activity when compared with the control.
Coag Cal N calibration plasma (i.e. normal human plasma) and FVIII- 
deficient plasma were used as positive and negative FVIII controls, 
respectively.
S.D. is the standard deviation where n = 3.
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Figure 3.4.4.4 Denaturation of native rFVIII and Polyethylene glycol (PEG)- 
modified rFVIII.
Samples of rFVIII and rFVIII modified with final concentrations of 
0.5X and 5X (with regard to lysine residues) PEG were incubated at 
55°C for 1 hour. Aliquots were withdrawn at regular intervals and 
assayed for FVIII activity.
Relative percentage activity was calculated as the percentage 
of activity at TO, remaining at a particular time.
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3.6.4.5 Xvlitol
Xylitol is a five carbon sugar alcohol which is used as a stabilising additive. It has 
little direct interaction with the protein but affects the bulk solution properties of 
water. It acts by stabilising the molecular lattice structure of water. This in turn 
stabilises the hydration shell around the protein and protects against aggregation 
(Schein, 1990).
The addition of xylitol to rFVIII causes substantial loss of activity, even at the lowest 
concentrations (Table 3.6.4.5).
Reactants AA/min ± S.D. at 405nm % Recovery
rFVIII (Control) .252 ± .024 100
rFVIII + lOmM Xylitol .032 ± .003 28
rFVIII + 50mM Xylitol .031 ± .004 32
rFVIII + lOOmM Xylitol .021 ± .002
Positive control .125 ± .011
Negative control .005 ± .001
TABLE 3.6.4.5 Reaction of rFVIII with Xylitol. rFVIII was reacted with lOmM, 
50mM and lOOmM Xylitol on ice for 30 minutes. The change in 
absorbance per minute (AA/min) was measured and used as an 
indicator of FVIII activity.
The presence of xylitol causes substantial loss of FVIII 
procoagulant activity.
Coag Cal N calibration plasma (i.e. normal human plasma) and 
FVIII-deficient plasma were used as positive and negative FVIII 
controls, respectively.
S.D. is the standard deviation where n = 3.
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3.7 Discussion
The e-amino group of lysine residues is usually located on the surface of a protein 
due to the positive charge it exhibits under physiological conditions. It’s strongly 
nucleophilic side chain is, thus, an ideal candidate for selective modification using 
bifunctional and other modifying reagents. The thiol group of cysteine residues is 
another major target for cross-linking experiments. This group is the strongest 
nucleophile among the functional groups of amino acids, reacting with most thiol- 
specific cross-linkers at an alkaline pH (Wong and Wong, 1992).
FVIII contains a number of activation sites, where arginine residues are predominant 
(Vehar et al., 1984) and so reagents which would alter these sites in any way were 
avoided. Carboxyl-specific reagents were not employed at any time since clusters of 
negatively charged carboxyl groups may bind the calcium ions essential for FVIII 
activity (Mikaelsson, 1983).
The buffer systems had to be compatible with the reagent being used. Thus, for most 
of the reactions, rFVIII was dissolved in Tris buffer. However, for the amino-specific 
reagents the protein was transferred to barbital buffer. Tris buffer contains quaternary 
amino groups which could interfere with the FVIII-modifier reaction.
The pH tolerance of FVIII is narrow. Inactivation occurs at pH values less than about 
6 and greater than 8. Thus, the pH of the reactions was controlled within the range 
pH 6-8. This reduced the number of cross-linkers which could be used, as many 
reagents act optimally outside this narrow pH range. This was particularly important 
for the heterobifunctional reagents, where each end of the molecule is selectively 
activated at different pH values. The range of such compounds which could be useful 
was, therefore, severely restricted.
Most chemical modifications of proteins are performed at protein concentrations 
about ten-fold higher than carried out here. While the clotting activity of rFVIII used 
was high, its protein concentration was about 0.15mg/ml (approximately 2pM). The 
amount of rFVIII available was greatly restricted because of the cost involved as well 
as the demand for the protein for use in replacement therapy in the treatment of 
haemophilia A. Therefore, concentration of the protein could not be carried out. This, 
together with activated FVffl’s extremely narrow pH tolerance, forced us to operate 
under very limited conditions, some of which were not ideal for the reagents in
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question. Imidoesters, for example, react with unprotonated amino groups and so 
reaction is favoured at mildly alkaline pH values which FVIII will not tolerate. The 
low protein concentration also prevented the characterisation of the chemical 
derivatives produced.
The only experimental parameter of activity or functional stability, therefore, was the 
FVIII procoagulant activity as determined by chromogenic assay. However, it is this 
activity of FVIII that is primarily important in any diagnostic or theraputic 
application of rFVin or any derivative.
There is a noteworthy difference between the effects of the amino and the thiol- 
specific reagents on rFVin. With the exception of 2-IT, all of the amino-group 
modifers, whether cross-linkers or not, inactivate most of the procoagulant activity. 
It is not clear why 2-IT alone did not inactivate rFVIII. In contrast, the thiol-specific 
reagents did not lead to rFVin inactivation. This suggests that some free 
amino groups are essential for rFVIII integrity and activity. At least some of the 
numerous free thiol groups can be modified, however, without adverse effects. 
Oxidation-type treatments were either neutral (attempts to create new disulphide links 
with Cu/o-ph) or deleterious (attempts to oxidise methionine residues with H20 2). A 
methionine residue is located at Arg 336 - Met 337 of native FVIII, one of a number 
of inactivation sites present in the FVffl molecule (Vehar et al., 1984). This is the 
site where activated Protein C, thrombin and activated Factor X can cleave the FVIII 
heavy chain, leading to inactivation (Manning et al., 1993). Attempts were made to 
oxidise this to the bulky sulphoxide form and thereby prevent inactivation cleavage. 
H20 2 is quite a strong oxidant, however, and may have reacted with residues other 
than methionine.
Attempts to alter the properties of the protein in solution caused total loss of FVIII 
procoagulant activity. The protein is inherently unstable in the absence of vWF and, 
thus, any changes in the hydration shell around the protein caused destabilisation 
leading to loss of activity.
Factor VHI undergoes many cleavages, some of which are necessary for molecular 
activation while others lead to inactivation. The activation cleavage sites at least must 
be preserved in any functional derivative which is to be prepared. Since it is also a
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large and complex molecule, any successful cross-linking or other modification are 
likyely to be extremely subtle.
These experiments have, nevertheless, demonstrated a qualitative difference between 
different amino acid side chains within FVIII in terms of their importance to it’s 
function. Amino groups seem to be essential for FVIII activity while thiol groups 
may be modified without causing adverse effects on FVIII activity. It appears 
therefore, that amino-groups play an important role in FVIII integrity and activity.
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CHAPTER 4 
PRODUCTION OF MONOCLONAL AND 
POLYCLONAL ANTI-rFVIII ANTIBODIES
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4.1 Introduction
The development of techniques which immortalise antibody-producing cells (Kohler and 
Milstein, 1975), allowing them both to survive and produce antibody in culture, has 
proved to be one of the most important developments of recent times. Today, 
monoclonal antibodies have a wide range of applications, from clinical use in the 
treatment and diagnosis of diseases, to preparative uses and use in basic research. 
Monoclonal antibodies have been used in the purification of a number of blood clotting 
proteins, including factors XII (Pixley et al., 1993), IX (Bajaj and Birktoft, 1993) and 
V (Kalafatis et al., 1993) as well as factor VIII (Lollar et al., 1993). They provide an 
ideal means of obtaining high purity blood products for use in the treatment of blood 
clotting disorders because of their specificity. The risks associated with the use of 
human-derived products are huge. Blood-borne viruses including hepatitis and human 
immunodeficiency virus (HIV) are well documented, but other potential infectious agents 
(perhaps as potent as these) may also be present. It is vital, therefore, that products for 
replacement therapy be contaminant free. Recombinant proteins are being increasingly 
used in replacement therapy. They provide a safe alternative to plasma-derived products, 
being largely contaminant free. However, some patients are prone to developing inhibitor 
antibodies against the recombinant protein as new antigenic determinants are exposed. 
In this chapter, the development of novel monoclonal and polyclonal antibodies against 
a recombinant FVIII is described.
4.2 Polyclonal Antibody Production
Polyclonal antibodies were produced as described in Section 2.12 (Figure 4.2.1). The 
rabbit was bled two weeks after booster injections and the titre measured by ELISA 
(Section 2.23.1). A titre of 1:100,000 was obtained (Table 4.2).
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Figure 4.2.1 Dot blot on immunised rabbit serum.
rFVm  was dotted onto nitrocellulose paper and free binding sites blocked 
with a 1% (w/v) solution of bovine serum albumin. Duplicate samples of 
immunised rabbit serum (B) and controls consisting of normal rabbit 
serum (A), and PBS (0.15M, pH 7.2) (C) were added. A substrate which 
produced an insoluble end-product (5-bromo-4-chloro-3 indolyl phosphate) 
was used, and the appearance of intense dark dots was indicative of the 
presence of anti-rFVIII antibodies.
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Dilution Immunized Rabbit Serum 
Absorbance ± SD at 620nm
Normal Rabbit Serum 
Absorbance ± SD at 620nm
1:1000 .451 ± .033 .055 ± .001
1:5000 .411 ± .017 .050 ± .001
1:10,000 .355 ± .031 .046 ± .001
1:50,000 .237 ± .021 .044 ± .001
1:100,000 .175 ± .006 .045 ± .001
PBS .000 ± .000 .000 ± .000
Table 4.2 The titre of serum from the immunised rabbit was measured by ELISA.
5pg/ml rFVIII was bound to the plate and free binding sites on the plate 
blocked. Dilutions of immunised and normal rabbit serum were added. 
Bound antibody was probed with alkaline phosphatase-labelled antibody. 
Substrate was added and absorbance measured at 620nm.
SD: Standard deviation where n=3.
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4.2.1 Purification of Polyclonal Antiserum
The rabbit serum was purified initially by ammonium sulphate precipitation (Section
2.16.1). The partially purified antibody was dialysed against 0.15M PBS, pH 7.2 at 4°C 
overnight, and the protein concentration measured.
The second stage of purification involved Protein A affinity chromatography (Section
2.16.3). The antibody was diluted in binding buffer, to within the binding range of the 
column (1:4). 2ml of this was then applied to the column and a total of 13 x 1ml 
fractions collected. Figure 4.2.1.1 shows the elution profile of the column. Bound 
antibody eluted in two fractions (fractions 9 and 10) and these were desalted on a 
Sephadex G-25 column (Figure 4.2.1.2). The protein concentration of each fractions was 
monitored and two were found to contain protein (anti-rFVIII antibody). The protein 
concentration was estimated to be 5mg/ml.
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Figure 4.2.1.1 Elution of polyclonal anti-rFVIII antibody from a Protein A affinity 
column.
The antibody was eluted with a 0.1M glycine buffer, pH 2.5 and 13 
fractions were collected. The concentration of protein in each fraction 
was determined using the BCA assay (Section 2.7). Peak B represents 
the eluted antibody fractions.
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Figure 4.2.1.2 Desalting of antibody-containing fractions on a 10ml Sephadex G-25
column. The antibodies were eluted with 0.1M PBS, pH 7.2, and 
11 fractions were collected. The concentration of protein in each 
fraction was determined using the BCA protein assay (Section 2.7).
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4.2.2 Conjugation of horseradish peroxidase to anti-rFVIII polyclonal antibody
Horseradish peroxidase (HRP) was conjugated to rabbit anti-rFVIII antibody as 
described in Section 2.21. A dot blot was carried out based on that described in Section
2.14.1 to ensure that conjugation had taken place. rFVIII was dotted onto nitrocellulose 
paper and the free binding sites blocked. The conjugate was added and, after incubation, 
unbound conjugate removed by washing and substrate (3,3’- diaminobenzidine 
tetrahydrochloride, DAB) added. This produced an insoluble end-product which could 
be observed visually (Figure 4.2.2.1).
The enzymic activity of the conjugate was also measured as described in Section 2.21.1. 
An ELISA (Section 2.23.1) was carried out to estimate the working dilution of the
conjugate (Table 4.2.2).
The protein concentration of the conjugate was estimated to be lmg/ml.
The purity of the conjugate was assessed using SDS-PAGE (Section 2.18) and is shown 
in Figure 4.2.2.2.
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Figure 4.2.2.1 Immunological activity of horseradish peroxide-labelled anti-rFVIII
antibodies. rFVIII was dotted onto nitrocellulose paper (NC) and the 
free binding sites blocked. Duplicate samples of the antibody 
conjugate were added to the rFVIII (lane A), and to control blots 
(lane B) where no rFVIII had been blotted. A control consisting of 
PBS (0.15M, pH 7.2) was also included (A3 and B3). Bound antibody 
detected using 3,3'-diaminobenzidine tetrachloride, (DAB) which 
produced an insoluble end-product. Some degree of non-specific 
binding was obtained because of the high binding capacity of NC.
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Dilution Absorbance ± SD 
at 492nm
1:100 1.828 ± .027
1:500 1.112 ± .044
1:800 1.090 ± .042
1:1000 .799 ± .056
1:1100 .494 ± .043
1:1300 .252 ± .024
PBS .000 ± .000
Table 4.2.2 Results of an ELISA to determine the working dilution of the polyclonal 
anti-rFVIII IgG/HRP conjugate.
5]ig/ml of rFV m  was immobilised onto the surface of wells of a microtitre 
plate and the remaining free binding sites were blocked using 1% (w/v) 
BSA. Dilutions of the conjugate were then added. Substrate (o- 
phenylenediamine) was added and the reaction terminated after 30 minutes 
by addition of 20% (v/v) H2S 04.
SD: Standard deviation where n=3.
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Figure 42.2.2 The purity of the anti-rFVIII antibody-horseradish peroxide conjugate 
assessed using SDS-PAGE.
The conjugate (lane A) produced a single band with a molecular weight 
of around 190 kDA. This corresponds to a conjugate consisting of IgG 
(Mr, 150 kDa) and horseradish peroxidase (Mr, 44 kDa).
Molecular weight markers are shown in lane B.
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4.3 Monoclonal Antibody Production
4.3.1 Immunisation
Male Balb/c mice were immunised with rFVIII as described in Section 2.13.1. The 
animal was bled at fortnightly intervals from the tail vein and the titre estimated by dot 
blotting (Section 2.14.1). When a sufficiently high titre was obtained (i.e, 1:5,000, 
Figure 4.3.1) the mouse was sacrificed, and a splenectomy performed. The splenocytes 
were subsequently used for fusing to generate monoclonal antibodies.
4.3.2 Fusion Results
Two fusions were carried out between immunized mouse splenocytes and NSO murine 
myeloma cells. In the first fusion an average of 14 wells per plate contained hybridomas 
from 10 fusion plates. 148 hybridomas were screened for anti-rFVIII antibody 
production by dot blot, and eight strongly positive clones were identified. These were 
cloned out by limiting dilution (Section 2.13.7) on two separate occasions to ensure 
monoclonality. Two monoclonal antibodies were isolated from these, M l and M2. 
Some cells were lost during expansion in vitro due to bacterial contamination. Infected 
wells could be identified by the acidic, cloudy medium. Samples were withdrawn from 
the suspected wells and a Gram stain carried out. This indicated the presence of both 
Gram positive and Gram negative bacteria. Thus a broad spectrum antibiotic 
(gentamycin) was used. Efforts to remove the infection by culturing in the presence of 
gentamycin (200jig/ml) proved unsuccessful. Because of the importance of the cells, if 
only one or two individual wells within a plate were found to be infected, the contents 
of these wells were aspirated and the well washed several times with 5M NaOH. The 
remaining wells were carefully monitored for signs of contamination and if any 
appeared, the plates were autoclaved and discarded.
The second fusion produced approximately 11 clones per plate from a total of 10 fusion 
plates. 115 hybridomas were screened for anti-rFVIII antibody production by dot 
blotting. 13 strongly positive hybridomas were identified and after cloning out by 
limiting dilution (twice) 1 monoclonal antibody was obtained (M10).
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Figure 4.3.1 The titre of mouse serum prior to fusion.
rFVIII was dotted onto nitrocellulose paper and free binding sites blocked 
with a 1% (w/v) solution of bovine serum albumin. Duplicate samples of 
a series of dilutions of immunised rabbit serum were added as shown.
A substrate which produced an insoluble end-product (5-bromo-4-chloro- 
3 indolyl phosphate) was used, and the appearance of dark dots was 
indicative of the presence of anti-rFVIII antibodies.
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Thus, from two fusions, 263 hybridomas were obtained, yielding three monoclonal anti- 
rFVIII antibodies.
The monoclonal antibodies were expanded in vitro as described in Section 2.15.1. Some 
of these were used to produce ascitic fluid (Section 2.15.2), while remaining stocks were 
frozen in liquid nitrogen (Section 2.11.3) for long-term storage.
Figure 4.3.2.1 shows the results of dot blots identifying hybridomas which are secreting 
anti-rFVIII antibodies.
4.4 Purification of Antibody from Ascitic Fluid by Ammonium Sulphate Precipitation 
The monoclonal antibodies were partially purified from ascitic fluid by precipitation with 
ammonium sulphate as described in Section 2.16.1. A dot blot was performed on the 
supernatants after each centrifugation step, as well as the final precipitate. After dialysis 
against 0.15M PBS, pH 7.2, the protein concentration was measured using the BCA 
protein assay (Section 2.7). Samples were stored at -20°C in small aliquots to prevent 
repeated freezing and thawing.
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Figure 4.3.2.1 Identification of clones secreting anti-rFVm antibody after a fusion.
Supernatants were withdrawn from 8 wells of a microtitre plate post­
fusion and duplicate samples were dotted onto nitrocellulose paper (Al, 
A2, B l, B2, C l, C2) and tested for the presence of antibody by dot 
blotting. A substrate which produced an insoluble end-product (5-bromo- 
4-chloro-3 indoyl phosphate) was used, and the appearance of dark dots 
was indicative of the presence of anti-rFVUI antibodies. Strongly positive 
( / / ) ,  weak (✓), and negative (X) clones could be identified.
142
4.5 Determination of Antibody Class
The isotype of the three monoclonal antibodies was determined using two isotyping kits 
(Section 2.17). The first, an ELISA based kit, indicated that the antibodies were IgM, 
with IgGj also present. The second kit, based on the principle of agglutination, also 
indicated that the antibodies were IgM. IgM is a pentameric molecule consisting of five 
IgG-like molecules held together by disulphide bonds between the Cp3 domains. These 
disulphide bonds are easily reduced, causing destruction of the pentameric structure and 
forming IgG-like molecules. This accounts for the identification of IgGj along with IgM 
in the samples. The results are summarized in Table 4.5.
Antibody Isotype according 
to Kit 1
Isotype according 
to Kit 2
M l IgM IgM
M2 IgM IgM
M10 IgM + IgG, IgM
Table 4.5 Isotypes of the three monoclonal anti-rFVIII antibodies.
All three were identified as IgMs with M10 having IgG, also present. IgM 
consists of 5 IgGi-like antibodies linked together. Thus the presence of IgG, 
suggests that the IgM has been broken down in some way.
Kit 1: Sigma Mouse Isotyping kit, based on ELISA.
Kit 2: Serotec Isotyping kit, based on agglutination
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4.6 Affinity Purification of M2 Monoclonal Antibody
The M2 monoclonal antibody was further purified by affinity chromatography. An 
affinity column consisting of rFVIII immobilised onto Sephadex G-25 was prepared as 
described in Section 2.16.2. Specific anti-rFVIII antibodies bind to the immobilised 
rFVIII, while non-specific contaminants were removed by washing. The antibodies were 
then eluted from the column. After checking for protein leaching off the column, 
partially-purified antibody (after (NHJ2S04 precipitation) was added (300pl of a 1 mg/ml 
solution). Seven 1 ml fractions were collected, and the protein concentration of each 
monitored using the BCA protein assay. Specific antibody was then eluted (4 x 1ml 
fractions). The elution profile of the column is shown in Figure 4.6.1.
Fractions were dialysed overnight at 4°C against 0.15M PBS, pH 7.2.
A dot blot was performed on all protein-containing fractions, and anti-rFVIII antibodies 
were identified in fraction 4, (Figure 4.6.2).
The protein concentration of the antibody-containing fraction was estimated (using the 
BCA protein assay) to be 0.2mg/ml.
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Figure 4.6.1 Elution of M2 monoclonal anti-rFVin antibody from a FVHl affinity 
column.
The antibody was eluted with a 0.1M glycine buffer, pH, 2.5, and 7 
fractions were collected. The concentration of protein in each fraction 
was determined using the BCA protein assay (Section 2.7). Peak A 
represents the unbound protein, and Peak B represents the eluted 
antibody fraction.
145
A B
a sc it ic ANTT-rFVm
1 FLUID CONTROL
FRACTION FRACTION
2 3 4
Figure 4.6.2 Dot blot identifying the fractions containing anti-rFVIII antibody after 
affinity purification of M2 antibody.
rFVIII was dotted onto nitrocellulose paper and free binding sites blocked 
with a 1% (w/v) solution of bovine serum albumin. Duplicate samples of 
(NH4)2S 04-purified ascitic fluid (Al), a control consisting of anti- 
rFYin polyclonal antibodies (Bl), fraction 3 (A2) and fraction 4 (B2) 
after affinity purification were added. A substrate which produced an 
insoluble end-product (5-bromo-4-chloro-3 indolyl phosphate) was used, 
and the appearance of dark dots was indicative of the presence of anti- 
rFVIII antibodies. Antibodies were identified in fraction 4 (indicated by 
the arrows) from the affinity cloumn.
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4.7 Protein A Purification of M10 Monoclonal Antibody
The M10 monoclonal antibody was further purified using a Protein A affinity column 
as described in Section 2.16.3.
The protein concentration of the ascitic fluid after ammonium sulphate precipitation was 
calculated to be 5mg/ml. Since the maximum binding capacity of the column was 6- 
8mg/ml, the antibody was diluted 1:1 with binding buffer, and 1.4ml of this was applied 
to the column.
lml fractions were collected and protein concentration monitored.
Figure 4.7.1 shows the elution profile of the column.
Fractions containing protein after elution were desalted on a Sephadex G-25 column
(Figure 4.7.2).
The protein concentration of the unbound fractions was calculated to be 4mg/ml and that 
of the eluted fractions (fractions 3 and 4) was 0.4mg/ml each. A dot blot was performed 
on all fractions and anti-rFVIII antibodies identified in fraction 3 (Figure 4.7.3).
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Figure 4.7.1 Elution of M10 monoclonal anti-rFVIII antibody from a Protein A 
affinity column.
The antibody was eluted with a 0.1M glycine buffer, pH 2.5 and 13 
fractions were collected. The concentration of protein in each fraction 
was determined using the BCA assay (Section 2.7). Peak A is the 
unbound proteins, while peak B represents the eluted antibody fractions.
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Figure 4.7.2 Desalting of antibody-containing fractions on a Sephadex G-25 column.
The M10 monoclonal antibodies were eluted with 0.1M PBS, pH 7.2, 
and 10 fractions were collected. The concentration of protein in each 
fraction was determined using the BCA protein assay (Section 2.7).
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Figure 4.7.3 Dot blot identifying the fractions containing anti-rFVIII antibody after 
Protein A affinity purification of M l antibody.
rFVIII was dotted onto nitrocellulose paper and free binding sites blocked 
with a 1% (w/v) solution of bovine serum albumin. Duplicate samples of 
(NH4)2S 04-purified ascitic fluid (Al, B l), a control consisting of anti- 
rFVIII polyclonal antibodies (A2, B2), fraction 3 (A3, B3) and fraction 4 
(A4, B4) after Protein A purification were added. A substrate which 
produced an insoluble end-product (5-bromo-4-chloro-3 indolyl phosphate) 
was used, and the appearance of dark dots was indicative of the presence 
of anti-rFVIII antibodies. Antibodies were identified in fraction 3 from the 
Protein A column.
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4.8 Purification of M l Monoclonal Antibody by Gel Filtration
The M l monoclonal was purified by passage through a size-exclusion column
(Sepharose-6B) as described in Section 2.16.4. The IgM antibody thus elutes in the void
volume.
lm l of antibody was applied and a total of 9 x 1ml fractions were collected (Figure
4.8.1). The protein concentration of each fraction was measured. A dot blot was carried 
out on all fractions, and anti-rFVHI activity was identified in fraction 3 (Figure 4.8.2).
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Figure 4.8.1 Elution of M l monoclonal anti-rFVm from a gel filtration column.
The antibody was eluted with a 0.1M imidazole buffer, pH, 7.2 and 9 
fractions were collected. The protein concentration of each fraction was 
determined using the BCA protein assay. The IgM antibody eluted in 
the void volumn (Peak A) beacuse of its size (900 kDa), while the 
remaining proteins eluted in later fractions (Peak B).
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Figure 4.8.2 Dot blot to identify the fractions containing anti-rFVIII antibody after gel 
filtration purification of M10 antibody.
rFVIII was dotted onto nitrocellulose paper and free binding sites blocked 
with a 1% (w/v) solution of bovine serum albumin. Duplicate samples of 
controls consisting of polyclonal anti-rFVIII antibodies (Al), and 
(NH4)2S 04-purified ascitic fluid (Bl) as well as fractions 3 (A2) and 
fraction 4 (B2) from the desalting column were added.
Anti-rFVIII antibody was identified in fraction 4.
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4.9 HPLC Analysis of Antibodies
Both monoclonal and polyclonal antibodies were analysed by HPLC as described in 
Section 2.20. Standards consisting of commercial rabbit IgG (Figure 4.9.1) and 
commercial mouse IgM (Figure 4.9.3) were also run. Table 4.9 summarises the retention 
times of the standards, the polyclonal and the monoclonal antibodies.
A sample of the polyclonal anti-rFVin antibody was analysed after Protein A 
purification (Figure 4.9.2).
Commercial IgM and samples of M2 and M10 monoclonal antibodies after purification 
were also examined by HPLC (Figures 4.9.4 and 4.9.5).
Antibody Retention Time (minutes)
Commercial IgM (Standard) 9.8
M2 Monoclonal 9.4
M10 Monoclonal 9.2
Commercial IgG (Standard) 14.5
Polyclonal after 
(NH4)2S 04 precipitation
14.0
Purified Polyclonal 
after Protein A
14.3
Table 4.9 Retention times of standards (commercial antibodies), purified monoclonal 
antibodies and polyclonal antibody samples after each stage of purification, 
on HPLC. lOpl of each sample was run on a Protein Pak SW 300, 10pm 
column. The mobile phase was 0.1M phosphate buffer, with a flow rate of 
0.5ml/min. Protein was detected by monitoring absorbance at 280nm.
The IgM antibodies elute in the void volume because of their size.
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HPLC chromatogram of commercial IgG antibodies. lOpl of sample 
was applied to a Waters Protein Pak SW 300. The mobile phase was 
0.1M phosphate buffer, pH 7.0, with a flow rate of 0.5ml/min. The 
presence of protein was detected by monitoring absorbance at 280nm. 
A retention time of 14.5 minutes was obtained for IgG. A smaller peak 
was also obtained which could have been caused by the protein added 
by the manufacturer as a stabilising additive.
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Figure 4.9.2 HPLC chromatogram of polyclonal anti-rFVIII antibodies after Protein 
A affinity purification.
lOpl of sample was applied to a Waters Protein Pak SW 300. The 
mobile phase was 0.1M phosphate buffer, pH 7.0, with a flow rate of 
0.5ml/min. The presence of protein was detected by monitoring 
absorbance at 280nm. A peak with a retention time of 14.3 minutes was 
obtained corresponding to pure IgG.
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HPLC chromatogram of commercial IgM antibodies. 
lOjul of sample was applied to a Waters Protein Pak SW 300. The 
mobile phase was 0.1M phosphate buffer, pH 7.0, with a flow rate of 
0.5ml/min. The presence of protein was detected by monitoring 
absorbance at 280nm. A peak with a retention time of 9.8 minutes was 
obtained for IgM.
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Figure 4.9.4 HPLC chromatogram of M10 monoclonal anti-rFVin antibody after 
Protein A affinity purification.
lOpl of sample was applied to a Waters Protein Pak SW 300. The 
mobile phase was 0.1M phosphate buffer, pH 7.0, with a flow rate of 
0.5ml/min. The presence of protein was detected by monitoring 
absorbance at 280nm. Two peaks were present with retention times of
9.2 and 14.4 minutes respectively. The first peak corresponds to IgM. 
The second peak, with a retention time of 14.4 minutes, was most 
likely fragments of the IgM molecule. These are IgG-like molecules 
with a molecular weight of around 200 kDa formed when the IgM 
molecule was reduced.
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HPLC chromatogram of M2 monoclonal anti-rFVni antibody after 
affinity purification.
lOpl of sample was applied to a Waters Protein Pak SW 300. The 
mobile phase was 0.1M phosphate buffer, pH 7.0, with a flow rate of 
0.5ml/min. The presence of protein was detected by monitoring 
absorbance at 280nm. A peak with a retention time of 9.4 minutes was 
obtained indicating IgM.
4.10 Electrophoresis
The purity of M10 monoclonal antibody was assessed using SDS-PAGE (Section 2.18). 
The unreduced form of the antibody was too large to enter the gel, but when run under 
reducing conditions in the presence of 2-mercaptoethanol, bands corresponding to 
molecular weights of approximately 80 and 30 kDaltons (kDa) were observed (Figure
4.10). These are characteristic of reduced fragments of IgM. Another band was visible, 
corresponding to a molecular weight of around 180 kDa. This could be an IgG-like 
fragment resulting from incomplete reduction of the IgM molecule.
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Figure 4.10 Assessment of the purity of M10 monoclonal antibody by SDS-PAGE.
A sample of the purified antibody was run under reducing conditions in 
the presence of 2-mercaptoethanol (lane B), as well as molecular weight 
markers (lane A). In lane B, bands were visible corresponding to the 
characteristic bands for reduced IgM molecules - 80 kDa and 30 kDa. 
Another band was visible, corresponding to a molecular weight of 
approximately 180 kDa. This could be an IgG-like fragment of the IgM 
molecule which had not been fully reduced.
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4.11 Western Blot Analysis
rFVIII was cleaved into its heavy and light chains by thrombin and separated by 
electrophoresis (Figure 4.11.1). These were then transferred onto nitrocellulose paper and 
probed as described in Section 2.19, using the monoclonal antibodies, to attempt to 
identify the binding sites of the antibodies. No sites could be identified, as the antibodies 
did not bind to the separated chains (Figure 4.11.2). A dot blot was carried out on 
rFVIII in sample buffer (Figure 4.11.3) and again the antibodies did not bind to the 
protein. The epitope, therefore, must be destroyed during unfolding of the protein in the 
presence of SDS in the sample buffer.
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Figure 4.11.1 Identification of the heavy and light chains of FVIII formed by thrombin 
digestion. rFVIII was reacted with 1 IU/ml of thrombin and then 
subjected to SDS-PAGE (lane B). The bands correspond to the 90 kDa 
heavy chain, consisting of the A1-A2 domains, and the 80 kDa light 
chain comprised of the A3-C1-C2 domains. Molecular weight markers 
were also included (lane A).
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Figure 4 1 ! il  Western blot analysis of M l monoclonal antibody.
rFV ni was separated into its heavy and light chains by thrombin 
digestion, and then subjected to SDS-PAGE Quae A), along with 
molecular weight markers (lane B). Separated bands were transferred 
onto nitrocellulose paper and probed using the monoclonal antibodies. 
No bands were identified by any of the three antibodies. The 
epitopes were most probably destroyed during some part of the 
experiment.
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Figure 4.11.3 Dot blots using three monoclonal antibodies on rFVIII before and after 
dilution in SDS-PAGE sample buffer.
rFVIII in 0.15M PBS, pH 7.2 (column A) and SDS-PAGE sample buffer 
(column B) was dotted onto nitrocellulose paper and probed with the 
three monoclonal antibodies (row 1: M l, row 2: M2, row 3: M10). When 
rFVIII was diluted in sample buffer (column B), none of the monoclonal 
antibodies bound to it, indicating that the binding epitopes of the 
antibodies were destroyed in the presence of SDS.
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4.12 The Effects of Antibody binding on FVIII Procoagulant Activity
rFVIII was reacted with both the polyclonal and the monoclonal antibodies to determine 
whether such binding caused any change in the procoagulant activity.
Binding of the polyclonal antibodies did not cause any loss of procoagulant activity 
(Table 4.12.1), whereas the binding of all three monoclonals caused complete loss of 
coagulant activity (Table 4.12.2).
Concentration of antibody AA/min ± S.D. 
at 405nm
Control (No antibody) .171 ± .012
5 pg/ml .132 ± .011
10 pg/ml .142 ± .009
50 pg/ml .153 ± .015
100 pg/ml .149 ± .010
Table 4.12.1 The effects of binding of polyclonal antiserum on rFVIII procoagulant 
activity.
Increasing concentrations of antibody were reacted with rFVIII, and 
FVIII procoagulant activity was measured using the chromogenic assay. 
Here, activity was calculated as a function of the change in absorbance 
per minute (AA/min) at a defined wavelength. The binding of the 
antibodies did cause some reduction in procoagulant activity, especially 
at the lower antibody concentrations (5 and lOpg/ml), but approximately 
90% of the control activity remained when the higher concentrations of 
antibody bound to rFVIII.
S.D.: Standard deviation where n=3.
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Monoclonal Antibody 
(10 pg/ml)
AA/min at 405nm 
± S.D.
Control (No antibody) .155 ± .007
M l .002 ± .000
M2 .006 ± .001
MIO .004 ± .001
Table 4.12.2 Effects of binding of monoclonal anti-rFVIII antibodies on rFVIII 
procoagulant activity.
10pg/ml of each monoclonal antibody was reacted with FVIII and FVIII 
activity measured by chromogenic assay. Here, activity was calculated 
as a function of the change in absorbance per minute (AA/min) at a 
defined wavelength.
The binding of all three monoclonals antibodies cause a complete 
loss of procoagulant activity.
S.D.: Standard deviation where n=3.
The polyclonal antibody/rFVIII complex was subjected to dénaturation as described in 
Section 2.5 to investigate whether the antibody binding imparted additional 
thermostability on rFVIII (Figure 4.12.1). Although some slight improvement was 
observed, no significant increase in thermostability was obtained.
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Figure 4.12.1 Thermodeactivation at 55“C of native rFVIII and rFVIII reacted with 
polyclonal anti-rFVIII antibody.
lOpg/ml of anti-rFVIII antibody in 0.1M PBS, pH 7.2, was reacted 
with rFVIII in 0.1M Tris-HCl buffer, pH 7.4, for 1 hour at 37°C. 
Thermodeactivation was carried out to investigate whether the binding 
of the antibody would increase the thermostability of rFVIII. No 
significant increase was observed
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4.13 Discussion
2 fusions were carried out between immunised mouse splenocytes and NSO murine 
myeloma cells. From these, a total of 263 hybridomas were obtained, yielding three 
monoclonals. These antibodies were identified by isotyping kits and by HPLC analysis 
as belonging to the IgM class.
IgM antibodies form the major proportion of the primary response to an antigen. In the 
secondary antigenic challenge, the antibody response is quicker, has a higher titre and 
consists mainly of IgG.
Immunization schedules are usually structured so as to ensure that the antibody response 
is in the secondary phase, and the antibodies are, therefore, most likely to be of the IgG 
class. The schedule followed for production of anti-rFVIII antibodies involved repeated 
immunization over a three month period. This would normally be sufficient for the 
production of IgG antibodies. In this case it appears that mainly IgM antibodies were 
produced. This would suggest that the animal was immune-compromised. Tests were 
carried out on the animals and they were diagnosed as being infected with mouse 
hepatitis virus (MHV). This is a highly infectious, single-stranded RNA virus of the 
genus Coronovirus. It infects many species of mammals and birds, causing respiratory 
or enteric infections. Many of the infections are subclinical.
The effects of this infection on the immune system of mice have been reported. Infected 
mice had a modified immune response to sheep red blood cells (Barthold, 1986). 
Immunodepression occurred during acute infections, if the mice were infected prior to 
antigen exposure (Barthold, 1986). Chronic immune-depression occurred in semi- 
susceptible mice with chronic infections (Virelizier, 1976). Infected mice show transient 
but significant functional disturbances in T and B lymphocytes (Barthold, 1976). It is 
not known whether the effects are due to direct or indirect action on the lymphoid 
tissue.
It appears therefore, that the infected mice were immunosuppressed. This accounts for 
the production of IgM rather than IgG antibodies.
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A total of 1 x 10 8 spleen cells was fused with 2.75 x 107 myeloma cells (a ratio of 
approximately 4:1). From this, 263 hybridomas were produced - a frequency of 
approximately 1 hybridoma per 5 x 105 cells. The hybridisation frequency is difficult to 
predict, and is dependent on many factors, including the number of stimulated B 
lymphocytes and the ratio of cell types. Generally however, the hybridisation frequency 
for a murine system is within the range 1-100 clones per 107 cells (Campbell, 1984). 
The presence of the MHV therefore, does appear to have affected the hybridization 
frequency as it is up to 100-fold lower than normally expected.
The choice of method of purification for IgM antibodies is limited as compared with 
methods available for IgG purification. IgMs are easily denatured by reduction of the 
disulphide bonds between the monomers. Recommended methods of purification include 
an initial precipitation step with saturated ammonium sulphate, followed by gel or anion- 
exchange chromatography (Oppermann, 1993). Other methods have recently been 
suggested, including polyethylene glycol precipitation (Noeh, 1986; Tatum, 1993). 
Here, three methods of purification were compared. Affinity chromatography, using 
rFVIII as a ligand, was an rapid and easy method of protein purification. As regards 
antibody purification, the availability of antigen in sufficient quantities may pose a 
problem. In this case, the quantity of rFVIII available was severely limited, allowing for 
only a small column to be prepared, and thus only small sample volumes to be applied. 
While the antibody eluted from the column was pure (Figure 4.8.1), the protein 
concentration was low and the final volume, small. Purification on a large scale would 
therefore be expensive and not always practical.
Protein A is a 42,000 molecular weight membrane protein isolated from Staphylococcus 
aureus. It exhibits a high binding capacity for the Fc portion of an IgG antibody 
(Tijssen, 1985). Polyclonal anti-rFVIII antibodies were successfully purified using this 
method. IgM, eluted from a Protein A column and analysed on HPLC, consisted of high 
molecular weight proteins (IgM) as well as proteins with molecular weight close to or 
slightly higher than that of an IgG molecule (Figure 4.9.4). These would appear to be 
fragments of the IgM molecule which have been denatured in the elution buffer, or by 
passage through the column.
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The fractions containing these fragments retain anti-rFVIII activity, but this may also 
be due to the presence of intact IgM molecules.
Protein A chromatography is not, therefore, recommended for purification of IgM 
antibodies as the final product while being relatively pure, was not necessarily a 
homogenous preparation of antibody.
Gel filtration is the recommended method for the purification of IgM antibodies. It is 
a relatively rapid, one-step method, capable of handling large and small volume samples. 
It was found that in this method, using a Sepharose-6B column, the monoclonal antibody 
eluted in the void volume. The remaining proteins eluted in later fractions. When the 
anti-rFVIII containing fraction was analysed by SDS-PAGE, the whole molecule was 
too large to enter the gel. When the molecule was reduced, the characteristic bands of 
a reduced IgM molecule were observed (Figure 4.10).
Thus, of the three methods investigated, gel-filtration was found to be the method of 
choice for the purification of IgM antibodies. It does not involve the harsh conditions 
(low pH buffers) necessary in affinity chromatography, which can cause denaturation of 
the antibodies.
Polyclonal antibodies were successfully purified using Protein A affinity 
chromatography, after an initial ammonium sulphate precipitation.
The effects of the binding of both polyclonal and monoclonal antibodies on rFVIII 
procoagulant activity was investigated. Both sets of antibodies reacted with rFVIII in an 
ELISA system. Binding of all three of the monoclonals resulted in the complete loss of 
rFVIII procoagulant activity. Binding of the polyclonal antisera resulted in some loss of 
procoagulant activity, but at higher concentrations (50 and lOOpg/ml), approximately 
90% of the control activity was retained. The fact that the monoclonal antibodies were 
of the IgM class could account for this major loss of activity. In binding, the antibody 
may cause some sort of distortion within the rFVIII tertiary structure, and given rFVIITs 
instability this may lead to loss of procoagulant activity. Also, the antibodies may be 
blocking the active site of the cofactor. The actual epitopes to which the monoclonals 
were binding could not be determined, as they were destroyed by unfolding of the 
protein.
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This suggests that the epitopes were in fact part of the tertiary structure. The subsequent 
loss of activity is probably, therefore, a combination of both of these factors.
Binding of the polyclonal antibodies did not cause any significant loss of procoagulant 
activity, especially at relatively high antibody concentrations (50 and lOOpg/ml). These 
antibodies were of the IgG class, and therefore do not cause the same degree of strain 
when binding to an antigen. None of the antibodies appear to bind to the active site or 
adjacent to it. Antibody binding to rFVin may give rise to additional, possibly 
thermostabilising intramolecular bridge(s). No increase in thermostability was observed 
in the presence of antibody, however.
The antibodies will be used in later chapters in the development of a number of 
methods, including an ELISA and an antibody-based immunosensor, for the detection 
and determination of rFVin (and FVIII) and anti-rFVUI antibodies. This is a critical 
area for the diagnosis and treatment of haemophilia.
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CHAPTER 5
DEVELOPMENT OF AN ELISA FOR THE 
DETECTION OF rFVHI AND ANTI-rFVIII 
ANTIBODIES
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5.1 Introduction
FVIII can be detected by either its coagulant activity (FVIII:C) or immunologically 
(FVniC:Ag) (Section 1.12). FVIII coagulant activity can be measured by one-stage, two- 
stage or chromogenic assays (Section 1.12.1). Inhibitor antibodies or autoantibodies have 
traditionally been used to immunologically detect FVIII using a range of immunoassays, 
including radioimmunoassays and enzyme immunoassays (Section 1.12.2). In 
approximately 10% of cases of severe haemophilia, i.e. patients have less than 5% of 
normal FVIII coagulant activity, FVIII can be detected immunologically, even though 
there is no procoagulant activity (Section 1.9.1). It is important to be able to identify and 
diagnose these patients with different FVIII:C and FVIIIC:Ag patterns, as it is critical 
in the treatment of haemophilia.
The risks associated with the use of blood-derived products are well documented. 
Haemophiliacs are a particularly high-risk group, and it has been estimated that 60% of 
haemophiliacs have been infected with HTV from contaminated blood products (Fox, 
1992). Thus, the risks associated with the use of inhibitor or autoantibodies from these 
patients are enormous. Recent advances in immunotechnology, especially the 
developments of monoclonal antibody production, has meant that antibodies with defined 
specifity and affinity can now be produced. These antibodies provide a safer alternative 
to inhibitor and autoantibodies for use in immunoassays. Recombinant FVIII is being 
increasingly used in the treatment of haemophilia (Section 1.9.2). It provides a 
contaminant-free alternative to human-derived FVIII, reducing the possibility of 
contamination from blood-borne viruses.
In this section the development of a number of ELISA systems is described using 
polyclonal and monoclonal anti-rFVIII antibodies generated previously (Chapter 4). The 
ELISAs provide a safe, rapid and reliable method for the detection of rFVIII and FVIII 
in normal human plasma. Anti-rFVIII antibodies can also be detected and determined.
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5.2 Anti gen-Capture ELISA
5.2.1 Binding of anti-rFVIII antibody to the solid phase
The binding of antibody to the solid phase in an ELISA is critically important as it 
provides the basis for the whole assay. The binding of five anti-FVin antibodies (rabbit 
polyclonals, three monoclonal antibodies and a commercial polyclonal sheep anti-FVin 
antibody) to a number of microtitre plates was examined. Three different binding buffers 
(50mM carbonate/bicarbonate, pH 9.6, lOmM Tris/HCl containing lOOmM NaCl, pH 8.5 
and 0.15M PBS, pH 7.2), in conjuction with several combinations of incubation times 
and temperatures, were examined. An IgG ELISA (Section 2.23.2) was used to 
investigate the binding properties of the antibodies to the plates under the different 
conditions. Antibody was bound to the plate and free binding sites blocked using a 1% 
(w/v) solution of BS A. Bound antibody was then detected using an alkaline phosphatase- 
labelled anti-rabbit antibody and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) in 2- 
amino-2-methyl-l-propanol (AMP) buffer. Absorbance was read at 620nm. 
Nunc-Immuno module Maxisorb F8 strips gave the highest signals with minimum 
background "noise". Adsorption in carbonate/bicarbonate buffer with subsequent 
incubations at 37°C for 1 hour were the optimum incubation conditions. Rabbit 
polyclonal anti-rFVIII antibodies when bound to the Nunc F8 strips gave the highest 
signal when compared with a commercial anti-FVIII (obtained from Serotec) (Table
5.2.1).
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Absorbance ± S.D. at 620nm
Antibody concentration
(pg/ml)
Rabbit anti-rFVIII Commercial anti-FVIII
1 .059 ± .001 .070 ± .002
2 .385 ± .033 .133 ± .002
5 .653 ± .052 .173 ± .005
10 .848 ± .028 .172 ± .011
15 .930 ± .073 .170 ± .001
20 1.174 ± .067 .167 ± .012
PBS .000 ± .000 .000 ± .000
Table 5.2.1 The binding of two anti-FVHI antibodies, (a commercial sheep anti-FVIII, 
and a rabbit anti-rFVin produced in the laboratory) to the surface of a 
Nunc-Immuno module Maxisorb microtitre well is shown. These 
antibodies were bound to the solid phase, and subsequently detected using 
alkaline phosphatase-labelled anti-rabbit or anti-sheep antibodies and 5- 
bromo-4-chloro-3-indolyl phosphate as substrate.
S.D. is the standard deviation where n = 3.
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5.2.2 Blocking of free binding sites
The choice of blocking buffer is another important consideration. The use of an 
unrelated protein which exhibits no cross-reactivity with any of the components of the 
ELISA is essential. A number of different proteins including BSA, gelatin ovalbumin 
and human fibrinogen (a normal constituent of blood) were examined. As Table 5.2.2 
shows, the rabbit polyclonal anti-rFVin antibodies showed no cross-reactivity with any 
of the protein solutions. For this system, a 1% (w/v) solution of BSA was chosen. BSA 
is readily available, the antibodies did not cross-react with it and the 1% (w/v) solution 
is just as effective as the 5% (w/v) solution but is more cost effective. Enzyme-labelled 
antibodies were diluted in blocking buffer in order to reduced non-specific binding to 
the plate.
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Blocking Buffer Absorbance + S.D. at 492nm
5pg/ml rFVIII
Absorbance ± S.D. at 492nm 
No rFVIII
PBS .061 ± .002 .000 ± .000
1% (w/v) BSA .471 ± .017 .057 ± .002
5% (w/v) BSA .508 ± .021 .061 ± .004
0.25% (w/v) Gelatin .517 ± .025 .070 ± .002
1% (w/v) Ovalbumin .569 ± .024 .056 ± .007
1% (w/v) Fibrinogen .407 ± .037 .061 ± .005
Table 5.2.2. 1 Opg/ml rFVIII was bound onto Nunc-Immuno module Maxisorb strips.
Free binding sites were blocked using 1% and 5% (w/v) bovine serum 
albumin (BSA), 0.25 % (w/v) gelatin, 1% (w/v) ovalbumin and 1% (w/v) 
fibrinogen. Bound rFVIII was detected using horseradish peroxidase- 
labelled anti-rFVIII antibodies.
Controls in which no rFVIII was bound to the plate were included to test 
for cross-reactivity of the antibody with the blocking buffer.
S.D. is the standard deviation where n= 3.
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5.2.3 Choice of Substrate
A variety of substrates for horseradish peroxidase, (HRP, the enzyme label for the 
secondary antibody) were examined. o-Phenylenediamine (OPD) is a commonly used 
substrate for HRP, with absorbance measured at 405nm or 492nm (if the reaction has 
been stopped by addition of 20% (v/v) H2S 04). An ELISA was carried out and after 
addition of OPD, absorbance was monitored at 5 minute intervals over a 60 minute 
period. From this, the optimum incubation time for the substrate was ascertained (Figure 
5.2.3). OPD is a hazardous substance, and so an alternative, safer substrate (3,3',5,5'- 
Tetramethylbenzidine, TMB) was examined. TMB, however, gave high background 
levels of absorbance (Table 5.2.3), and so OPD was retained as substrate for HRP. 
The minimum detection limit for rFVIII in the antigen-capture ELISA was O.lpg/ml, 
with an optimum rFVIII concentration of lOug/ml.
Antibody (1 Opg/ml) Absorbance ± S.D. 
at 492nm (OPD)
Absorbance ± S.D. 
at 450nm (TMB)
Rabbit Polyclonal .123 ± .010 .390 ± .006
M l Monoclonal .151 ± .017 .302 ± .016
M2 Monoclonal .144 ± .020 .296 ± .001
M10 Monoclonal .131 ± .003 .259 ± .006
PBS .046 ± .001 .272 ± .006
Table 5.2.3 Comparison between o-phenylenediamine (OPD) and 3,3',5,5'-
tetramethylbenzidine (TMD) as substrates for horseradish peroxidase. 
rFVIII was bound to the solid phase and detected using horseradish 
peroxidase-labelled anti-rFVIII antibody. The substrates were then added 
and absorbance read at the respective wavelength.
S.D. is the standard deviation where n=3.
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Figure 5.2.3 Substrate kinetics for o-phenylenediamine (OPD).
Anti-rFVni antibody was bound to Nunc Maxisorb F8 strips and rFVIII 
added. Bound rFVIII was detected using horseradish peroxidase (HRP)- 
labelled anti-rFVIII antibodies and OPD. Absorbance at 405nm was read 
at 5 minute intervals over 60 minutes.
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5.3 ELISA using a goat anti-rabbit antibody linking layer
In order to increase the sensitivity of the ELISA, a layer of goat anti-rabbit antibody was 
first coated, (in 50mM carbonate/bicarbonate buffer, pH 9.6) onto the bottom of the 
well. A range of concentrations were bound to the plate, and an optimum was found to 
be 1 Opg/ml (Figure 5.3.1). This immobilised anti-rabbit antibody captured and bound the 
rabbit anti-rFVIII antibody, which was in turn was detected using a goat anti-rabbit 
antibody labelled with alkaline phosphate (GAR-AP). Colour was developed with BCIP 
in AMP buffer. The absorbances obtained using this method were on average higher 
than those observed in the corresponding IgG ELISAs, where the anti-rFVIII antibodies 
were bound directly to the plate. The detection limit was improved by a factor of 50 
allowing concentrations as low as lOng of antibody to be detected (Figure 5.3.2).
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Figure 5.3.1 Optimisation of the binding of goat anti-rabbit antibody (GAR) onto Nunc 
Maxisorb F8 strips. A range of concentrations of GAR were bound to the 
solid phase and detected using an alkaline phosphatase-labelled anti-goat 
antibody and 5-bromo-4-chloro-3-indoyl phosphate (BCIP) in 2-amino-2- 
methyl-1-propanol (AMP) buffer.
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Figure 5.3.2 Comparison between the goat anti-rabbit (GAR) and direct ELISA for the 
detection of rFVIII.
In the GAR ELISA, a layer of GAR antibody was used to capture rabbit 
anti-rFVIII antibodies. These were detected with alkaline phosphatase- 
labelled anti-rabbit antibody and 5-bromo-4-chloro-3-indoyl phosphate 
(BCIP) in 2-amino-2-methyl-l-propanol (AMP) buffer.
In the Indirect ELISA, the anti-rFVIII antibodies were bound directly to 
the plate and detected in the same way.
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5.4 Indirect ELISA
Using the results obtained in the antigen-capture ELISA, an indirect ELISA was 
developed, where rFVIII was bound directly to the solid phase. The solid phase, coating 
buffer, incubation conditions and blocking buffer were all the same as those used above 
(Sections 5.2.1 and 5.2.2). After coating and blocking, anti-rFVIII antibody in PBS 
(0.15M, pH 7.2) was added. Any bound IgG was detected using GAR-AP in blocking 
buffer. Colour was developed using BCIP in AMP buffer, and absorbance was read at 
620nm. A range of concentrations of the rFVIII antigen was bound to the plate (0.1- 
20|ig/ml) and an optimal concentration found to be 5pg/ml. (Figure 5.4.1).
The four antibodies were all tested in this system, and similar binding patterns to those 
found in the capture ELISA were obtained. The rabbit polyclonal antibodies again 
proved to be more reactive than the monoclonal antibodies (Table 5.4). The optimal 
concentration for the rabbit polyclonal antibodies was found to be lOpg/ml (Figure 5.4.2) 
and the lowest concentration at which rFVIII (which was bound to the plate) could be 
determined was 0.2pg/ml.
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Figure 5.4.1 Binding of rFVIII to the solid phase for use in an indirect ELISA.
A range of concentrations of rFVIII were bound to Nunc Maxisorb F8 
strips. Anti-rFVIII antibodies were added and bound antibody detected 
using alkaline phosphate-labelled goat anti-rabbit antibody and 5-bromo-4- 
chloro-3-indolyl phosphate (BCIP) in 2-amino-2-methyl-l-propanol 
(AMP) buffer.
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Absorbance ± S.D. at 620nm
Antibody concentration M l M2 M10
(pg/ml) Monoclonal Monoclonal Monoclonal
1 .070 ± .001 .057 ± .003 .061 ± .005
2 .088 ± .002 .062 ± .006 .067 ± .007
5 .089 ± .005 .071 ± .002 .073 ± .002
10 .080 ± .007 .091 ± .008 .095 ± .007
PBS .000 ± .000 .000 ± .000 .000 ± .000
Table 5.4 The reaction of four antibodies with different concentrations of rFVIII in 
an indirect ELISA. rFVIII was bound to the solid phase, and the anti- 
rFVHI antibodies added. Bound antibody was detected using alkaline 
phosphatase-labelled antibodies and 5-bromo-4-chloro-3-indoyl phosphate 
as substrate.
S.D. is the standard deviation where n = 3.
The substrate characteristics were also examined, with absorbance at 620nm being 
monitored over 60 minutes. The optimal incubation period was taken to be 30 minutes 
(Figure 5.4.3).
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Figure 5.4.2 Concentration of primary anti-rFVIII antibody in an indirect ELISA. 
5pg/ml rFVIII was bound onto the solid phase, and a range of 
concentrations of anti-rFVIII ployclonal antibody added. Bound antibody 
was detected with alkaline phosphatase-labelled anti-rabbit antibody and 
5-bromo-4-chloro-3-indoyl phosphate (BCIP) in 2-amino-2-methy 1-1- 
propanol (AMP) buffer.
The optimal primary antibody concentration chosen for use was lOjjg/ml.
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Figure 5.4.3 Substrate kinetics for 5-bromo-4-chloro-3-indoyl phosphate (BCIP).
rFVIII was bound onto the solid phase and anti-rFVIII antibodies added. 
Bound antibody was detected with alkaline phosphatase-labelled anti­
rabbit antibody, and 5-bromo-4-chloro-3-indoyl phosphate (BCIP) in 2- 
amino-2-methyl-l-propanol (AMP) buffer. The absorbance at 620nm was 
read at 5 minute intervals over 60 minutes.
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5.5 ELISA using a Luminescent Substrate
The method used was as described for the capture and indirect ELISAs with the 
exception that Dynatech MicroFLUOR plates were used. In the capture ELISA a range 
of concentrations of anti-rFVIE antibodies (monoclonal and polyclonal) were bound to 
these plates, and the effectiveness of blocking free binding sites was examined. It was 
found that there was minimal difference in signals between the blocked and unblocked 
wells (Figure 5.5.1). Despite using the optimised parameters from the antigen-capture 
ELISA (Section 5.2), no luminescent signal was obtained. This could have been caused 
by the different binding properties of the opaque plates required for use with a 
luminescent substrate. ELISA plates are manufactured and processed to maximise 
protein binding. The MicroFLUOR plates are not manufactured with the same specifity 
as the ELISA plates and, thus, do not exhibit the same binding characteristics. This may 
have contribituted to the failure to obtain a signal using the antigen-capture ELISA 
format.
An indirect ELISA format was used, based on that optimised in Section 5.4. The range 
of rFVIII which bound to the plates was greater than that found in Section 5.4, and the 
optimum binding concentration was higher, 1 Opg/ml (a two-fold increase) (Figure 5.5.2). 
Anti-rFVIII antibodies samples were added, and bound antibodies were detected using 
goat anti-rabbit IgG linked to HRP (GAR-HRP). The signal was developed using ECL 
reagent and luminescence was monitored on an Amersham Amerlite luminometer.
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Figure 5.5.1 The effectiveness of blocking free binding sites on opaque plates designed 
for use with a luminescent substrate.
5pg/ml of rFVIII was bound to wells of Dynatech MicroFLUOR plates 
and the free binding sites in wells of one half of the plate were blocked, 
and the remaining half left unblocked. Dilutions of anti-rFVIII antibody 
were added and bound antibody probed using a horseradish peroxidase- 
labelled anti-rabbit antibody and a luminescent substrate (ECL). 
Luminescence was monitored using an Amersham Amerlite luminometer.
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Figure 5.5.2 Binding of rFVIII to the surface of Dynatech MicroFLOUR microtitre 
plates for use in an indirect luminescent ELISA.
A range of concentrations of rFVIII were bound to the solid phase and 
detected using a horseradish peroxidase-labelled anti-rFVIII antibody and 
a luminescent substrate (ECL).
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5.6 Detection of FV m  in Plasma
Normal human plasma, Coag Cal N calibration plasma and FVIII-deficient plasma 
spiked with rFVIII were all used in an attempt to detect FVIII in "real samples". Using 
the antigen-capture ELISA format, FVIII could not be detected in whole Coag Cal N 
samples or in samples in which FVIII had been separated from vWF by high ionic 
strength buffers (Section 2.27) (Table 5.6.1). The lower detection limit was 1.5 times 
the background value (the background value was determined in a well containing all the 
reagents minus the sample (rFVIII)). FVIII was activated by thrombin (Section 2.25), 
but a clot formed before the FVIII sample could be added to the ELISA. Two anti­
coagulants, heparin and 0.11M sodium citrate, were used to prevent clot formation. In 
both cases, no FVIII could be detected in Coag Cal N by any of the four antibodies 
(Table 5.6.2).
FVIII in normal human plasma could be detected once the sample had been partially 
purified, and the FVIII/vWF complex separated (Section 2.27). Absorbances obtained 
were comparable with controls using a similar concentration of rFVIII (Table 5.6.3). The 
antibodies did not cross-react with any component in FVIII-deficient plasma. Therefore, 
FVIII-deficient plasma was spiked with a range of concentrations of FVIII which were 
detected in an antigen-capture ELISA (Table 5.6.4).
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FVIII Sample Absorbance ± S.D. at 492nm
Coag Cal N
Undiluted .055 ± .002
1:10 Dilution .054 ± .004
FVIII-deficient Plasma
Undiluted .051 ± .001
1:10 Dilution .052 ± .003
rFVIII Control
5pg/ml .073 ± .000
lOpg/ml .105 ± .001
PBS 0.000 ± .002
Table 5.6.1 The reaction of Coag Cal N calibration plasma and FVIII-deficient plasma 
in an antigen-capture ELISA. Anti-rFVIII antibody was bound to the solid 
phase and samples of Coag Cal N and FVIII-deficient plasma added. 
Bound FVIII was detected using horseradish peroxidase-labelled anti- 
rFVIII antibodies and o-phenylenediamine as substrate. The anti-rFVIII 
antibodies did not react with FVIII in Coag Cal N in any way.
Controls consisting of 5pg/ml and 10 pg/ml rFVIII were included.
S.D. is the standard deviation where n=3.
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Absorbance ± S.D. at 492nm
Anti-rFVIII
Antibody
rFVIII
(lOpg/ml)
Coag Cal N Citrated
Plasma
FVIII-deficient
Plasma
Rabbit Polyclonal .190 ± .002 .051 ± .005 .010 ± .001 .040 ± .007
M l Monoclonal .210 ± .007 .055 ± .001 .059 ± .003 .061 ± .005
M2 Monoclonal .121 ± .011 .057 ± .002 .095 ± .010 .063 ± .007
M10 Monoclonal .200 ± .021 .062 ± .007 .061 ± .001 .060 ± .001
PBS .000 ± .000 .000 ± .000 .000 ± .000 .000 ± .000
Table 5.6.2 The reaction of four anti-rFVIII antibodies with different sources of FVIII 
in an antigen-capture ELISA. Anti-rFVIII antibody was bound to the solid 
phase, and the above samples of FVIII added. Bound FVIII was detected 
using horseradish peroxidase-labelled anti-rFVIII antibodies and o- 
phenylenediamine as substrate.
Citrated plasma consisted of thrombin-activated Coag Cal N, containing 
0.11M sodium citrate as an anti-coagulant. Coag Cal N and FVIII-deficient 
plasma are commercial calibration plasmas.
S.D. is the standard deviation where n = 3.
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FVIII Source Absorbance ± S.D. 
at 492nm
Coag Cal N Calibration Plasma .055 ± .001
Purified Plasma (neat) .330 ± .007
Purified Plasma (1:5 dilution) .216 ± .005
Purified Plasma (1:10 dilution) .160 ± .008
Control (5pg/ml rFVIII) .131 ± .010
PBS .000 ± .000
Table 5.6.3 Detection of FVIII in normal human plasma using an antigen-capture
ELISA. Anti-rFVIII antibody was bound to the solid phase and partially- 
purified plasma added. Bound FVIII was detected using horseradish 
peroxidase-labelled anti-rFVin antibodies and o-phenylenediamine as 
substrate. The plasma was purified by gel filtration chromatography 
through a Sepharose 6B column.
S.D. is the standard deviation where n = 3.
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FVIII source Absorbance ± S.D. 
at 492nm
FVIII-deficient Plasma .056 ± .000
FVIII-deficient Plasma 
+ 5pg/ml rFVIQ
.087 ± .002
FVIII-deficient Plasma 
+ lOpg/ml rFVIII
.112 ± .010
Control (lOpg/ml rFVIII) .111 ± .012
PBS .000 ± .000
Table 5.6.4 Detection of rFVin in spiked samples of FVIII-deficient Plasma using an 
antigen capture ELISA. Anti-rFVIII antibody was bound to the solid phase 
and spiked and unspiked samples of FVIII-deficient plasma added. Bound 
FVIII was detected using horseradish peroxidase-labelled anti-rFVm 
antibodies and o-phenylenediamine as substrate.
S.D. is the standard deviation where n = 3.
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5.7 Competitive ELISA
Competitive ELISAs using a number of different formats were developed to detect
rFVHI and antibodies to rFVIII.
In the first format, the antigen (rFVIII) was immobilised onto the solid phase. This then 
competes with free rFVIII in the sample (or standard) for enzyme-labelled specific anti- 
rFVIII antibody in solution. The amount of product formed was inversely proportional 
to the concentration of free rFVIII in solution. Concentration of rFVIII as low as 
().5pg/ml could be detected using this system.
In the second format, both enzyme-labelled and free antibody competed for binding 
rFVIII which had been immobilised onto the surface of the microtitre plate. In this case, 
the amount of colour obtained was inversely proportional to the level of free antibody 
present.
In this system, concentrations of 0.5pg/ml of anti-rFVIII antibody could be detected. 
When absorbance was plotted against antigen (rFVIII) or antibody concentration, the 
graphs show second order characteristics (Figures 5.7.1 and 5.7.2). For rFVIII 
measurement k,= 2.35 ±0.1 and k2= 0.042 ± 0.001, while for antibody measurement, 
k,= 3.78 ± 0.2 and k2= 0.007 ± 0.001.
These ELISAs could be useful in the determination of FVIII, rFVIII or anti-rFVIII 
antibodies in plasma. When samples of normal human plasma, and Coag Cal calibration 
plasma were tested in this system, no signal was obtained for any of the samples. This 
may be caused by non-specific binding of components of plasma to the surface of the 
well, blocking the antibodies, and preventing binding of rFVIII. Alternatively, the 
labelled antibodies may be cross-reacting with some other constituant of plasma. This 
is likely, because the labelled antibodies are polyclonal, and thus contain antibodies 
against a wide range of determinants, which may not be unique to rFVIII.
"Real samples" of anti-FVIII antibodies were not tested, as the risks of contamination 
from blood-borne infectious agents (such as HIV and hepatitis) are high, especially from 
haemophiliacs receiving replacement FVIII therapy.
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Figure 5.7.1 Competitive ELISA for the detection of rFVIII.
rFVIII was bound to the solid phase and equal volumes of horseradish 
peroxide (HRP)-labelled anti-rFVin antibodies and free rFVIII were added. 
o-Phenylenediamine (OPD) was added and absorbance measured at 492nm. 
The absorbance was inversely proportional to the concentration of free 
rFVIII in solution.
The graph follows second order characteristics with k;= 2.35 and k^= 
0.042. r = 0.99, where r is the correlation coefficient.
198
CU
RR
EN
T 
(nA
)
C o n c e n tr a t io n  o f  anti-rFVIII a n t ib o d y  ( / ¿ g / m l )
Figure 5.7.2 Competitive ELISA for the detection of anti-rFVIII antibodies.
rFVIII was bound to the solid phase and equal volumes of horseradish 
peroxide (HRP)-labelled anti-rFVIII antibodies and unlabelled anti-rFVIII 
antibodies were added. o-Phenylenediamine (OPD) was added and 
absorbance measured at 492nm. The absorbance was inversely proportional 
to the concentration of unlabelled anti-rFVIII antibodies in solution.
The graph follows second order characteristics with k,= 3.78, and 
0.007. r = 0.97, where r is the correlation coefficient.
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5.8 Discussion
The choice of solid phase is one of the fundamental factors in the development of an 
ELISA system. Carriers can be classified into two categories - high and low capacity 
binders. High capacity materials include nitrocellulose, cellulose and cyanogen bromide- 
activated agarose. These are stable and can be stored for long periods of time. They are 
particularly useful for relatively impure antigen preparations, viral, or bacterial antigens 
(Kemeny, 1991). The disadvantages of these are that they are difficult to wash, and give 
high background binding. Low-capacity carriers, such as plastic and PVC, are easier to 
wash, and give low background binding. However, they are more difficult to coat 
effectively (Kemeny, 1992).
The capacity of the solid phase is limited (lpg/cm2 for IgG) (Porstmann et al., 1992) and 
therefore it is important to optimise the concentration of the bound protein (O’Kennedy, 
1989). If the concentration is too high, multiple layers can form consisting of proteins 
binding to each other. These protein-protein interactions are weaker than the protein- 
solid phase ones, and so are more easily disrupted. Dissociation or leaching can occur, 
and the dissociated proteins can interfere with the assay. Generally, the concentration 
should be within the range l-10pg/ml (Kemeny, 1992).
Charge and hydrophobic interactions are thought to be important in the binding of the 
proteins to the solid phase (Kemeny, 1991). The charge on a protein is influenced by 
the pH of the buffer. It was found that a buffer with a high pH (i.e., pH 9.6), gave the 
highest degree of binding.
The need to block free binding sites, once the antigen or antibody has been immobilised, 
is the subject of conflicting reports (Sch0nheyder and Andersen, 1984; Mohammed and 
Esen, 1990). Sites were blocked using a 1% (w/v) solution of BSA. It has been proposed 
that the size of the protein molecule could be an important factor in the choice of 
blocking buffer, with small protein molecules being more effective than larger ones 
(Kemeny, 1992). The need for a blocking step in the ELISA using a luminescent 
substrate was eliminated. Different plates were used in this system (Dynatech 
MicroFLUOR plates), which perhaps did not have the same binding characteristics as 
the specially treated Nunc Maxisorb strips. The Dynatech plates did bind a greater range 
of rFVIII concentrations, suggesting that the plates could be coated more effectively, and 
the risk of non-specific binding reduced.
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The binding of an antibody to the solid phase can compromise the integrity of the 
molecule, resulting in loss of activity, or the alteration or loss of some antigenic sites 
in the case of an antigen. A layer of linking agent can be used to prevent this happening. 
For antigens, cross-linking reagents such as glutaraldehyde and carbodiimide (Place and 
Schroeder, 1982; Rotmans and Scheven, 1984) have been successfully used. Anti-mouse 
or rabbit IgG is generally used as the linking agent for antibodies. This method proved 
useful for the detection of the anti-rFVIII antibodies: the limit of detection was 
improved 50 fold to allow concentrations of antibody as low as lOng/ml to be detected. 
Compared with this, the limit of detection of the IgG ELISA was 500ng/ml. This goat 
anti-rabbit ELISA, however, involves an additional step resulting in a longer assay time, 
as well as the additional expense of another antibody layer. The goat anti-rabbit antibody 
linker could not be used in the full capture ELISA because the secondary enzyme- 
labelled antibody was also a rabbit antibody, and would cross-react with the linking 
agent.
The absorbanses recorded with the monoclonal antibody-based ELISAs are generally 
lower than those of the polyclonal antibody-based assays. The lower avidity and small 
fraction of high-affinity antibodies (which are dominant in polyclonal sera) are reasons 
for lower detectability of monoclonal antibodies in enzyme-immunoassay (EIA) when 
compared with polyclonal antibodies, despite lower concentration of antibody in the 
latter (Tijssen, 1985). Affinity (the strength of a single antigen-antibody bond) and 
avidity (the overall binding strength of an antibody for an antigen, it is dependant on the 
affinity and the valency of the antibody) are significant. Avidity is an important 
characteristic of polyclonal antisera, since they generally contain antibodies against all 
determinants of a given antigen, which contribute to the avidity. Monoclonal antibodies 
on the other hand, react with a single unique epitope with a defined specifity and 
affinity and, therefore, generally do not exhibit the same levels of avidity as polyclonal 
antisera (Tijssen, 1985). It is therefore, essential that the monoclonal antibodies have 
high affinity for their determinants. The monoclonal antibodies used in the ELISAs 
described here were of the IgM class. IgM is a pentameric molecule, but because of lack 
of flexibility in the molecule leading to steric hindrance, it has a reduced valency of 5 
(Roitt, 1980). These antibodies tend to have lower affinity than IgG antibodies, but 
higher avidity because of their valency.
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There are other problems associated with the use of monoclonal antibodies in EIA. 
When an antigen binds to the solid phase, the single epitope recognised by the antibody 
may be hidden or changed in some way, and this may prevent antibody binding. 
Polyclonal preparations, containing a mixture of antibodies, are capable of recognising 
a number of different epitopes. Therefore, some epitopes are generally available for 
binding under most conditions. The monoclonal antibodies were not used as a capture 
layer in the antigen-capture ELISA. They recognise only single epitopes and therefore, 
the level of antigen which would be captured and bound would be severely restricted. 
If the binding site was altered in any way by the binding of the antibody to the solid 
phase, no binding at all could take place. Polyclonal antiserum binds to a range of 
epitopes, and thus provides an ideal capture layer, as many alternative sites will be 
available.
von Willebrand Factor (vWF) comprises approximately 99% of the mass of the 
vWF/FVIII complex (Manning et al., 1993), and so it has proved very difficult to detect 
FVIH immunologically in normal plasma. Attempts to isolate and immunodetect FVIII 
from normal human calibration plasma (Coag Cal N) proved unsuccessful. This was the 
case regardless of whether or not FVIII had been separated from the FVIH/vWF 
complex using high ionic strength buffers (Hoyer, 1981). However, FVIII was 
successfully detected in normal human plasma after separation of the complex and in 
FVm-deficient plasma spiked with the recombinant protein. It was discovered that the 
antibodies were targeted against conformational epitopes on the rFVIII molecule (Section
4.11). These epitopes could have been destroyed during the lyophilisation process in the 
preparation of Coag Cal N without affecting the functional properties of the FVIH 
molecule.
A number of ELIS As have been developed using several formats (Figure 5.8.1).
The antigen-capture ELISA is primarily used to quantitate antigens in a test solution or 
for the titration of antisera (Tijssen, 1985). The ELISA described here provides a simple 
and reliable method for the detection of rFVIII or its antibody. Its main advantage over 
the direct ELISA is that the antigen does not have to be bound directly to the plate, 
avoiding problems of poor epitope orientation or structural change on binding. 
Modifications can be made to speed up the assay, including overnight blocking, or use 
of a luminescent substrate where a signal can be read after 5 minutes.
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A. INDIRECT ELISA
B. GOAT ANTI-RABBIT ANTIBODY 
LINKER ELISA
E. COMPETITIVE ELISA 
Enzyme-labelled secondary antibody
A  Antigen (rFVIII)
Primary antibody
Figure 5.8.1 Formats used in the development of an ELISA for the detection 
of rFVIII and anti-rFVIII antibodies
The indirect ELISA on the other hand, is widely used for the determination of antibody 
activity (Tijssen, 1985). Anti-rFVIII antibodies were successfully detected and quantified 
using this method. rFVIII can be readily adsorbed onto the surface of wells, as compared 
with the normal FVIII molecule, because of its reduced size. It can, therefore, provide 
an alternative to normal FVIII for this purpose. Inhibitor antibodies, which develop in 
haemophliacs receiving FVIII replacement therapy, could be detected using this assay. 
Competitive assays allow for the quantitation of a particular antigen or antibody, even 
when they cannot be isolated from the medium in which they are found (Kemeny, 
1991). Antibodies to disease-causing organisms have been successfully detected and 
quantified using ELISAs (Tijssen, 1985). In this section, competitive ELISAs have been 
developed for the quantitation of rFVIII and anti-rFVIII antibodies. FVIII in normal 
human samples could not be detected, as other components of plasma possibly interfered 
with the assay. A partial purification of the plasma still did not eliminate the interfering 
substance. Blood and plasma are complex matrices, with a wide variety of constituants. 
The antibodies used in the ELISA were polyclonal, and thus were directed against a 
large number of antigenic determinants, some of which were not necessarily unique to 
rFVIII. There was, therefore, a possibility of cross-reactivity with other components of 
plasma. A labelled monoclonal antibody antibody would reduce the chances of cross­
reactivity, but for reasons outlined earlier, the antibody would have to be highly specific 
and have high affinity for its antigenic determinant.
The competitive ELISA for the detection of anti-rFVIII antibodies could be useful in the 
monitoring of inhibitor antibodies. Levels of inhibitor antibodies are an important 
consideration in the treatment of haemophilia (Section 1.11.2).
Inhibitor antibodies (or antibody fragments) have been used as a capture layer coated 
onto the solid phase (Dinesen and Feddersen, 1983; Nordfang et al., 1985). In these 
assays, the sample was added and bound FVIII detected using either labelled inhibitor 
antibodies or an anti-FVIII monoclonal antibody. These was subsequently detected using 
a HRP-labelled goat anti-mouse antibody. In the system described in this chapter, 
monoclonal and polyclonal anti-rFVIII antibodies were employed, providing a safe and 
reliable alternative to human-derived inhibitor antibodies. A number of different formats 
have been developed allowing for alterations in the methodology. Using these, rFVIII 
itself or antibodies against it can be successfully detected and quantitated.
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CHAPTER 6
DEVELOPMENT OF AN ANTIBODY-BASED 
BIOSENSOR FOR THE DETECTION OF 
rFVIII AND ANTI-rFVIII ANTIBODIES
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6.1 Introduction
In the system described here, rFVIII is immobilised onto the surface of an electrode. 
Horseradish peroxidase (HRP)-labelled anti-rFVIII antibodies bind to the antigen and a 
signal is produced via a mediator (hydroquinone) (Figure 6.1.1). HRP catalyses the 
reaction between hydrogen peroxide (H20 2) and hydroquinone (HQ) forming 
benzoquinone (BQ). HQ is regenerated by reduction of BQ at the electrode surface at 
an applied potential of -0.03V, generating a measurable signal:
H A  + HQ > 2H20  + BQ
Applied Pot. -0.03V 
BQ + 2H+ + 2e' ------------------------------ > HQ
Figure 6.1.2 shows the current-time response for the modified electrode.
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Figure 6.1.1 Generation of a signal from the reduction of of a substrate by an enzyme, 
via a mediator. The substrate in this system is hydrogen peroxide (H20 2). 
The mediator, hydroquinone, catalyses the reduction of H ,02 by the 
enzyme horseradish peroxidase. The mediator is regenerated by reduction 
at the electrode surface, generating a signal.
207
Figure 6.1.2 Current-time responses for successive ImM injections of hydrogen
peroxide at rFVIII-modified electrodes. The operating potential was -0.03V 
with a stirring rate of 450rpm. The electrolyte was 0.1M phosphate buffer, 
pH 7.2 and contained 2mM hydroquinone. The modified electrode 
contained 20pg/ml rFVin, and had been incubated in a 33.3 pg/ml solution 
of HRP-labelled anti-rFVIII antibody for 1 hour at 37°C.
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6.2 Preparation of the Modified Electrode
A modified electrode was prepared by immobilising rFVIII onto the surface of a glassy 
carbon electrode using a perfluorinated, ion-exchange polymer (Nafion). Both the Nafion 
and rFVIII concentrations were optimised.
6.2.1 Nafion Concentration
Nafion was used to immobilise rFVIII onto the surface of a glassy carbon electrode.
A concentration 5% (v/v) Nafion was used to coat lOpl of 30pg/ml rFVIII onto the 
electrode surface, forming a stable film. It was found that at concentrations below this, 
the film was unstable and cracked, exposing the electrode surface. This allowed labelled 
antibody to bind non-specifically to the exposed electrode surface creating false positive 
signals.
6.2.2 Concentration of rFVIII on the electrode surface
The concentration of rFVIII on the surface of the electrode is critically important. It is 
important to have sufficient antigen incorporated into the membrane to allow for 
antibody recognition while, at the same time, allowing access to the electrode surface 
by the flow of electrons within the cell. Overloading the electrode surface can lead to 
the generation of a blanket-like structure, which the electrons cannot penetrate easily, 
resulting in a slow signal.
A range of rFVIII concentrations were examined (Figure 6.2.2). The current increased 
up to a concentration of 50pg/ml, but decreased at 75pg/ml. At concentrations higher 
than this, the film became unstable and cracked.
A concentration of 30pg/ml rFVIII was chosen for future work.
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Figure 6.2.2 Determination of the optimum concentration of rFVIII immobilised onto 
the surface of a glassy carbon electrode.
lOpl of rFVIII in 5% (v/v) Nafion was pipetted onto the electrode surface. 
The organic solvent evaporated leaving the rFVIII immobilised onto the 
surface. The electrode was incubated with labelled anti-rFVIII antibody 
and introduced into the electrochemical cell. Mediator (hydroquinone) was 
added to a final concentration of 2mM, followed by ImM substrate (HjOJ 
and the signal measured.
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6.3 Labelled Antibody Concentration
The coated electrode was incubated for 1 hour in a range of concentrations of anti- 
rFVIIl antibody labelled with HRP (prepared as in Section 2.21), in 0.1M phosphate 
buffer, pH 7.1 (Figure 6.3).
The concentration of the enzyme-labelled antibody was considerably lower than that 
used in an ELISA (Section 5.2). In that system, rFVIII bound to an anti-rFVIII antibody 
which had been immobilised onto surface of a microtitre plate. rFVIII was subsequently 
detected using a HRP-labelled anti-rFVIII antibody. The same batch of labelled antibody 
was used but in the ELISA, the dilution used was 1:1000 (lpg/ml) whereas, for 
electrochemical detection, at least a 1:100 dilution (lOpg/ml) was necessary. This 
represents a tenfold increase in concentration. This was also despite the fact that only 
threefold more protein was immobilised onto the electrode (30pg/ml as opposed to 
lOpg/ml on a well of a microtitre plate). The generation of a signal in the 
electrochemical assay involved the flow of electrons (current) produced by the reduction 
of a product at the electrode surface. In an ELISA, a signal was produced by the 
reduction of a substrate forming a coloured product which absorbes light at a defined 
wavelength. The difference between the two methods of generating a signal could 
account for the difference in labelled antibody concentration.
It was important to use the same batch of conjugate when developing the system, owing 
to batch to batch variability in the production of antibody-enzyme conjugates. In order 
to ensure this, a 1:30 dilution of labelled antibody was chosen despite the fact that a 
1:15 dilution produced higher signals.
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Figure 6.3 Incubation of the modified electrode with dilutions of horseradish
peroxidase (HRP)-labelled anti-rFVIII antibody. 30 pg/ml of rFVIII in 5% 
(v/v) Nafion was pipetted onto the electrode surface. The organic solvent 
evaporated leaving the rFVIII immobilised onto the surface. The electrode 
was incubated with different dilutions of HRP-labelled anti-rFVIH antibody 
and introduced into the electrochemical cell. Mediator (hydroquinone) was 
added to a final concentration of 2mM, followed by ImM substrate (H20 2) 
and the signal measured.
2 1 2
6.4 Incubation Temperature
The incubation temperature for antibody-antigen interactions in ELISA is generally taken 
as 37°C. This is not always the most suitable, and therefore, it was important to optimize 
the temperature at which a particular antibody reacts with its antigen in a certain 
environment in order to maximise assay specificity.
The temperature at which anti-rFVII-labelled antibody reacts with rFVIII immobilised 
onto the electrode surface was investigated. A range of temperatures were studied (20°C, 
30°C, 37°C and 45°C) and from these it was seen that when incubated at 37°C the 
antibody-antigen interactions were maximised (Figure 6.4).
Thus, 37°C was chosen as the temperature for all further incubations.
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Figure 6.4 Determination of the optimal incubation temperature for the
rFVIII/horseradish peroxidase (HRP)-labelled anti-rFVIII antibody 
interaction. 30pg/ml of rFVIII in 5% (v/v) Nafion was pipetted onto the 
electrode surface. The organic solvent evaporated leaving the rFVIII 
immobilised onto the surface. The electrode was incubated in HRP-labelled 
anti-rFVIII antibody at different temperatures, and then introduced into the 
electrochemical cell. Mediator (hydroquinone) was added to a final 
concentration of 2mM, followed by ImM substrate (H20 2) and the signal 
measured.
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6.5 Competitive Immunoassay
A competitive immunoassay was developed for the detection of rFVIII, and FVIII in 
normal plasma. The system was based on the competition between rFVIII immobilised 
onto the electrode surface, and free rFVIII (or FVIII in plasma), for binding to HRP- 
labelled anti-rFVIII antibodies (Figure 6.5.1). The signal generated is inversely 
proportional to the concentration of free rFVIII (or FVIII) in solution. Using the 
optimized experimental parameters, increasing concentrations of rFVIII were incubated 
with an equal volume of labelled antibody and the signal measured. A calibration curve 
was prepared using these signals, and is shown in Figure 6.5.2. Concentrations as low 
as O.lpg/ml could be detected using this method.
Samples of normal human plasma were also tested. When undiluted plasma was used, 
only a very small signal could be detected. The sample was, therefore, partially purified 
by gel filtration (Section 2.27). FVIII, because of its size (molecular weight approx. 335 
kDa), eluted just after the void volume, and its presence could be determined by FVIII 
activity assay. FVIII activity was identified in fraction 3 (Table 6.5.1). The protein 
concentration of the purified sample was 50- to 100-fold less than that of whole plasma. 
When a sample of this fraction was tested, a signal was obtained and the concentration 
of FVIII in the plasma determined (Table 6.5.2).
Commercial calibration plasma (Coag Cal N) was also tested and similar results to those 
in Section 5.6 (where Coag Cal N was analysed by ELISA) were obtained. No signal 
was produced by samples of whole unpurified Coag Cal N. The plasma was partially 
purified by gel filtration on a size exclusion column with a fractionation range of Mr 
10,000 to 4,000,000 Da., and FVIII activity identified in fraction 4. The protein 
concentration of the purified sample was 50-fold less than that of whole plasma (Table
6.5.1). The FVIII-containing fraction was analysed using the electro-immunoassay, and 
a signal was obtained, from which the concentration of FVIII in the sample was 
calculated (Table 6.5.2).
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Figure 6.5.1 Competitive immunoassay for the detection of rFVIII in solution.
rFVIII was immobilised onto the surface of the electrode and incubated 
in a solution containing equal volumes of free rFVIII and horseradish 
peroxidase (HRP)-labelled anti-rFVin antibody. Both free and bound 
rFVIII compete for binding of the labelled antibody. The signal is 
inversely proportional to the concentration of the free rFVIII in solution.
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Figure 6.5.2 Calibration curve for the determination of rFVIII by electrochemical
immunoassay. 20pg/ml of rFVIII in 5% (v/v) Nafion was immobilised onto 
the electrode surface. The electrode was incubated at 37°C with equal 
volumes of rFVIII and HRP-labelled anti- rFVIII antibody (33.3 jig/ml), 
r  = 0.98, where r is the correlation coefficient
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Fraction FVIII Activity 
(IU/ml)
Protein Concentration
(mg/ml)
Plasma Sample 1
1
2
3 1.10 1.8
4 0.03 > 3.0
5 - > 3 .0
6 - > 3 .0
Plasma Sample 2
1
2
3 0.95 1.0
4 0.20 > 3.0
5 - > 3 .0
6 - > 3 .0
Coag Cal N Calibration Plasma
1 -  0.20
2 - 0.17
3 - 1.80
4 1.34 > 3.00
5 0.40 0.60
6 - 0.40
7
Table 6.5.1 Partial purification of whole normal plasma and calibration plasma. Plasma 
was purified by gel filtration on a Sepharose 6B column. This was a size 
exclusion column with a fractionation range of Mr 10 to 4,000 kDa.
The protein concentration and FVIII activity of all fractions was monitored. 
FVIH-containing fractions were subsequently analysed by immunosensor. 
The spectrophotometer was capable only of reading absorbances up to 
approximately 3.5 absorbance units which corresponded to a protein 
concentration of 3 mg/ml. Above this value, only a tiny percentage of light 
was transmitted.
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Sample Signal (nA) FVffl concentration 
(pg/ml)
Plasma Sample 1 0.25 3.0
Plasma Sample 2 0.20 7.5
Coag Cal N 
Calibration Plasma
0.50 0.5
Table 6.5.2 Determination of the concentration of FVIII in normal human plasma and 
commercial calibration plasma using a competitive electro-immunoassay. 
The plasmas were partially-purified by gel-filtration on a Sepharose 6B 
column.
A 1:5 dilution of the FVIII-containing fraction in PBS (0.15M, pH 7.2) 
was incubate with a modified glassy carbon electrode (with rFVIII 
immobilised onto the surface), and an equal volume of horseradish 
peroxidase-labelled anti-rFVin antibodies. A signal was recorded after 
addition of mediator (hydroquinone) and substrate (H20 2).
Taking into consideration the sensitivity of the recorder, the signal 
obtained was converted into current, where:
1 cm on the graph = 0.5nA
The difference in values reflects the considerable variation in normal FVIII 
concentrations.
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A similar competitive immunoassay to that for the detection of rFVIH was developed 
to detect anti-rFVni antibodies in solution. Labelled and un-labelled anti-rFVni antibody 
in solution compete for binding to the rFVin immobilised onto the electrode surface 
(Figure 6.5.3). A calibration graph was prepared (Figure 6.5.4). Anti-FVTO antibodies 
develop in haemophiliac patients receiving FVHI replacement therapy. "Real" samples 
therefore, were not tested because of the risks of contamination with blood-borne 
viruses, especially hepatitis and human immunodeficiency virus (HTV).
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Figure 6.5.3 Competitive immunoassay for the detection of anti-rFVni antibodies in 
solution.
rFVIII was immobilised onto the surface of the electrode and incubated 
in a solution containing equal volumes of horseradish peroxidase (HRP)- 
labelled and unlabelled anti-rFVIII antibody. Both labelled and unlabelled 
antibodies compete for binding to the immobilised rFVin on the electrode 
surface. The signal is inversely proportional to the concentration of the 
unlabelled anti-rFVIII antibodies in solution.
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Figure 6.5.4 Calibration curve for the determination of anti-rFVm antibodies by
electrochemical immunoassay. 20pg/ml of rFVIII in 5% (v/v) Nafion was 
immobilised onto the electrode surface. The electrode was incubated at 
37°C with equal volumes of anti-rFVIII antibody and HRP-labelled anti- 
rFVIII antibody (33.3 jig/ml), 
r = 0.975, where r is the correlation coefficient.
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6.6 Discussion
The immobilisation of rFVIII onto the surface of a glassy carbon electrode was 
accomplished using Nafion, a perfluorosulphonic acid polymer. It consists of a 
hydrophobic fluorocarbon backbone with anionic sulphonated side chains (Bindra and 
Wilson, 1989) and is, therefore, an anionic ion-exchange material. It particularly suitable 
for the immobilisation of proteins onto electrode surfaces because of its cationic 
selectivity, and exclusion of anionic species.
Nafion is soluble only in organic solvents, and so it is important to select the appropriate 
dilution and volume of polymer required. lOpl of FVIII in 5% (v/v) Nafion proved to 
give stable and reproducible films. Any dilution of Nafion lower than 5% (v/v) caused 
the FVIII film to crack, exposing the electrode surface.
The cationic selectivity of Nafion means that the coated electrode is sometimes prone 
to fouling. Other cationic species in the medium could become attracted to the electrode 
and interfere with the assay. This is particularly relevant in biosensors, as the analyte 
is generally present in a complex matrix (plasma, for example), where there is an 
abundance of cationic species and other possible interfering substance.
The incubation conditions for the labelled antibody are similar to those used in an 
ELISA. The concentration of the labelled-antibody used in this system was, however, 
at least 10-fold higher than that used in ELISA. This may be as a result of the different 
ways in which the signal is generated. In the electrochemical system the signal was 
generated by the flow of electrons (current) via a mediator. In an ELISA, the signal was 
generated by the oxidation of the substrate by the enzyme. The level of reducing agent 
(i.e., the enzyme HRP) necessary to generate each signal differed, provided the substrate 
was in excess. More HRP was required to provide enough electrons to generate current, 
while the oxidation of substrate in the ELISA was a single event, and, therefore, 
required less enzyme. The orientation of the antigen (rFVIII) on the electrode surface 
could also have been a factor. rFVIII is immobilised onto the electrode surface in an 
ion-exchange membrane. Some of the epitopes may be hidden or altered in some way, 
preventing some of the antibodies from binding. As a result, it may not have been
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possible for some of the high-affmity antibodies to bind to the antigen necessitating a 
higher overall concentration of the labelled-antibody.
It is important to determine the optimal incubation temperature for the antigen-antibody 
interaction, as the optimal conditions for the reaction may be different in different 
systems. The optimal conditions for an ELISA may not always be optimal for other 
systems. Generally speaking, the temperature at which binding is maximised is 37°C 
(Tijssen, 1985). This was found to be the case in this immunoassay.
The protein concentration of FVIII in normal serum is about 5-10pg/ml (Hoyer, 1981) 
out of a total protein concentration of around 100 mg/ml. It circulates in normal plasma 
as part of a complex with vWF. The two components can be separated using high ionic 
strength buffers (Section 1.7). In order to separate FVIII from vWF and to reduce the 
protein concentration (and thus possible interfering substances), plasma was partially 
purified on a size exclusion column. This facilitated recognition of FVIII by the specific 
antibodies in the immunosensor. Samples of whole and calibration plasma (lyophilised 
normal human plasma) did not produce a signal prior to the clean-up step, probably 
because of electrode fouling by contaminating proteins. After separation of the complex 
and sample clean-up a signal was obtained.
FVIII concentration in normal human plasma is usually within the range 5-10 pg/ml, but 
the levels are prone to daily physiological fluctuations. FVIII levels are raised during 
pregnancy, stress, after exercise, in inflammatory and neoplastic diseases and in patients 
with current thromboses (Spaethe, 1984). FVIII is, therefore, usually quantitated by 
activity, where 1 unit is defined as the amount of FVIII activity in 1 ml of normal 
plasma. In the determination of FVIII activity, there is a broad reference range from 50- 
200% (100% corresponds to the activity in a normal reference sample; reference range 
is the range covering 95% of all examined samples showing normal clotting function).
The FVIII concentrations of the normal plasma samples as determined by the FVIII 
immunosensor appear to be within the reference range (approximately 2.5-20 pg/ml). 
Competitive immunoassays for the detection of rFVIII could also detect FVIII in normal 
human plasma, and in Coag Cal N calibration plasma.
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No FVni could be detected in Coag Cal N samples assayed by antigen-capture ELISA 
(Section 5.2) or in normal human plasma assayed by competitive ELISA (Section 5.7). 
In the antigen-capture ELISA anti-rFVIII antibodies immobilised onto the surface of a 
microtitre plate captured and bound FVin. The bound FVIII antibodies were 
subsequently detected using a labelled anti-rFVIII antibody and a chromogenic substrate 
(OPD). In the immunosensor, FVIII was measured by competitive assay. The use of an 
ion-selective membrane reduced the possibility of non-specific binding which may have 
contributed to the failure to obtain a signal in the competitive ELISA. The membrane 
selectively excluded anionic species, many of which are present in plasma 
(Gunasingham and Tan, 1989). This in turn minimised the risks of electrode fouling 
which would reduce the sensitivity of the assay. The reactants also remain in solution 
in the immunoassay, and so the chances of alteration of the binding sites when the 
antibodies are bound to the solid phase are eliminated.
A competitive immunosensor was developed for the quantification of anti-rFVIII 
antibodies. "Real samples" were not used because of the risks of contamination from 
blood-bome infectious agents (such as HIV or hepatitis), which are especially high in 
samples from haemophiliacs receiving FVIII replacememt therapy. The immunosensor 
provides an excellent means of quantitating rFVIII, FVIII and anti-rFVIII antibodies. 
The assay is simple to use, no expensive equipment is required and the assay time is 
considerably shorter than that of an ELISA. It was also more sensitive, allowing 
concentrations as low as 0. lpg/ml rFVIII to be detected, as compared with 0.5pg/ml of 
rFVIII which could be detected by competitive ELISA (Section 5.7). The assay time 
could be reduced even further with the use of a reusable modified electrode. rFVIII (or 
any antigen) could be immobilised onto the surface of the electrode, and incubated with 
the labelled-antibody. After the signal had been read, the antibody would be removed 
without disrupting the electrode surface. This is a critical point, as the electrode must 
be standardised for use throughout the complete assay, and not be subject to 
degeneration. A low pH glycine buffer (0.1M, pH 2.5) was used for this purpose, but 
it was found that the time required for complete antibody dissociation disrupted the film 
on the electrode surface, leading to variations in the signal. The development of reusable 
modified electrodes, however, will be an important step in biosensor technology.
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In conclusion, the system described in this chapter provides a novel way of monitoring 
antibody-antigen interactions. The electrochemical immunoassay has proved to be a 
simple, highly selective and sensitive method for the determination of rFVIII and anti- 
rFVIII antibodies. The assay time was considerably shorter than that of an ELISA, with 
only three steps (two incubation periods, and the measurement of signal), and a response 
time of aproximately 1 minute. This is characteristic of most bioprobes (Bardeletti et al., 
1991). The assay time could be reduced further, by shortening the immobilisation step, 
and decreasing the antigen-antibody incubation step, or by use of a reusable modified 
electrode. The electroimmunoassay is safer than EIA, as it does not require the use of 
hazardous chemicals which are often used as enzyme substrates in ELISAs.
With the current developments in biosensor technology, electrochemical immunoassays 
are set to become a wide-spread alternative to the more traditional methods such as EIA.
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CHAPTER 7
CONCLUSIONS
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FVIII is inherently unstable in the absence of vWF. One of the aims of this project was 
to investigate the effects of chemical cross-linkers and protein modifying reagents on 
recombinant FVIII procoagulant activity, and determine whether any modification caused 
by these reagents resulted in an increase in the thermostability of rFVffi. A range of 
amino- and thiol-specific reagents were employed. It was discovered that the reaction 
of amino-specific cross-linking reagents caused a complete loss of FVIII procoagulant 
activity. In contrast, the thiol-specific reagents did not lead to rFVIII inactivation. This 
suggests that some free amino groups play an integral role in the expression of FVIII 
procoagulant activity. At least some of the free thiol groups can be modified without 
adverse effects on FVIII activity. However, any changes introduced into the molecule 
did not result in any increase in thermostability.
Polyclonal and monoclonal antibodies were raised against rFVIII. The effects of the 
binding of these antibodies on FVIII procoagulant activity and thermostability were 
investigated. The monoclonal antibodies were of the IgM class and binding of these 
antibodies caused complete loss of FVIII activity. The binding epitopes could not be 
identified by Western blot analysis. This suggested that the antibodies were directed 
against some part of the tertiary structure of the molecule, which was destroyed during 
the course of the experiment (possibly by SDS). The antigenic determinants could have 
been located at or adjacent to the thrombin cleavage sites, preventing access to the 
cleavage sites by steric hindrance. Alternatively, the binding of the pentameric IgM 
molecule may cause some degree of strain within rFVIII, distorting the molecule and 
destroying procoagulant activity.
The polyclonal antibodies bound to rFVIII without causing the same degree of 
inactivation. These antibodies were of the IgG class and, therefore, would not induce the 
same degree of strain or steric hindrance in the antigen. As the preparation was 
polyclonal it was composed of a variety of antibodies with different specificities and 
affinities, which may not have been targeted near the active portion of rFVIII. The 
binding of these did result in a small increase in thermostability. Monoclonal IgG 
antibodies directed against sites near to the inactivation sites may prove to increase the 
half-life of active FVIII, by preventing access to the cleavage sites.
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Alternatively, antibodies that link the heterotrimer (which constitutes the active form of 
FVIII) together may stabilise the protein by preventing dissociation of the subunits.
Another objective of these studies was to develop analytical methods for the detection 
and quantitation of FVIII. It is extremely important to be able to quantify FVIII levels 
in the diagnosis and treatment of haemophilia, the deficiency disease of FVIII. Current 
methods rely on the ability of FVIII to correct the prolonged bleeding time of FVIII- 
deficient plasma. These methods are difficult to standardise and are prone to error, as 
they are dependant on the operator. rFVIII is being increasingly used in replacement 
therapy for the treatment of haemophilia. It provides a safer alternative to human-derived 
FVIII, and should be less immunogenic than animal derived FVIII. The development of 
an ELISA for the detection of rFVIII and anti-rFVIII antibodies allows for the detection 
and quantitation of rFVIII and anti-rFVIII antibodies which may develop in patients. It 
is a simple, reliable and easy to use method. A number of modifications can be made 
which allow for different specifities: different incubation conditions for blocking free 
binding sites, a 50-fold increase in sensitivity with the use of a linker layer, shorter 
assay times with the use of a luminescent substrate. The use of polyclonal and 
monoclonal antibodies in this system provides a safer alternative to the human-derived 
antibodies traditionally used. The risk of infection from blood-borne viruses is 
eliminated.
Biosensors provide an ideal analytical device for the modem era. A biosensor was 
developed which incorporated rFVIII onto the surface of an electrode, and was capable 
of detecting FVIII in normal human plasma, as well as rFVIII in solution. The assay is 
simple to use, does not involve the use of hazardous chemicals, is sensitive with an 
assay time of only hours. This may be reduced even further, with the development of 
a reusable modified electrode. This could prove to be an exciting development, as future 
commercial applications may be important. The possibility of a home test to monitor 
FVIII and anti-FVHI antibodies levels could reduce the cost of treatment, and 
revolutionise the treatment of disorders such as haemophilia.
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